Citation Report
List of articles citing

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

DOI: 10.1016/0092-8674(87)90579-4
Cell, 1987, 51, 919-28.

Source: https://exaly.com/paper-pdf/19089771/citation-report.pdf
Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2251	Muscular Dystrophic Mice: Apparently Hypertrophied Muscles and Bone-Muscle Growth Imbalance Hypothesis. **1992**, 37, 52-66		1
2250	Molecular approaches in the prenatal diagnosis and therapy of genetic disorders. **1987**, 2, 160-8		
2249	Human gene mapping 9. Paris conference (1987). Ninth International Workshop on Human Gene Mapping. **1987**, 46, 1-762		31
2248	Satellite cells from dystrophic (mdx) mouse muscle are stimulated by fibroblast growth factor in vitro. **1988**, 39, 42-9		74
2247	Complex glycerol kinase deficiency: molecular-genetic, cytogenetic, and clinical studies of five Japanese patients. **1988**, 31, 603-16		20
2246	Effect of mazindol on growth hormone levels in patients with Duchenne muscular dystrophy. **1988**, 31, 821-33		12
2245	Molecular genetics in muscular dystrophy research: revolutionary progress. **1988**, 11, 683-93		3
2244	Dual-label autoradiographic analysis of human skin fibroblast and myoblast proteins by two-dimensional polyacrylamide gel electrophoresis using immobilised pH gradients in the first dimension. **1988**, 9, 547-54		7
2243	Actin-binding proteins are conserved from slime molds to man. **1988**, 9, 521-30		36
2242	Ultrastructure of the skeletal muscle in the X chromosome-linked dystrophic (mdx) mouse. Comparison with Duchenne muscular dystrophy. **1988**, 77, 69-81		105
2241	Laser spectroscopy for studying chemical processes. **1988**, 46, 221-236		15
2240	On the nature of the Duchenne muscular dystrophy locus: a portion of a complex of related gene clusters of recent pseudoautosomal origin?. **1988**, 81, 103-19		6
2239	The Duchenne muscular dystrophy gene product is localized in sarcolemma of human skeletal muscle. **1988**, 333, 466-9		596
2238	Duchenne muscular dystrophy. Localizing the gene product. **1988**, 333, 798-9		27
2237	Transcription of the dystrophin gene in human muscle and non-muscle tissue. **1988**, 333, 858-60		710
2236	Immunostaining of skeletal and cardiac muscle surface membrane with antibody against Duchenne muscular dystrophy peptide. **1988**, 333, 861-3		531
2235	Immunoelectron microscopic localization of dystrophin in myofibres. **1988**, 333, 863-6		427

2234	The homologue of the Duchenne locus is defective in X-linked muscular dystrophy of dogs. **1988**, 334, 154-6	349
2233	Increased protein degradation results from elevated free calcium levels found in muscle from mdx mice. **1988**, 335, 735-8	377
2232	Proteolytic fragment or new gene product?. **1988**, 336, 210	12
2231	The molecular genetics of Duchenne muscular dystrophy: the beginning of the end?. **1988**, 4, 27-30	14
2230	X-linked muscular dystrophy in the dog. **1988**, 4, 30	6
2229	The molecular genetics of Duchenne muscular dystrophy: the beginning of the end?. **1988**, 4, 27-30	10
2228	Diversity of fast myosin heavy chain expression during development of gastrocnemius, bicep brachii, and posterior latissimus dorsi muscles in normal and dystrophic chickens. **1988**, 130, 220-31	60
2227	Calmodulin-binding profiles for nebulin and dystrophin in human skeletal muscle. **1988**, 234, 267-71	8
2226	Distinct dystrophin mRNA species are expressed in embryonic and adult mouse skeletal muscle. **1988**, 242, 47-52	22
2225	An historical account of studies on muscle. **1988**, 99, 259-97	2
2224	Canine X-linked muscular dystrophy. An animal model of Duchenne muscular dystrophy: clinical studies. **1988**, 88, 69-81	209
2223	Dystrophin and nebulin in the muscular dystrophies. **1988**, 87, 315-26	59
2222	The problem of Duchenne muscular dystrophy. **1988**, 319, 275-84	2
2221	Genetics of Duchenne muscular dystrophy. **1988**, 22, 601-29	103
2220	An explanation for the phenotypic differences between patients bearing partial deletions of the DMD locus. **1988**, 2, 90-5	946
2219	Abnormal response to calmodulin in vitro of dystrophic chicken muscle membrane Ca2+-ATPase activity. **1988**, 27, 7519-24	4
2218	Characterization of dystrophin in muscle-biopsy specimens from patients with Duchenne's or Becker's muscular dystrophy. **1988**, 318, 1363-8	801
2217	Early abnormal development of calmodulin gene expression and calmodulin-resistant Ca2+-ATPase activity in avian dystrophic muscle. **1988**, 151, 1434-40	6

2216	Molecular biology of Duchenne muscular dystrophy. **1988**, 11, 480-4		21
2215	The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. *Cell*, **1988**, 53, 219-28	56.2	1360
2214	Friedreich's ataxia in Kathikas-Arodhes, Cyprus. **1988**, 1, 587		26
2213	Cell and fiber-type distribution of dystrophin. **1988**, 1, 411-20		193
2212	Reviews of Books. **1988**, 332, 427-428		
2211	Gene studies in newborn males with Duchenne muscular dystrophy detected by neonatal screening. **1988**, 2, 425-7		27
2210	Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. *Cell*, **1988**, 52, 503-13	56.2	468
2209	Nebulin cDNAs detect a 25-kilobase transcript in skeletal muscle and localize to human chromosome 2. **1988**, 2, 1-7		75
2208	Cloning and expression of human nebulin cDNAs and assignment of the gene to chromosome 2q31-q32. **1988**, 2, 249-56		32
2207	Clones from an 840-kb fragment containing the 5' region of the DMD locus enriched by pulsed field gel electrophoresis. **1988**, 3, 177-86		14
2206	Dystrophin. **1988**, 332, 429-430		
2205	Duchenne muscular dystrophy: deficiency of dystrophin at the muscle cell surface. *Cell*, **1988**, 54, 447-52	56.2	552
2204	Dystrophin: a triumph of reverse genetics and the end of the beginning. **1988**, 318, 1392-4		15
2203	Expression of the murine Duchenne muscular dystrophy gene in muscle and brain. **1988**, 239, 1416-8		171
2202	Smooth-muscle involvement in Duchenne's muscular dystrophy. **1988**, 319, 1418-9		3
2201	Clinical concepts of Duchenne muscular dystrophy. The impact of molecular genetics. **1988**, 111 (Pt 3), 479-95		33
2200	Gastric hypomotility in Duchenne's muscular dystrophy. **1988**, 319, 15-8		123
2199	Duchenne muscular dystrophy gene expression in normal and diseased human muscle. **1988**, 239, 1418-20		55

2198	Molecular approaches to dysmorphology. **1988**, 25, 473-9	3
2197	The localization of G6pd, glucose-6-phosphate dehydrogenase, and mdx, muscular dystrophy in the mouse X chromosome. **1988**, 52, 195-201	11
2196	Immunological identification of a high molecular weight protein as a candidate for the product of the Duchenne muscular dystrophy gene. **1988**, 85, 4491-5	13
2195	Canine muscular dystrophy: confirmation of X-linked inheritance. **1988**, 79, 405-8	32
2194	A monoclonal antibody against a synthetic polypeptide fragment of dystrophin (amino acid sequence from position 215 to 264).. **1988**, 64, 205-208	24
2193	Negative immunostaining of Duchenne muscular dystrophy(DMD) and mdx muscle surface membrane with antibody against synthetic peptide fragment predicted from DMD cDNA.. **1988**, 64, 37-39	79
2192	Prenatal diagnosis of common genetic disorders. **1988**, 297, 502-6	5
2191	Biochemie und molekulare Biologie 1987. **1988**, 36, 139-157	
2190	Recent Advances in Duchenne and Becker Muscular Dystrophy. **1988**, 6, 429-453	22
2189	The chicken dystrophin cDNA: striking conservation of the C-terminal coding and 3? untranslated regions between man and chicken.. **1988**, 7, 4157-4162	76
2188	Localization of the mdx mutation within the mouse dystrophin gene.. **1988**, 7, 3017-3021	83
2187	Molecular genetics and human disease. Implications for modern psychiatric research and practice. **1988**, 152, 741-53	24
2186	Use of DNA probes in detecting carriers of Duchenne muscular dystrophy: selected case studies.. **1989**, 35, 679-683	9
2185	Molecular analysis of Duchenne and Becker muscular dystrophies. **1989**, 45, 659-80	13
2184	A new 400-kD protein from isolated adherens junctions: its localization at the undercoat of adherens junctions and at microfilament bundles such as stress fibers and circumferential bundles. **1989**, 109, 2905-15	37
2183	Dystrophin-related muscular dystrophies. **1989**, 4, 251-71	9
2182	Dystrophin analysis in the diagnosis of muscular dystrophy. **1989**, 64, 1501-3	7
2181	Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. **1989**, 320, 1592-7	412

2180	The Duchenne dystrophy story: from phenotype to gene and potential treatment. **1989**, 4, 240-50	21
2179	Detection of a specific isoform of alpha-actinin with antisera directed against dystrophin. **1989**, 108, 503-10	46
2178	Medical Genetics. **1989**, 261, 2855	
2177	High resolution deletion breakpoint mapping in the DMD gene by whole cosmid hybridization. **1989** , 17, 5611-21	56
2176	The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. **1989**, 244, 1578-80	1038
2175	Screening for Duchenne muscular dystrophy. **1989**, 64, 1017-21	15
2174	Fibroblast growth factor in the extracellular matrix of dystrophic (mdx) mouse muscle. **1989**, 244, 688-90	228
2173	A membrane fluidizing factor in sera from Duchenne muscular dystrophy patients: effect on lymphocyte membranes of incubation in patient and control lipoproteins. **1989**, 25, 656-9	1
2172	Prednisone therapy for Duchenne's muscular dystrophy. **1989**, 320, 1621-3	12
2171	Clonal derivation of a rat muscle cell strain that forms contraction-competent myotubes. **1989**, 25, 471-6	22
2170	Developmental expression of dystrophin on the plasma membrane of rat muscle cells. **1989**, 151, 11-18	23
2169	Effect of mazindol on dystrophic mice and on growth in young rats. **1989**, 92, 385-9	1
2168	Altered contents of tocopherols in chickens with inherited muscular dystrophy. **1989**, 41, 234-45	5
2167	Maps of linkage and synteny homologies between mouse and man. **1989**, 5, 82-6	205
2166	Update on neuromuscular diseases of childhood. **1989**, 19, 113-66	4
2165	Prenatal diagnosis of Duchenne muscular dystrophy: a three-year experience in a rapidly evolving field. **1989**, 12 Suppl 1, 174-90	11
2164	Dystrophin and the integrity of the sarcolemma in Duchenne muscular dystrophy. **1989**, 45, 175-7	37
2163	Increased susceptibility to lipid peroxidation in skeletal muscles of dystrophic hamsters. **1989**, 45, 747-9	4

2162 Unraveling the mysteries of Duchenne and Becker muscular dystrophy. **1989**, 10, 15-20

2161 Sick molecules and our concepts of disease. **1989**, 225, 221-7 3

2160 Biological roles of actin-binding proteins in Dictyostelium discoideum examined using genetic techniques. **1989**, 14, 69-74 15

2159 Human molecular genetics and the elucidation of the primary biochemical defect in Duchenne muscular dystrophy. **1989**, 14, 163-8 5

2158 Counting and measuring IMPs and pits: why accurate counts are exceedingly rare. **1989**, 13, 204-15 7

2157 Proteins of muscle subcellular fractions in Duchenne progressive muscular dystrophy stained with "stains-all" cationic carbocyanine dye and with Coomassie Blue. **1989**, 12, 273-80 4

2156 Mdx muscle grafts retain the mdx phenotype in normal hosts. **1989**, 12, 401-9 22

2155 Dystrophin immunocytochemistry in muscle culture: detection of a carrier of Duchenne muscular dystrophy. **1989**, 32, 268-73 25

2154 Estimate of the proportion of Duchenne muscular dystrophy with autosomal recessive inheritance. **1989**, 32, 407-10 42

2153 Hypothesis: the existence of embryonic and adult isoforms of mRNA dystrophin provides an explanation for unusual clinical findings. **1989**, 32, 438-41 6

2152 Molecular-genetic study of Duchenne and Becker muscular dystrophies: deletion analyses of 45 Japanese patients and segregation analyses in their families with RFLPs based on the data from normal Japanese females. **1989**, 34, 555-61 23

2151 Molecular biology of Duchenne and Becker's muscular dystrophy: clinical applications. **1989**, 26, 189-94 14

2150 Localization of dystrophin in cultures of human muscle. **1989**, 12, 594-7 10

2149 Dystrophin distribution in heterozygote MDX mice. **1989**, 12, 861-8 54

2148 Localization and characterization of dystrophin in muscle biopsy specimens from Duchenne muscular dystrophy and various neuromuscular disorders. **1989**, 12, 1009-16 29

2147 Biochemical properties of isolated transverse tubular membranes. **1989**, 21, 163-213 43

2146 Muscle hypertrophy in Duchenne muscular dystrophy. A pathological and morphometric study. **1989**, 236, 43-7 64

2145 Duchenne muscular dystrophy carriers. Proton spin-lattice relaxation times of skeletal muscles on magnetic resonance imaging. **1989**, 31, 373-6 15

2144	Molecular deletion patterns in Duchenne and Becker type muscular dystrophy. **1989**, 81, 343-8	71
2143	Impairment of capping in lymphoblastoid cell lines of Duchenne patients indicates an intrinsic cellular defect. **1989**, 83, 217-9	2
2142	Characterization of patients with glycerol kinase deficiency utilizing cDNA probes for the Duchenne muscular dystrophy locus. **1989**, 83, 122-6	26
2141	DNA restriction fragment length polymorphisms in differential diagnosis of genetic disease: application in neuromuscular diseases. **1989**, 82, 55-8	4
2140	Detection of Duchenne muscular dystrophy carriers by dosage analysis using the DMD cDNA clone 8. **1989**, 81, 193-5	40
2139	Conversion of mdx myofibres from dystrophin-negative to -positive by injection of normal myoblasts. **1989**, 337, 176-9	784
2138	Localization of muscle gene products in nuclear domains. **1989**, 337, 570-3	269
2137	Association of dystrophin and an integral membrane glycoprotein. **1989**, 338, 259-62	625
2136	Alternative splicing of human dystrophin mRNA generates isoforms at the carboxy terminus. **1989**, 338, 509-11	322
2135	An autosomal transcript in skeletal muscle with homology to dystrophin. **1989**, 339, 55-8	462
2134	Calcium regulation in muscle diseases; the influence of innervation and activity. **1989**, 991, 155-242	22
2133	Dystrophin abnormalities in Duchenne/Becker muscular dystrophy. **1989**, 2, 1019-29	299
2132	Muscle proteins and muscular dystrophy. **1989**, 1, 110-4	2
2131	Gene mapping and genetic diseases. **1989**, 1, 460-5	1
2130	Toward a physical map of the Xq28 region in man: linking color vision, G6PD, and coagulation factor VIII genes to an X-Y homology region. **1989**, 4, 460-71	59
2129	Molecular analysis of the Duchenne muscular dystrophy locus. **1989**, 93, 125-31	2
2128	Some studies of the Duchenne and autosomal recessive types of muscular dystrophy. **1989**, 11, 91-7	21
2127	Immunological study of dystrophin in Duchenne fetus. **1989**, 2, 1212-3	15

2126	The pathological damage in Duchenne muscular dystrophy may be due to increased intracellular OXY-radical generation caused by the absence of dystrophin and subsequent alterations in Ca2+ metabolism. **1989**, 29, 187-93	27
2125	Immunohistochemical dystrophin reaction in synaptic regions. **1989**, 11, 344-6	59
2124	Xamoterol and the failing heart. **1989**, 2, 1213-4	2
2123	Treatment of muscular dystrophies. **1989**, 20, 263-8	3
2122	A self-inducing runaway-replication plasmid expression system utilizing the Rop protein. **1989**, 78, 73-84	9
2121	Dystrophin and the membrane hypothesis of muscular dystrophy. **1989**, 10, 437-9	11
2120	Monoclonal IgMs with anti-Gal(beta 1-3) GalNAc activity in lower motor neuron disease; identification of glycoprotein antigens in neural tissue and cross-reactivity with serum immunoglobulins. **1989**, 23, 167-74	51
2119	Distribution of dystrophin, nebulin and Ricinus communis I (RCA-I)-binding glycoprotein in tissues of normal and mdx mice. **1989**, 89, 199-211	14
2118	Expression of class I and class II MHC antigens in neuromuscular diseases. **1989**, 89, 213-26	86
2117	Fatty acid composition of lipids in tongue and hindleg muscles of muscular dystrophic mice. **1989**, 91, 337-44	7
2116	Is there a maturation defect related to calcium in muscle mitochondria from dystrophic mice and Duchenne and Becker muscular dystrophy patients. **1989**, 90, 299-306	24
2115	Axonal transport in mdx mouse sciatic nerve. **1989**, 92, 267-79	5
2114	Lymphocytic beta-adrenergic receptors in X-linked muscular dystrophy. **1989**, 92, 281-90	2
2113	Possible systemic smooth muscle layer dysfunction due to a deficiency of dystrophin in Duchenne muscular dystrophy. **1989**, 93, 11-7	55
2112	Immunochemical study of connectin (titin) in neuromuscular diseases using a monoclonal antibody: connectin is degraded extensively in Duchenne muscular dystrophy. **1989**, 93, 147-56	27
2111	Dystrophin in skeletal muscle. I. Western blot analysis using a monoclonal antibody. **1989**, 94, 125-36	157
2110	Dystrophin in skeletal muscle. II. Immunoreactivity in patients with Xp21 muscular dystrophy. **1989**, 94, 137-46	124
2109	Sarcolemma blebs and cell damage in mammalian skeletal muscle. **1989**, 21, 211-7	2

2108	Chromosome maps of man and mouse. IV. **1989**, 53, 89-140	176
2107	Detection of dystrophin on two-dimensional gel electrophoresis. **1989**, 161, 726-31	19
2106	Racial effect on serum creatine-kinase: implications for estimation of heterozygosity risks for females at-risk for Duchenne dystrophy. **1989**, 179, 163-8	6
2105	Transcription of the dystrophin gene in Duchenne muscular dystrophy muscle. **1989**, 252, 95-8	16
2104	Human gene for torsion dystonia located on chromosome 9q32-q34. **1989**, 2, 1427-34	207
2103	Applications of molecular genetics to gastrointestinal and liver diseases. I. Technical approaches. **1989**, 4, 183-93	2
2102	Deletion analysis for Duchenne (and Becker) muscular dystrophy. **1989**, 25, 292-5	
2101	Genetics and congenital heart disease: perspectives and prospects. **1989**, 13, 1458-68	21
2100	Molecular cardiology: new avenues for the diagnosis and treatment of cardiovascular disease. **1989**, 13, 265-82	24
2099	Tissue-specific isoforms of dystrophin. **1989**, 12, 235-8	8
2098	Dystrophin, the protein product of the Duchenne/Becker muscular dystrophy gene. **1989**, 14, 412-5	44
2097	Long-range mapping in the research and diagnosis of genetic disease. **1989**, 31, 730-6	
2096	Die Chorea Huntington - eine präsymptomatisch diagnostizierbare Erkrankung. **1989**, 16, 179-183	
2095	Proceedings of the Physiological Society, 6-7 April 1989, University College London and Middlesex School of Medicine Meeting: Communications. **1989**, 415, 79-126	
2094	Animal models of Duchenne and Becker muscular dystrophy. **1989**, 45, 703-18	40
2093	The use of high UV photon densities for physicochemical studies in the life sciences. **1989**, 93, 245-249	2
2092	Recombinant DNA and the major psychiatric disorders. **1989**, 6, 95-99	
2091	Duchenne/Becker muscular dystrophy: a short overview of the gene, the protein, and current diagnostics. **1989**, 45, 630-43	39

2090	Dystrophin diagnosis: comparison of dystrophin abnormalities by immunofluorescence and immunoblot analyses. **1989**, 86, 7154-8	126
2089	Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. **1989**, 86, 1292-6	185
2088	Oxidation state of tissue thiol groups and content of protein carbonyl groups in chickens with inherited muscular dystrophy. **1989**, 260, 359-64	109
2087	Cell fractionation studies indicate that dystrophin is a protein of surface membranes of skeletal muscle. **1989**, 258, 837-41	54
2086	Isolation of dystrophin in denatured form from rabbit skeletal muscle myofibrils.. **1989**, 65, 207-210	2
2085	Expression of a dystrophin-like protein on the surface membrane of muscle cells in mdx mice.. **1989**, 65, 238-241	9
2084	Myogenic regulation of dystrophin gene expression. **1989**, 45, 681-702	21
2083	Biochemical neonatal screening. **1990**, 300, 1667-8	2
2082	The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. **1990**, 10, 634-42	418
2081	Detection and isolation of a 30 kDa abnormal protein in avian dystrophic muscle. **1990**, 107, 51-5	4
2080	Proceedings of the Physiological Society, 5-6 January 1990, Liverpool Meeting: Communications. **1990**, 424, 6-65	
2079	The beta-adrenergic system in man: Physiological and pathophysiological response: Regulation of receptor density and functioning. **1990**, 50, 25-43	15
2078	Protein turnover is elevated in muscle of mdx mice in vivo. **1990**, 268, 795-7	38
2077	A novel product of the Duchenne muscular dystrophy gene which greatly differs from the known isoforms in its structure and tissue distribution. **1990**, 272, 557-60	167
2076	Human brain n-chimaerin cDNA encodes a novel phorbol ester receptor. **1990**, 272, 767-73	132
2075	Antiserum against the synthetic polypeptide fragment of dystrophin cross-reacts with Myofibrillar C-protein.. **1990**, 66, 19-22	
2074	Molecular shape of dystrophin purified from rabbit skeletal muscle myofibrils.. **1990**, 66, 96-99	11
2073	Paralysis of innervated cultured human muscle fibers affects enzymes differentially. **1990**, 54, 223-9	9

2072	Elevated MHC class I and II antigens in cultured human embryonic myoblasts following stimulation with gamma-interferon. **1990**, 68 (Pt 4), 235-41	41
2071	Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. **1990**, 343, 180-2	491
2070	Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. **1990**, 345, 315-9	837
2069	Localization of dystrophin to postsynaptic regions of central nervous system cortical neurons. **1990** , 348, 725-8	384
2068	Muscular dystrophies. **1990**, 57, 337-44	
2067	Calcium currents in normal and dystrophic human skeletal muscle cells in culture. **1990**, 11, 507-14	25
2066	Oxidative muscular injury and its relevance to hyperthyroidism. **1990**, 8, 293-303	105
2065	Plasma thyroxine levels in Duchenne muscular dystrophy. **1990**, 46, 301-3	
2064	Dystrophin protein and RFLP analysis for fetal diagnosis and carrier confirmation of Duchenne muscular dystrophy. **1990**, 10, 703-15	5
2063	Difference in the expression pattern of dystrophin on the surface membrane between the skeletal and cardiac muscles of mdx carrier mice. **1990**, 93, 447-52	22
2062	Developmental expression of dystrophin on the rat myocardial cell membrane. **1990**, 94, 449-53	7
2061	Heterogeneity of dystrophin expression in patients with Duchenne and Becker muscular dystrophy. **1990**, 80, 239-50	134
2060	Observations on the muscle plasma membrane-associated cytoskeletons of mdx mice by quick-freeze, deep-etch, rotary-shadow replica method. **1990**, 80, 618-23	18
2059	Effect of denervation on regenerating muscle plasma membrane integrity: freeze-fracture and dystrophin immunostaining analyses. **1990**, 80, 401-5	13
2058	Myoglobin is a sensitive marker of increased muscle membrane vulnerability. **1990**, 237, 234-8	35
2057	Duchenne muscular dystrophy: evidence for somatic reversion of the mutation in man. **1990**, 237, 494-5	9
2056	Emetine-induced myopathy and carnitine deficiency. **1990**, 237, 495-6	14
2055	From dystrophia muscularis progressiva to dystrophin. On the 150th anniversary of Wilhelm Erb's birthday. **1990**, 237, 333-5	4

2054	Direct carrier detection by in situ suppression hybridization with cosmid clones of the Duchenne/Becker muscular dystrophy locus. **1990**, 85, 581-6	77
2053	A normal male with an inherited deletion of one exon within the DMD gene. **1990**, 84, 207-9	15
2052	Aland Island eye disease (Forsius-Eriksson ocular albinism) and an Xp21 deletion in a patient with Duchenne muscular dystrophy, glycerol kinase deficiency, and congenital adrenal hypoplasia. **1990**, 36, 23-8	27
2051	Characterization of deletions in the dystrophin gene giving mild phenotypes. **1990**, 37, 136-42	28
2050	An unusual variant of Becker muscular dystrophy. **1990**, 27, 578-81	19
2049	Single skinned muscle fibers in Duchenne muscular dystrophy generate normal force. **1990**, 27, 636-41	14
2048	Dystrophin analysis in Duchenne and Becker muscular dystrophy carriers: correlation with intracellular calcium and albumin. **1990**, 28, 674-9	44
2047	Normal dystrophin in McLeod myopathy. **1990**, 28, 720-2	19
2046	Image analysis techniques for automatic evaluation of two-dimensional electrophoresis. **1990**, 11, 407-15	6
2045	Ca-dependent slow action potentials in neuromuscular diseases. **1990**, 143, 590-5	
2044	Analysis of dystrophin in fast- and slow-twitch skeletal muscles from mdx and dy2J mice at different ages. **1990**, 13, 6-11	22
2043	Excitation contraction coupling in normal and mdx mice. **1990**, 13, 16-20	67
2042	Dystrophin is localized to the plasma membrane of human skeletal muscle fibers by electron-microscopic cytochemical study. **1990**, 13, 376-80	54
2041	A noninvasive procedure to detect muscle weakness in the mdx mouse. **1990**, 13, 480-4	67
2040	Immunocytochemical study of dystrophin at the myotendinous junction. **1990**, 13, 493-500	86
2039	Serum parvalbumin, an indicator of muscle disease in murine dystrophy and myotonia. **1990**, 13, 551-5	17
2038	Neuromuscular transmission in the mdx mouse. **1990**, 13, 742-9	64
2037	Soleus-specific myopathy induced by passive stretching under local tetanus. **1990**, 13, 923-32	6

2036	A tetrodotoxin- and Mn2(+)-insensitive Na+ current in Duchenne muscular dystrophy. **1990**, 13, 939-48	10
2035	Duchenne and Becker Muscular Dystrophies: Genetics, Prenatal Diagnosis, and Future Prospects. **1990**, 17, 845-863	21
2034	Antibody against the C-terminal portion of dystrophin crossreacts with the 400 kDa protein in the pia mater of dystrophin-deficient mdx mouse brain. **1990**, 107, 510-3	39
2033	[Dystrophin in the differentiation between Duchenne and Becker muscular dystrophies: an immunohistochemical study compared with clinical stage, serum enzymes and muscle biopsy]. **1990** , 48, 454-64	5
2032	In vitro Processing of Aleurain, a Barley Vacuolar Thiol Protease. **1990**, 2, 1091	14
2031	mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. **1990**, 10, 1609-21	231
2030	Inheritance of Kidney and Urinary Tract Diseases. **1990**,	
2029	Asymptomatic hyperCKemia: detection of an isolated carrier of Duchenne muscular dystrophy. **1990**, 5, 351-3	10
2028	A beta-spectrin isoform from Drosophila (beta H) is similar in size to vertebrate dystrophin. **1990**, 111, 1849-58	69
2027	In Vitro Processing of Aleurain, a Barley Vacuolar Thiol Protease. **1990**, 2, 1091-1106	92
2026	Book Review: XVIIth Epilepsy International Symposium (Advances in Epileptology, volume 17), edited by Judith Manelis, Ephraim Bental, Joop N. Loeber, and Fritz E. Dreifuss. Published in 1989 by Raven Press, New York, 527 pages, $135.00. **1990**, 5, 353-354	
2025	Isolated dystrophin molecules as seen by electron microscopy. **1990**, 87, 7851-5	77
2024	Increased activity of calcium leak channels in myotubes of Duchenne human and mdx mouse origin. **1990**, 250, 673-6	326
2023	Physiological properties of skinned fibres from normal and dystrophic (Duchenne) human muscle activated by Ca2+ and Sr2+. **1990**, 420, 337-53	64
2022	Normal myogenic cells from newborn mice restore normal histology to degenerating muscles of the mdx mouse. **1990**, 111, 2437-49	214
2021	Becker muscular dystrophy: correlation of deletion type with clinical severity. **1990**, 27, 236-9	25
2020	The dystrophin gene is autosomally located on a microchromosome in chicken. **1990**, 8, 536-40	17
2019	Dystrophin: a clinical perspective. **1990**, 6, 3-12	24

2018	Dystrophin analysis in the differential diagnosis of autosomal recessive muscular dystrophy of childhood and Duchenne muscular dystrophy. **1990**, 6, 265-8		3
2017	Mosaic pattern of dystrophins in Duchenne muscular dystrophy. **1990**, 6, 54-6		6
2016	Etiology of intellectual impairment in Duchenne muscular dystrophy. **1990**, 6, 57-9		25
2015	Ultrastructural localization of dystrophin in human muscle by using gold immunolabelling. **1990**, 240, 197-210		86
2014	Approaches to the Diagnosis of Renal Genetic Disorders Using DNA Analysis. **1990**, 53-63		
2013	Dystrophin-deficient mdx muscle fibers are preferentially vulnerable to necrosis induced by experimental lengthening contractions. **1990**, 100, 9-13		188
2012	Canine X-linked muscular dystrophy: morphologic lesions. **1990**, 97, 1-23		89
2011	Changes in surface morphology and basal lamina of cultured muscle cells from Duchenne muscular dystrophy patients. **1990**, 95, 77-88		16
2010	Age-related calmitine distribution in mitochondria of normal and mdx mouse skeletal muscle. **1990**, 99, 349-53		5
2009	Somatic reversion/suppression of the mouse mdx phenotype in vivo. **1990**, 99, 9-25		260
2008	Kinetic properties and isozyme composition of myosin in the mdx mutant mouse. **1990**, 97, 207-19		1
2007	Immunoreactivity of antibodies raised against synthetic peptide fragments predicted from mid portions of dystrophin cDNA. **1990**, 97, 241-50		28
2006	Degradation of connectin (titin) in Fukuyama type congenital muscular dystrophy: immunochemical study with monoclonal antibodies. **1990**, 98, 155-62		9
2005	Dystrophin immunostaining in muscles from patients with different types of muscular dystrophy: a Brazilian study. **1990**, 98, 221-33		33
2004	Effect of dystrophin gene deletions on mRNA levels and processing in Duchenne and Becker muscular dystrophies. *Cell*, **1990**, 63, 1239-48	56.2	153
2003	The incidence and evolution of cardiomyopathy in Duchenne muscular dystrophy. **1990**, 26, 271-7		506
2002	Specificity of expression of the muscle and brain dystrophin gene promoters in muscle and brain cells. **1990**, 5, 881-8		65
2001	Structural predictions for the central domain of dystrophin. **1990**, 262, 87-92		51

2000	Monoclonal antibodies against defined regions of the muscular dystrophy protein, dystrophin. **1990**, 262, 237-40	42
1999	A second isoform of chicken brush border myosin I contains a 29-residue inserted sequence that binds calmodulin. **1990**, 267, 126-30	46
1998	Monoclonal antibody evidence for structural similarities between the central rod regions of actinin and dystrophin. **1990**, 272, 109-12	18
1997	Dystrophin as a focal adhesion protein. Collocalization with talin and the Mr 48,000 sarcolemmal protein in cultured Xenopus muscle. **1990**, 274, 171-4	38
1996	Identification of dystrophin in cardiac sarcolemmal vesicles. **1990**, 169, 565-70	5
1995	Detection of a fast isoform of C-protein with an antiserum directed against the N-terminal portion of dystrophin. **1990**, 169, 57-63	4
1994	Molecular genetics of Duchenne and Becker muscular dystrophy. **1990**, 117, 1-15	47
1993	Genetic aspects of Wilson's disease. **1990**, 5, 483-90	55
1992	Gold-labelled dystrophin molecule in muscle plasmalemma of mdx control mice as seen by electron microscopy of deep etching replica. **1991**, 82, 178-84	21
1991	Dystrophin and disease. **1991**, 12, 175-94	29
1990	Duchenne's cardiomyopathy in a canine model: electrocardiographic and echocardiographic studies. **1991**, 17, 812-20	67
1989	Recent advances in neuromuscular disorders in childhood. **1991**, 33, 198-205	5
1988	Myoblast transfer therapy for Duchenne muscular dystrophy. **1991**, 33, 206-15	39
1987	Dystrophin abnormality in progressive muscular dystrophy--a review article. **1991**, 33, 216-21	1
1986	Cystic fibrosis and seizures. **1991**, 338, 259	7
1985	Vascular alterations in Fukuyama type congenital muscular dystrophy. **1991**, 13, 77-81	13
1984	Fetal dystrophin to diagnose carrier status. **1991**, 338, 258-9	5
1983	Allografts of muscle precursor cells persist in the non-tolerized host. **1991**, 1, 345-55	11

1982	Dystrophin-related protein is localized to neuromuscular junctions of adult skeletal muscle. **1991**, 7, 499-508	334
1981	Dystrophin in central nervous system: a developmental, regional distribution and subcellular localization study. **1991**, 124, 87-91	35
1980	Steroids in Duchenne muscular dystrophy--deflazacort trial. **1991**, 1, 261-6	80
1979	Canine X-linked muscular dystrophy: selective involvement of muscles in neonatal dogs. **1991**, 1, 31-8	44
1978	Dystrophin in control and mdx retina. **1991**, 13, 135-7	23
1977	Appearance and localization of dystrophin in normal human fetal muscle. **1991**, 9, 607-12	14
1976	Recent advances in dystrophin research. **1991**, 1, 420-9	22
1975	Dystrophin abnormalities in polymyositis and dermatomyositis. **1991**, 1, 333-9	9
1974	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy. **1991**, 165, 728-32	38
1973	Energy status of cells lacking dystrophin: an in vivo/in vitro study of mdx mouse skeletal muscle. **1991**, 1096, 115-20	41
1972	Congenital muscular dystrophy in Marinesco-Sj□gren syndrome. **1991**, 7, 296-8	13
1971	Passive avoidance behaviour deficit in the mdx mouse. **1991**, 1, 121-3	81
1970	Analysis of a dystrophin gene deletion by amplification of mRNA isolated from DMD myotubes cultured in vitro. **1991**, 10, 551-7	6
1969	Point mutation in the human dystrophin gene: identification through western blot analysis. **1991**, 10, 457-60	71
1968	Myotube phospholipid synthesis and sarcolemmal ATPase activity in dystrophic (mdx) mouse muscle. **1991**, 69, 835-41	15
1967	Dystrophin: a sensitive and reliable immunochemical assay in tissue and cell culture homogenates. **1991**, 181, 1164-72	22
1966	A homologue of dystrophin is expressed at the neuromuscular junctions of normal individuals and DMD patients, and of normal and mdx mice. Immunological evidence. **1991**, 282, 161-5	70
1965	Dystrophin constitutes 5% of membrane cytoskeleton in skeletal muscle. **1991**, 283, 230-4	68

1964	Dystrophin is tightly associated with the sarcolemma of mammalian skeletal muscle fibers. **1991**, 192, 278-88		36
1963	Skeletal muscle cytochrome c in X-linked muscle dystrophies. **1991**, 202, 89-93		
1962	Fiber regeneration is not persistent in dystrophic (MDX) mouse skeletal muscle. **1991**, 148, 314-21		161
1961	Developmental study of the expression of dystrophin in cultured human muscle aneurally and innervated with fetal rat spinal cord. **1991**, 565, 280-9		14
1960	Negative halothane-caffeine contracture test in mdx (dystrophin-deficient) mice. **1991**, 40, 883-7		2
1959	Identification of glycoconjugates which are targets for anti-Gal(beta 1-3)GalNAc autoantibodies in spinal motor neurons. **1991**, 34, 69-76		21
1958	Membrane organization of the dystrophin-glycoprotein complex. *Cell*, **1991**, 66, 1121-31	56.2	1130
1957	Developmental regulation of mechanosensitive calcium channels in skeletal muscle from normal and mdx mice. **1991**, 245, 173-7		35
1956	Asthma, atopy, and genetic linkage. **1991**, 629, 26-30		14
1955	Mechanisms of exercise-induced muscle fibre injury. **1991**, 12, 184-207		367
1954	Methylprednisolone increases dystrophin levels by inhibiting myotube death during myogenesis of normal human muscle in vitro. **1991**, 101, 73-81		48
1953	Molecular diagnostics of Duchenne/Becker dystrophy: new additions to a rapidly expanding literature. **1991**, 101, 129-32		8
1952	Immunofluorescence dystrophin study in Duchenne dystrophy through the concomitant use of two antibodies directed against the carboxy-terminal and the amino-terminal region of the protein. **1991**, 101, 141-7		44
1951	Preservation of the C-terminus of dystrophin molecule in the skeletal muscle from Becker muscular dystrophy. **1991**, 101, 148-56		83
1950	Is dystrophin labelling always discontinuous in Becker muscular dystrophy?. **1991**, 101, 187-92		9
1949	Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy. **1991**, 102, 190-6		110
1948	Characterisation of dystrophin in carriers of Duchenne muscular dystrophy. **1991**, 102, 197-205		44
1947	Immunocytochemical analysis of dystrophin in congenital muscular dystrophy. **1991**, 105, 79-87		39

1946	Total ion content of skeletal and cardiac muscle in the mdx mouse dystrophy: Ca2+ is elevated at all ages. **1991**, 103, 226-31	61
1945	Limb-girdle syndrome: a genetic study of 22 large Brazilian families. Comparison with X-linked Duchenne and Becker dystrophies. **1991**, 103, 65-75	10
1944	Muscle regeneration after imposed injury is better in younger than older mdx dystrophic mice. **1991**, 104, 190-6	38
1943	Normal transitions in synthesis of replacement histones H2A.Z and H3.3 during differentiation of dystrophic myotube cells. A brief note. **1991**, 59, 299-305	9
1942	Nerve growth factor receptor immunoreactivity on the tunica adventitia of intramuscular blood vessels in childhood muscular dystrophies. **1991**, 1, 135-41	8
1941	Dystrophin immunofluorescence pattern in manifesting and asymptomatic carriers of Duchenne's and Becker muscular dystrophies of different ages. **1991**, 1, 177-83	16
1940	Mobility of tibial tuberosity in Osgood-Schlatter's disease. **1991**, 338, 259-60	1
1939	Immunolocalization and developmental expression of dystrophin related protein in skeletal muscle. **1991**, 1, 185-94	221
1938	Localization of dystrophin relative to acetylcholine receptor domains in electric tissue and adult and cultured skeletal muscle. **1991**, 113, 1133-44	132
1937	Free radicals, calcium and damage in dystrophic and normal skeletal muscle. **1991**, 139-148	1
1936	Sodium current and membrane potential in EDL muscle fibers from normal and dystrophic (mdx) mice. **1991**, 261, C718-25	17
1935	Estimate of the intrafamilial correlation for serum creatine kinase and pyruvate kinase in females at risk for Duchenne and Becker muscular dystrophies. **1991**, 41, 370-8	
1934	Molecular analysis of X-autosome translocations in females with Duchenne muscular dystrophy.. **1991**, 10, 3931-3939	18
1933	Chapter 8 The Animal Models of Duchenne Muscular Dystrophy: Windows on the Pathophysiological Consequences of Dystrophin Deficiency. **1991**, 113-154	40
1932	Duchenne's muscular dystrophy: review and recent scientific findings. **1991**, 302, 118-23	5
1931	Mapping of human microtubule-associated protein 1B in proximity to the spinal muscular atrophy locus at 5q13. **1991**, 88, 7873-6	59
1930	Proceedings of the Physiological Society, 25-26 March 1991, University College of London Meeting: Communications. **1991**, 438, 145-204	
1929	[Importance of germ cell mosaic for genetic counseling of families with Duchenne and Becker muscular dystrophy]. **1991**, 203, 354-8	3

1928	Antibody-decorated Dystrophin Molecule of Murine Skeletal Myofiber as Seen by Freeze-etching Electron Microscopy. **1991**,	
1927	Proceedings of the Physiological Society, 9-10 November 1990, Mill Hill Meeting: Communications. **1991**, 434, 9-68	2
1926	Proceedings of the Physiological Society, 25-26 March 1991, University College of London Meeting: Communications. **1991**, 438, 145-204	
1925	Effects of contractile activity on muscle damage in the dystrophin-deficient mdx mouse. **1991**, 80, 367-71	48
1924	Glutathione depletion during experimental damage to rat skeletal muscle and its relevance to Duchenne muscular dystrophy. **1991**, 80, 559-64	11
1923	Acute effects of phorbol esters on the protein-synthetic rate and carbohydrate metabolism of normal and mdx mouse muscles. **1991**, 275 (Pt 2), 477-83	15
1922	Prostaglandin metabolism in dystrophin-deficient MDX mouse muscle. **1991**, 19, 177S	7
1921	DNA concentrations are increased in mdx mouse muscles. **1991**, 19, 178S	
1920	Enhanced lipid peroxidation in Duchenne dystrophy muscle may be secondary to muscle damage. **1991**, 19, 180S	8
1919	A Dystrophin Homologue on the Surface Membrane of Embryonic and Denervated mdx Mouse Muscle Fibers.. **1991**, 67, 125-128	1
1918	Electrophoresis of mutant proteins in inherited diseases. **1991**, 569, 407-19	1
1917	Force transmission across muscle cell membranes. **1991**, 24 Suppl 1, 43-52	133
1916	Molecular study of Duchenne and Becker muscular dystrophies in Japanese. **1991**, 14, 819-24	5
1915	Altered allosteric properties of cytoskeleton-bound phosphofructokinase in muscle from mice with X chromosome-linked muscular dystrophy (mdx). **1991**, 45, 319-25	19
1914	Molecular biology of human muscle disease. **1991**, 9, 41-6	3
1913	Decreased osmotic stability of dystrophin-less muscle cells from the mdx mouse. **1991**, 349, 69-71	301
1912	Expression of recombinant dystrophin and its localization to the cell membrane. **1991**, 349, 334-6	84
1911	The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. **1991**, 352, 536-9	734

1910	Gene therapy. Muscle transfection made easy. **1991**, 352, 757-8	14
1909	Human dystrophin expression in mdx mice after intramuscular injection of DNA constructs. **1991**, 352, 815-8	446
1908	Changes in muscle plasma membranes in young mice with X chromosome-linked muscular dystrophy: a freeze-fracture study. **1991**, 17, 335-44	12
1907	Animal models of muscular dystrophy--what can they teach us?. **1991**, 17, 353-63	68
1906	Different localization of dystrophin in developing and adult human skeletal muscle. **1991**, 14, 1-7	48
1905	X-irradiation improves mdx mouse muscle as a model of myofiber loss in DMD. **1991**, 14, 42-50	129
1904	Dystrophin: localization and presumed function. **1991**, 14, 113-9	65
1903	Invited review: myoblast transfer: a possible therapy for inherited myopathies?. **1991**, 14, 197-212	207
1902	Dystrophic changes in mdx muscle regenerating from denervation and devascularization. **1991**, 14, 268-79	38
1901	Assessment of locomotor function in young boys with Duchenne muscular dystrophy. **1991**, 14, 462-9	8
1900	Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. **1991**, 14, 771-4	30
1899	Antidystrophin stains triadic junctions in regenerating rat muscles. **1991**, 14, 1177-81	6
1898	Linkage analysis in families with autosomal recessive limb-girdle muscular dystrophy (LGMD) and 6q probes flanking the dystrophin-related sequence. **1991**, 38, 140-6	7
1897	DNA polymorphisms and deletion analysis of the Duchenne-Becker muscular dystrophy gene in the Chinese. **1991**, 38, 593-600	13
1896	Screening of male patients with autosomal recessive Duchenne dystrophy through dystrophin and DNA studies. **1991**, 39, 38-41	11
1895	Three years' experience with neonatal screening for Duchenne/Becker muscular dystrophy: gene analysis, gene expression, and phenotype prediction. **1991**, 39, 68-75	24
1894	Discordance of muscular dystrophy in monozygotic female twins: evidence supporting asymmetric splitting of the inner cell mass in a manifesting carrier of Duchenne dystrophy. **1991**, 40, 354-64	68
1893	Single-gene neurological disorders in South Wales: an epidemiological study. **1991**, 30, 411-4	26

1892	Is the carboxyl-terminus of dystrophin required for membrane association? A novel, severe case of Duchenne muscular dystrophy. **1991**, 30, 605-10	86
1891	Human monoclonal antineurofilament antibody cross-reacts with a neuronal surface protein. **1991**, 29, 319-25	15
1890	Hereditary human myopathies in muscle culture. **1991**, 12, 257-68	3
1889	Is dystrophin present in the nerve terminal at the neuromuscular junction? An immunohistochemical study of the heterozygote dystrophic (mdx) mouse. **1991**, 7, 135-40	12
1888	Duchenne muscular dystrophy and dystrophin: sequence homology observations. **1991**, 16, 681-6	6
1887	Structure and function of the neuromuscular junction in young adult mdx mice. **1991**, 20, 969-81	154
1886	Expression of a dystrophin-related protein associated with the skeletal muscle cell membrane. **1991**, 96, 1-5	70
1885	Genotype-phenotype correlation and germline mosaicism in DMD/BMD patients with deletions of the dystrophin gene. **1991**, 87, 353-60	16
1884	Molecular deletion patterns in families from southern France with Duchenne/Becker muscular dystrophies. **1991**, 88, 179-84	7
1883	Experimental serotonin myopathy as an animal model of muscle degeneration and regeneration in muscular dystrophy. **1991**, 81, 510-6	8
1882	Dystrophin immunohistochemistry in a symptomatic carrier of Becker muscular dystrophy. **1991**, 238, 375-8	5
1881	Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin. **1991**, 19, 5889-94	29
1880	Localization of the DMDL gene-encoded dystrophin-related protein using a panel of nineteen monoclonal antibodies: presence at neuromuscular junctions, in the sarcolemma of dystrophic skeletal muscle, in vascular and other smooth muscles, and in proliferating brain cell lines. **1991**, 115, 1695-700	249
1879	Dystrophin-glycoprotein complex is highly enriched in isolated skeletal muscle sarcolemma. **1991**, 112, 135-48	258
1878	The subcellular distribution of dystrophin in mouse skeletal, cardiac, and smooth muscle. **1991**, 115, 411-21	213
1877	Dystrophin is a component of the subsynaptic membrane. **1991**, 115, 1069-76	51
1876	Dystrophin-associated proteins are greatly reduced in skeletal muscle from mdx mice. **1991**, 115, 1685-94	371
1875	Dystrophin as a diagnostic marker in Duchenne and Becker muscular dystrophy. Correlation of immunofluorescence and western blot. **1991**, 22, 152-62	34

1874 Myopathies and cardiomyopathies: histochemical and biochemical analyses. **1991**, 12 Suppl D, 169-70 11

1873 Dystrophin is transcribed in brain from a distant upstream promoter. **1991**, 88, 1276-80 167

1872 Identification of the neurofibromatosis type 1 gene product. **1991**, 88, 9658-62 225

1871 Molecular basis of mouse developmental mutants. **1991**, 5, 1115-23 42

1870 A Japanese family with two types of muscular dystrophy: DNA analysis and the dystrophin test. **1991**, 6, 251-6 4

1869 Increased calcium influx in dystrophic muscle. **1991**, 115, 1701-12 236

1868 Immunohistochemical studies show truncated dystrophins in the myotubes of three fetuses at risk for Duchenne muscular dystrophy. **1991**, 28, 505-10 8

1867 Review. **1991**, 29,

1866 A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy. **1991**, 48, 575-9 100

1865 Tissue distribution of the dystrophin-related gene product and expression in the mdx and dy mouse. **1991**, 88, 3243-7 114

1864 Myopathies. **1991**, 1, 359-370

1863 Reduced level of epidermal growth factor in the skeletal muscle of mice with muscular dystrophy. **1992**, 24, 138-9 4

1862 The frequency of revertants in mdx mouse genetic models for Duchenne muscular dystrophy. **1992**, 32, 128-31 124

1861 The man behind the syndrome: Guillaume Duchenne. **1992**, 1, 145-54 2

1860 Confocal laser microscopy of dystrophin localization in guinea pig skeletal muscle fibers. **1992**, 119, 543-8 74

1859 Expression and localization of dystrophin in human cardiac Purkinje fibers. **1992**, 86, 147-53 62

1858 Human and murine dystrophin mRNA transcripts are differentially expressed during skeletal muscle, heart, and brain development. **1992**, 20, 1725-31 141

1857 UK clinicians' knowledge of and attitudes to the prenatal diagnosis of single gene disorders. **1992**, 29, 20-3 23

1856	Dystrophin colocalizes with beta-spectrin in distinct subsarcolemmal domains in mammalian skeletal muscle. **1992**, 117, 997-1005	199
1855	Recent advances in understanding muscular dystrophy. **1992**, 67, 1310-2	8
1854	The subcellular distribution of chromosome 6-encoded dystrophin-related protein in the brain. **1992**, 119, 357-66	97
1853	Localization of dystrophin COOH-terminal domain by the fracture-label technique. **1992**, 118, 1401-9	16
1852	Direct visualization of the dystrophin network on skeletal muscle fiber membrane. **1992**, 119, 1183-91	128
1851	Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame. **1992**, 29, 892-6	27
1850	A TaqI map of the dystrophin gene useful for deletion and carrier status analysis. **1992**, 29, 14-9	4
1849	Gene Transfer and Therapy in the Nervous System. **1992**,	3
1848	Molecular biology of neurological diseases. **1992**, 68, 237-41	1
1847	The muscular dystrophies. **1992**, 68, 500-6	9
1846	Distal transcript of the dystrophin gene initiated from an alternative first exon and encoding a 75-kDa protein widely distributed in nonmuscle tissues. **1992**, 89, 7506-10	126
1845	Acidic fibroblast growth factor (aFGF) in developing normal and dystrophic (mdx) mouse muscles. Distribution in degenerating and regenerating mdx myofibres. **1992**, 7, 97-106	32
1844	A human gene (AHNAK) encoding an unusually large protein with a 1.2-microns polyionic rod structure. **1992**, 89, 5472-6	106
1843	Perturbations of Drosophila alpha-actinin cause muscle paralysis, weakness, and atrophy but do not confer obvious nonmuscle phenotypes. **1992**, 116, 911-22	65
1842	Quantitative Southern blot analysis in the dystrophin gene of Japanese patients with Duchenne or Becker muscular dystrophy: a high frequency of duplications. **1992**, 29, 897-901	19
1841	Contractile properties and susceptibility to exercise-induced damage of normal and mdx mouse tibialis anterior muscle. **1992**, 82, 227-36	93
1840	Accumulation of calcium by normal and dystrophin-deficient mouse muscle during contractile activity in vitro. **1992**, 82, 455-9	28
1839	Evolutionary conservation of the dystrophin central rod domain. **1992**, 287 (Pt 3), 755-9	49

1838	Demonstration of cathepsins B, H and L in xenografts of normal and Duchenne-muscular-dystrophy muscles transplanted into nude mice. **1992**, 288 (Pt 2), 643-8	21
1837	Monoclonal antibodies for dystrophin analysis. Epitope mapping and improved binding to SDS-treated muscle sections. **1992**, 288 (Pt 2), 663-8	39
1836	Isolation and characterization of different C-terminal fragments of dystrophin expressed in Escherichia coli. **1992**, 288 (Pt 3), 1037-44	26
1835	Current status of Duchenne muscular dystrophy. **1992**, 39, 879-94	12
1834	Where are the guidelines for treating hypertension in elderly patients?. **1992**, 305, 845-6	8
1833	Transferring myoblasts in Duchenne dystrophy. **1992**, 305, 844-5	1
1832	Feasibility, safety, and efficacy of myoblast transfer therapy on Duchenne muscular dystrophy boys. **1992**, 1, 235-44	90
1831	Detection of dystrophin in the postsynaptic density of rat brain and deficiency in a mouse model of Duchenne muscular dystrophy. **1992**, 89, 11642-4	120
1830	Proteinase-sensitive sites on isolated rabbit dystrophin. **1992**, 112, 433-9	33
1829	Cardiac Electrophysiology in Duchenne Muscular Dystrophy: From Basic Science to Clinical Expression. **1992**, 3, 394-409	14
1828	Possible influences on the expression of X chromosome-linked dystrophin abnormalities by heterozygosity for autosomal recessive Fukuyama congenital muscular dystrophy. **1992**, 89, 623-7	22
1827	Anesthesia-induced rhabdomyolysis in infants with unsuspected Duchenne dystrophy. **1992**, 81, 716-9	16
1826	Cognitive functions in Duchenne muscular dystrophy: a reappraisal and comparison with spinal muscular atrophy. **1992**, 2, 371-8	111
1825	Mosaic expression of dystrophin in the cerebellum of heterozygote dystrophic (mdx) mice. **1992**, 2, 311-21	5
1824	Myoblast transfer in muscular dystrophy: panacea or pie in the sky?. **1992**, 2, 305-10	4
1823	The molecular and biochemical basis of Duchenne muscular dystrophy. **1992**, 17, 289-92	53
1822	Dystrophin at the plasma membrane of human muscle fibers shows a costameric localization. **1992**, 2, 99-109	58
1821	Identification of a 2 base pair nonsense mutation causing a cryptic splice site in a DMD patient. **1992**, 1, 645-6	27

1820	Prenatal diagnosis of Duchenne muscular dystrophy by fetal muscle biopsy. **1992**, 90, 34-40	17
1819	Upper gastrointestinal tract motility in children with progressive muscular dystrophy. **1992**, 121, 720-4	25
1818	Congenital myopathy associated with abnormal accumulation of desmin and dystrophin. **1992**, 2, 169-75	26
1817	Absence of dystrophin in two patients with Becker type Xp21 muscular dystrophy. **1992**, 147, 37-40	4
1816	Immunoreactivity of skate electrocytes towards monoclonal antibodies against human dystrophin and dystrophin-related (DMDL) protein. **1992**, 138, 27-31	3
1815	Localization of dystrophin in the Purkinje cells of normal mice. **1992**, 137, 105-8	37
1814	Neonatal screening for Duchenne/Becker muscular dystrophy; Reconsideration based on molecular diagnosis and potential therapeutics. **1992**, 1, 99-113	10
1813	[Homologies between membrane proteins result in expected or unexpected relations between neuromuscular and erythrocyte diseases]. **1992**, 13, 156-61	2
1812	Human-mouse homologies in the region of the polycystic kidney disease gene (PKD1). **1992**, 13, 35-8	23
1811	Prevention of myonecrosis in mdx mice: effect of immobilization by the local tetanus method. **1992** , 14, 319-22	18
1810	Dystrophin-like immunoreactivity in monkey and human brain areas involved in learning and motor functions. **1992**, 141, 181-6	25
1809	Phenotypic Duchenne muscular dystrophy with C-terminal domain. **1992**, 8, 310-2	4
1808	Localization of dystrophin and dystrophin-related protein at the electromotor synapse and neuromuscular junction in Torpedo marmorata. **1992**, 48, 995-1003	35
1807	Dystrophin deficiency causes lethal muscle hypertrophy in cats. **1992**, 110, 149-59	104
1806	Increased leakage of calcium ion from the sarcoplasmic reticulum of the mdx mouse. **1992**, 110, 160-4	36
1805	Delayed expression of dystrophin on regenerating muscle from two siblings with Becker muscular dystrophy. **1992**, 110, 165-8	6
1804	Dystrophin isoforms and/or cross-reactive proteins on neurons and glial cells in control and mdx central nervous systems. **1992**, 108, 214-20	15
1803	Characterisation of dystrophin in fetuses at risk for Duchenne muscular dystrophy. **1992**, 111, 82-91	14

1802	31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport. **1992**, 109, 188-95	47
1801	Calcium, calmodulin and 3',5'-cyclic nucleotide phosphodiesterase activity in human muscular disorders. **1992**, 109, 215-8	5
1800	A 31P-NMR study of muscle exercise metabolism in mdx mice: evidence for abnormal pH regulation. **1992**, 113, 108-13	30
1799	A homologue of dystrophin is expressed at the blood vessel membrane of DMD and BMD patients: immunological evidence. **1992**, 107, 233-8	10
1798	A human skeletal muscle cell line obtained from an adult donor. **1992**, 1134, 247-55	13
1797	The long QT syndrome: a G or not a G?. **1992**, 20, 504-5	4
1796	Abnormalities in structure and function of limb skeletal muscle fibres of dystrophic mdx mice. **1992** , 248, 163-9	106
1795	Alterations of protein degradation and 2-D protein pattern in muscle cells of MDX and DMD origin. **1992**, 189, 1484-90	13
1794	Calmodulin specifically binds three proteins of the dystrophin-glycoprotein complex. **1992**, 185, 753-9	45
1793	Myocardial patchy staining of dystrophin in Becker's muscular dystrophy associated with cardiomyopathy. **1992**, 123, 1088-9	15
1792	Regulation of intracellular free calcium in normal and dystrophic mouse cerebellar neurons. **1992**, 578, 49-54	36
1791	Calpain concentration is elevated although net calcium-dependent proteolysis is suppressed in dystrophin-deficient muscle. **1992**, 203, 107-14	45
1790	PDGF-receptor concentration is elevated in regenerative muscle fibers in dystrophin-deficient muscle. **1992**, 203, 141-9	22
1789	Expression of the N-terminal domain of dystrophin in E. coli and demonstration of binding to F-actin. **1992**, 301, 243-5	117
1788	Retroviral-mediated transfer of a dystrophin minigene into mdx mouse myoblasts in vitro. **1992**, 296, 128-34	65
1787	Quantitative analysis of dystrophin in fast- and slow-twitch mammalian skeletal muscle. **1992**, 304, 187-91	22
1786	Glycoprotein-binding site of dystrophin is confined to the cysteine-rich domain and the first half of the carboxy-terminal domain. **1992**, 308, 154-60	163
1785	Construction of dystrophin fusion proteins to raise targeted antibodies to different epitopes. **1992**, 308, 293-7	3

1784	[Early differentiation between Duchenne and Becker muscular dystrophy: clinical, laboratory, electrophysiology, histochemical, and immunohistochemical study of 138 cases]. **1992**, 50, 468-77	4
1783	Molecular Genetic Analysis of Duchenne/Becker Muscular Dystrophy Families1. **1992**, 46-59	
1782	Desmin and vimentin as markers of regeneration in muscle diseases. **1992**, 85, 88-92	71
1781	The fate of dystrophin during the degeneration and regeneration of the soleus muscle of the rat. **1992**, 83, 140-8	16
1780	Dystrophin and a dystrophin-related protein in intrafusal muscle fibers, and neuromuscular and myotendinous junctions. **1992**, 84, 141-6	21
1779	The mouse pink-eyed dilution locus: a model for aspects of Prader-Willi syndrome, Angelman syndrome, and a form of hypomelanosis of Ito. **1992**, 3, 187-91	34
1778	A light and electron microscopic study of dystrophin localization at the mouse neuromuscular junction. **1992**, 10, 83-93	13
1777	Diagnostic approaches to renal genetic disorders using DNA analysis. **1992**, 6, 113-8	
1776	Dystrophin deficiency in a case of congenital myopathy. **1992**, 239, 76-8	19
1775	Immunocytochemical study of dystrophin in cultured mouse muscle cells by the quick-freezing and deep-etching method. **1992**, 24, 383-92	7
1774	Primary structure of dystrophin-associated glycoproteins linking dystrophin to the extracellular matrix. **1992**, 355, 696-702	1194
1773	Normal dystrophin transcripts detected in Duchenne muscular dystrophy patients after myoblast transplantation. **1992**, 356, 435-8	363
1772	Deficiency of the 50K dystrophin-associated glycoprotein in severe childhood autosomal recessive muscular dystrophy. **1992**, 359, 320-2	234
1771	RADIOGRAPHIC AND ULTRASONOGRAPHIC FEATURES OF HYPERTROPHIC FELINE MUSCULAR DYSTROPHY IN TWO CATS. **1992**, 33, 357-364	11
1770	Normal hearing in Splotch (Sp/+), the mouse homologue of Waardenburg syndrome type 1. **1992**, 2, 75-9	75
1769	Molecular biology for the cardiologist. **1992**, 17, 1-72	
1768	Molecular analysis of the fragile X syndrome. **1992**, 15, 532-8	0
1767	Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene. **1992**, 15, 539-50	13

1766	The membrane hypothesis of Duchenne muscular dystrophy: quest for functional evidence. **1992**, 15, 565-77	28
1765	Somatic mosaicism for a deletion of the dystrophin gene in a carrier of Becker muscular dystrophy. **1992**, 151, 112-6	11
1764	Prenatal Diagnosis of Duchenne Muscular Dystrophy (DMD) by the Polymerase Chain Reaction (PCR). **1992**, 32, 179-184	1
1763	Dystrophin or a "related protein" in Duchenne muscular dystrophy?. **1992**, 86, 8-14	44
1762	Carrier detection of deletions in female relatives of X-linked disorders by non-isotopic in situ hybridisation. **1992**, 14, 421-6	3
1761	Cell transplantation and gene therapy in muscular dystrophy. **1992**, 14, 641-5	35
1760	Effect of low Ca2+ solution on muscle contraction of developing, preclinical dystrophic (dy2j) mice. **1992**, 15, 77-86	2
1759	Myosin isoforms in hindlimb muscles of normal and dystrophic (ReJ129 dy/dy) mice. **1992**, 15, 199-208	15
1758	Becker muscular dystrophy: detection of unusual disease courses by combined approach to dystrophin analysis. **1992**, 15, 214-8	38
1757	Lack of anionic phospholipid calcium binding sites in Duchenne muscular dystrophy. **1992**, 15, 325-31	5
1756	Muscle energy metabolism in female DMD/BMD carriers: a 31P-MR spectroscopy study. **1992**, 15, 344-8	35
1755	Human myoblast transplantation: preliminary results of 4 cases. **1992**, 15, 550-60	209
1754	Differential expression of muscular dystrophy in diaphragm versus hindlimb muscles of mdx mice. **1992**, 15, 1105-10	112
1753	A PCR-based assay for the wild-type dystrophin gene transferred into the mdx mouse. **1992**, 15, 1133-7	17
1752	Canine X-linked muscular dystrophy as an animal model of Duchenne muscular dystrophy: a review. **1992**, 42, 352-6	93
1751	Two distinct mutations in a single dystrophin gene: chance occurrence or premutation?. **1992**, 42, 688-92	19
1750	Molecular genetic and immunological analysis of dystrophin of a young patient with X-linked muscular dystrophy. **1992**, 43, 580-7	6
1749	X inactivation and dystrophin studies in a t(X;12) female: evidence for biochemical normalization in Duchenne muscular dystrophy carriers. **1992**, 43, 1012-5	16

1748	Additional dystrophin fragment in Becker muscular dystrophy may result from proteolytic cleavage at deletion junctions. **1992**, 44, 378-81	9
1747	Additional dystrophin fragment in Becker muscular dystrophy patients: correlation with the pattern of DNA deletion. **1992**, 44, 382-4	7
1746	The first decade of molecular genetics in neurology: changing clinical thought and practice. **1992**, 32, 207-14	8
1745	The potential for gene therapy in Duchenne muscular dystrophy and other genetic muscle diseases. **1993**, 16, 1141-53	53
1744	Constructing reference ranges. **1993**, 16, 1415-6	1
1743	Dystrophin as a mechanochemical transducer in skeletal muscle. **1993**, 15, 413-9	38
1742	Distribution of dystrophin and neurofilament protein in muscle spindles of normal and Mdx-dystrophic mice: an immunocytochemical study. **1993**, 235, 501-10	10
1741	Three-dimensional cytoarchitecture of complex branched fibers in soleus muscle from mdx mutant mice. **1993**, 237, 338-44	28
1740	In utero fetal muscle biopsy for the diagnosis of Duchenne muscular dystrophy in a female fetus "suddenly at risk". **1993**, 46, 309-12	16
1739	Two distinct mutations in a single dystrophin gene: identification of an altered splice-site as the primary Becker muscular dystrophy mutation. **1993**, 46, 563-9	34
1738	Myoblast transfer in Duchenne muscular dystrophy. **1993**, 34, 8-17	263
1737	The gp120 glycoprotein of human immunodeficiency virus type 1 binds to sensory ganglion neurons. **1993**, 34, 855-63	49
1736	Prednisolone enhances myogenesis and dystrophin-related protein in skeletal muscle cell cultures from mdx mouse. **1993**, 35, 363-72	43
1735	H-Y (SDM) antibody specifically binds Müllerian inhibiting substance. **1993**, 91, 515-8	5
1734	Hereditary hydronephrosis and the short arm of chromosome 6. **1993**, 91, 514-5	10
1733	Proteolysis results in altered leak channel kinetics and elevated free calcium in mdx muscle. **1993**, 133, 243-51	78
1732	Colocalization of retinal dystrophin and actin in postsynaptic dendrites of rod and cone photoreceptor synapses. **1993**, 100, 473-9	39
1731	Fibres of intermediate type 1C and 2C are found continuously in mdx soleus muscle up to 52 weeks. **1993**, 100, 271-6	9

1730	Size and localization of dystrophin molecule: immunoelectron microscopic and freeze etching studies of muscle plasma membranes of murine skeletal myofibers. **1993**, 86, 567-77	17
1729	Migration of lacZ positive cells from the tibialis anterior to the extensor digitorum longus muscle of the X-linked muscular dystrophic (mdx) mouse. **1993**, 14, 121-32	24
1728	Isolation and characterization of a genomic clone from the murine utrophin locus. **1993**, 4, 608-11	
1727	Exercise intolerance and recurrent myoglobinuria as the only expression of Xp21 Becker type muscular dystrophy. **1993**, 240, 269-71	40
1726	The use of monoclonal antibodies in diagnostic tests for Becker and Duchenne muscular dystrophy. **1993**, 240, 21-4	5
1725	Decrease in urinary excretion of 3-methylhistidine by patients with Duchenne muscular dystrophy during glucocorticoid treatment. **1993**, 240, 181-6	14
1724	The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. I. Natural history. **1993**, 240, 98-104	119
1723	The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. **1993**, 240, 105-12	99
1722	Dystrophin abnormalities in Duchenne and Becker dystrophy carriers: correlation with cytoskeletal proteins and myosins. **1993**, 240, 455-61	9
1721	Overexpression of dystrophin in transgenic mdx mice eliminates dystrophic symptoms without toxicity. **1993**, 364, 725-9	261
1720	The structural and functional diversity of dystrophin. **1993**, 3, 283-91	566
1719	Dystrophin expression in the human retina is required for normal function as defined by electroretinography. **1993**, 4, 82-6	141
1718	New mdx mutation disrupts expression of muscle and nonmuscle isoforms of dystrophin. **1993**, 4, 87-93	172
1717	A dystrophin-immunoreactive protein in mammalian brain. **1993**, 60, 435-41	7
1716	Muscular dystrophy: dystrophin and partners at the cell surface. **1993**, 3, 109-11	5
1715	Critical evaluation of cytosolic calcium determination in resting muscle fibres from normal and dystrophic (mdx) mice. **1993**, 14, 473-83	105
1714	Dystrophin expression improves myofiber survival in mdx muscle following intramuscular plasmid DNA injection. **1993**, 2, 2055-61	68
1713	Dystrophinopathy in two young boys with exercise-induced cramps and myoglobinuria. **1993**, 152, 848-51	19

1712	Dystrophin-related protein, utrophin, in normal and dystrophic human fetal skeletal muscle. **1993**, 25, 554-561	119
1711	Human genetic therapy. **1993**, 14, 451-546	6
1710	Trans-activation of the murine dystrophin gene in human-mouse hybrid myotubes. **1993**, 320, 155-9	8
1709	Defective association of dystrophin with sarcolemmal glycoproteins in the cardiomyopathic hamster heart. **1993**, 329, 227-31	46
1708	Restoration of dystrophin-associated proteins in skeletal muscle of mdx mice transgenic for dystrophin gene. **1993**, 320, 276-80	28
1707	Differential expression of dystrophin, utrophin and dystrophin-associated proteins in peripheral nerve. **1993**, 334, 281-5	57
1706	Monoclonal antibodies targeted against the C-terminal domain of dystrophin or utrophin. **1993**, 322, 10-4	25
1705	Purification of dystrophin-related protein (utrophin) from lung and its identification in pulmonary artery endothelial cells. **1993**, 326, 289-93	27
1704	A quantitative ELISA for dystrophin. **1993**, 161, 23-8	6
1703	Long-term correction of mouse dystrophic degeneration by adenovirus-mediated transfer of a minidystrophin gene. **1993**, 5, 130-4	192
1702	Asymptomatic Becker muscular dystrophy: histological changes in biopsied muscles. **1993**, 35, 409-11	3
1701	Recovery from disuse osteopenia coincident to restoration of muscle strength in mdx mice. **1993**, 14, 625-34	30
1700	Very small dystrophin molecule in a family with a mild form of Becker dystrophy. **1993**, 3, 65-70	15
1699	An introduction to the molecular genetics of neurological disease. Recent advances. **1993**, 50, 1123-8	7
1698	A genetic linkage map of the mouse: current applications and future prospects. **1993**, 262, 57-66	496
1697	Dystrophin and dystrophin-related proteins: a review of protein and RNA studies. **1993**, 3, 5-21	49
1696	Complementary distributions of vinculin and dystrophin define two distinct sarcolemma domains in smooth muscle. **1993**, 120, 1159-67	151
1695	Limb-girdle muscular dystrophy is closely linked to the fibrillin locus on chromosome 15. **1993**, 29, 13-21	3

1694	An unusual case of Duchenne muscular dystrophy. **1993**, 15, 313-5	
1693	The "rescue" of dystrophin synthesis in boys with Duchenne muscular dystrophy. **1993**, 3, 525-31	25
1692	Myopathy with abnormal distribution of dystrophin, growth retardation, mental retardation, and hypospadia. **1993**, 9, 239-42	3
1691	Two forms of mouse syntrophin, a 58 kd dystrophin-associated protein, differ in primary structure and tissue distribution. **1993**, 11, 531-40	198
1690	alpha-Methylprednisolone promotes skeletal myogenesis in dystrophin-deficient and control mouse cultures. **1993**, 155, 171-4	22
1689	Diagnosis of dystrophinopathies: review for the clinician. **1993**, 9, 3-9	21
1688	Neuromuscular disorders: gene location. **1993**, 3, 341-6	
1687	Sarcolemmal distribution of abnormal dystrophin in Xp21 carriers. **1993**, 3, 135-40	2
1686	Dystrophin-associated protein complex: clinical implications. **1993**, 341, 528-9	6
1685	Dystrophin-positive myotubes in innervated muscle cultures from Duchenne and Becker muscular dystrophy patients. **1993**, 3, 119-27	4
1684	Manifesting carriers of Xp21 muscular dystrophy; lack of correlation between dystrophin expression and clinical weakness. **1993**, 3, 141-8	24
1683	Deficiency of dystrophin-associated proteins: a common mechanism leading to muscle cell necrosis in severe childhood muscular dystrophies. **1993**, 3, 109-18	50
1682	Dystrophin and dystrophin-related protein expression in Torpedo marmorata electric organ. **1993**, 155, 51-6	9
1681	Asymptomatic Becker muscular dystrophy: expression of dystrophin and dystrophin-related protein. **1993**, 9, 207-9	2
1680	Facioscapulohumeral muscular dystrophy: the impact of genetic research. **1993**, 95, 9-21	4
1679	Dystrophin and dystrophin-related protein (utrophin) distribution in normal and dystrophin-deficient skeletal muscles. **1993**, 3, 507-14	40
1678	Characterization and subcellular localization of the dystrophin-protein 71 (Dp71) from brain. **1993**, 3, 515-8	33
1677	Morphometric analysis of mdx diaphragm muscle fibres. Comparison with hindlimb muscles. **1993**, 3, 463-9	69

1676	Myoblast transplantation between monozygotic twin girl carriers of Duchenne muscular dystrophy. **1993**, 3, 583-92	63
1675	Monomelic muscle atrophy. **1993**, 3, 311-7	6
1674	Immunoblot analysis of dystrophin-related protein (DRP). **1993**, 1180, 257-61	16
1673	The distribution of dystrophin in the murine central nervous system: an immunocytochemical study. **1993**, 54, 167-87	148
1672	Muscular weakness in the mdx mouse. **1993**, 120, 71-7	68
1671	Sodium is elevated in mdx muscles: ionic interactions in dystrophic cells. **1993**, 114, 76-80	40
1670	Developmental studies of dystrophin-positive fibers in mdx, and DRP localization. **1993**, 114, 104-8	19
1669	Age-related changes in replication of myogenic cells in mdx mice: quantitative autoradiographic studies. **1993**, 119, 169-79	137
1668	Intrafamilial variability in dystrophin abundance correlated with difference in the severity of the phenotype. **1993**, 119, 38-42	18
1667	Reciprocal expression of dystrophin and utrophin in muscles of Duchenne muscular dystrophy patients, female DMD-carriers and control subjects. **1993**, 119, 43-52	64
1666	Further impairment of muscle phosphate kinetics by lengthening exercise in DMD/BMD carriers. An in vivo 31P-NMR spectroscopy study. **1993**, 119, 65-73	26
1665	Immunohistological evidence for second or somatic mutations as the underlying cause of dystrophin expression by isolated fibres in Xp21 muscular dystrophy of Duchenne-type severity. **1993**, 118, 56-63	20
1664	Exercise metabolism in Duchenne muscular dystrophy: a biochemical and [31P]-nuclear magnetic resonance study of mdx mice. **1993**, 251, 201-6	29
1663	Diseases and disorders of muscle. **1993**, 37, 339-423	8
1662	Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. **1993**, 30, 737-44	43
1661	Brief report: deletion of the dystrophin muscle-promoter region associated with X-linked dilated cardiomyopathy. **1993**, 329, 921-5	359
1660	Mdx transgenic mouse: restoration of recombinant dystrophin to the dystrophic muscle. **1993**, 4, 273-81	32
1659	A role for the dystrophin-glycoprotein complex as a transmembrane linker between laminin and actin. **1993**, 122, 809-23	1137

1658	Duchenne-Becker muscular dystrophy and the nondystrophic myotonias. Paradigms for loss of function and change of function of gene products. **1993**, 50, 1227-37	23
1657	The utrophin and dystrophin genes share similarities in genomic structure. **1993**, 2, 1765-72	84
1656	Analysis of dystrophin expression after activation of myogenesis in amniocytes, chorionic-villus cells, and fibroblasts. A new method for diagnosing Duchenne's muscular dystrophy. **1993**, 329, 915-20	35
1655	Dystrophin expression in Duchenne patients with "in-frame" gene deletions. **1993**, 24, 93-7	13
1654	Effects of electrical stimulation on muscles of children with Duchenne and Becker muscular dystrophy. **1993**, 24, 189-92	26
1653	Distal myopathies and dystrophies. **1993**, 13, 247-55	17
1652	Characterization of translational frame exception patients in Duchenne/Becker muscular dystrophy. **1993**, 2, 737-44	81
1651	Dystrophin-glycoprotein complex and laminin colocalize to the sarcolemma and transverse tubules of cardiac muscle. **1993**, 72, 349-60	105
1650	Heterokaryon myotubes with normal mouse and Duchenne nuclei exhibit sarcolemmal dystrophin staining and efficient intracellular free calcium control. **1993**, 4, 963-72	9
1649	Dystrophin analysis using a panel of anti-dystrophin antibodies in Duchenne and Becker muscular dystrophy. **1993**, 56, 26-31	23
1648	Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups. **1993**, 30, 728-36	58
1647	Point mutation in a Becker muscular dystrophy patient. **1993**, 2, 75-7	27
1646	Is the maintainance of the C-terminus domain of dystrophin enough to ensure a milder Becker muscular dystrophy phenotype?. **1993**, 2, 39-42	29
1645	Functional significance of dystrophin positive fibres in Duchenne muscular dystrophy. **1993**, 68, 632-6	53
1644	MEF2C, a MADS/MEF2-family transcription factor expressed in a laminar distribution in cerebral cortex. **1993**, 90, 1546-50	185
1643	Dystrophin protects the sarcolemma from stresses developed during muscle contraction. **1993**, 90, 3710-4	1134
1642	Free radicals and muscle damage. **1993**, 49, 630-41	56
1641	Chapter 11 The (CA2+-Mg2+)-ATPase and other membrane proteins: what reconstitution tells us about the biological membrane. **1993**, 25, 259-299	4

1640	Comparing the frequencies of restriction fragment length polymorphisms for dystrophin gene in Chinese with those from Japanese and Caucasian populations. **1993**, 3, 39-47	1
1639	Progressive deterioration of muscles in mdx mice induced by overload. **1993**, 84, 145-50	28
1638	Expression of the glucose transporter GLUT4 in the muscular dystrophic mdx mouse. **1993**, 291 (Pt 1), 257-61	15
1637	Dystrophin is phosphorylated by endogenous protein kinases. **1993**, 293 (Pt 1), 243-7	44
1636	Cell transplantation as an experimental treatment for Duchenne muscular dystrophy. **1993**, 2, 485-505	72
1635	Results of a triple blind clinical study of myoblast transplantations without immunosuppressive treatment in young boys with Duchenne muscular dystrophy. **1993**, 2, 99-112	302
1634	Myoblast Transplantation: What's Going on?. **1993**, 2, 49-57	23
1633	X-linked dilated cardiomyopathy. Molecular genetic evidence of linkage to the Duchenne muscular dystrophy (dystrophin) gene at the Xp21 locus. **1993**, 87, 1854-65	410
1632	Toward a new concept of cell motility: cytoskeletal dynamics in amoeboid movement and cell division. **1993**, 144, 85-127	51
1631	Improved electrophoretic method for the analysis of dystrophin in human muscle. **1993**, 53, 73-82	2
1630	Contractile properties of skinned muscle fibres from young and adult normal and dystrophic (mdx) mice. **1993**, 460, 51-67	40
1629	Membrane potential, resting calcium and calcium transients in isolated muscle fibres from normal and dystrophic mice. **1993**, 469, 11-9	81
1628	Ca2+ levels in myotubes grown from the skeletal muscle of dystrophic (mdx) and normal mice. **1993**, 460, 1-13	74
1627	Dystrophin negative skeletal and myocardial muscle cells in a carrier of Duchenne's muscular dystrophy. **1993**, 14, 989-92	11
1626	Muscle relaxation and sarcoplasmic reticulum function in different muscle types. **1993**, 122, 69-147	53
1625	Adaptations in myosin heavy chain expression and contractile function in dystrophic mouse diaphragm. **1993**, 265, C834-41	135
1624	Disorders and diseases of the motor system. **1993**, 125-167	
1623	Distribution of dystrophin isoforms and dystrophin-associated proteins 43DAG (A3a) and 50DAG (A2) in various monkey tissues. **1993**, 114, 936-41	41

1622	Muscle damage progression in Duchenne muscular dystrophy evaluated by a new quantitative computed tomography method. **1993**, 74, 507-14	57
1621	Molecular Diagnosis and Modern Management of Duchenne Muscular Dystrophy. **1994**, 12, 699-725	20
1620	Immunoelectron Microscopic Localization of C-Terminus of 43-kDa Dystrophin-Associated Glycoprotein in Normal Human Skeletal Myofibers. **1994**,	
1619	Expression of dystrophin-associated protein 35DAG (A4) and 50DAG (A2) is confined to striated muscles. **1994**, 115, 162-7	51
1618	Inherited cardiomyopathies. **1994**, 330, 913-9	271
1617	Myotubes from transgenic mdx mice expressing full-length dystrophin show normal calcium regulation. **1994**, 5, 1159-67	25
1616	Utrophin localization in normal and dystrophin-deficient heart. **1994**, 90, 369-74	61
1615	Reduction of the transient outward potassium current in canine X-linked muscular dystrophy. **1994**, 90, 1350-6	16
1614	Apo-dystrophin-1 and apo-dystrophin-2, products of the Duchenne muscular dystrophy locus: expression during mouse embryogenesis and in cultured cell lines. **1994**, 3, 1309-16	49
1613	Dystrophin and DNA diagnosis in a large pediatric muscle clinic. **1994**, 9, 162-6	5
1612	Familial dilated cardiomyopathy. **1994**, 72, S35-41	37
1611	Dilated cardiomyopathy and the dystrophin gene: an illustrated review. **1994**, 72, 344-8	34
1610	Localisation and characterisation of dystrophin in the central nervous system of controls and patients with Duchenne muscular dystrophy. **1994**, 57, 426-9	42
1609	Coisogenic all-plus-one immunization: a model for identifying missing proteins in null-mutant conditions. Antibodies to dystrophin in mdx mouse after transplantation of muscle from normal coisogenic donor. **1994**, 25, 176-82	11
1608	Cell and gene therapy in Duchenne muscular dystrophy. **1994**, 5, 165-73	46
1607	Dystrophin is not essential for the integrity of the cytoskeleton. **1994**, 87, 377-84	15
1606	Germline and somatic mosaicism in a female carrier of Duchenne muscular dystrophy. **1994**, 93, 541-4	25
1605	Intracellular Ca2+ concentrations are not elevated in resting cultured muscle from Duchenne (DMD) patients and in MDX mouse muscle fibres. **1994**, 426, 499-505	51

1604	Dystrophin and dystrophin-related protein in the central nervous system of normal controls and Duchenne muscular dystrophy. **1994**, 87, 129-34	23
1603	The dystrophin superfamily: variability and complexity. **1994**, 15, 595-606	11
1602	Prenatal exclusion of Duchenne muscular dystrophy by fetal muscle biopsy. **1994**, 14, 235-8	8
1601	Abnormal dystrophin expression in patients with limb girdle syndromes. **1994**, 241, 210-7	8
1600	A 400-kb tandem duplication within the dystrophin gene leads to severe Becker muscular dystrophy. **1994**, 241, 331-4	2
1599	Dystrophin predominantly localizes to the transverse tubule/Z-line regions of single ventricular myocytes and exhibits distinct associations with the membrane. **1994**, 130, 57-65	17
1598	Dystrophin-related protein is found in the central nervous system of mice at various developmental stages, especially at the postsynaptic membrane. **1994**, 37, 728-34	29
1597	Amphiphilic properties of molecular forms of acetylcholinesterase in normal and dystrophic muscle. **1994**, 38, 505-14	12
1596	Experimental challenge for the treatment of Duchenne muscular dystrophy using a vascularized free muscle graft. **1994**, 15, 871-6	
1595	Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies. **1994**, 17, 2-15	277
1594	Expression of utrophin (dystrophin-related protein) and dystrophin-associated glycoproteins in muscles from patients with Duchenne muscular dystrophy. **1994**, 17, 206-16	53
1593	The effects of altered metabolism (hypothyroidism) on muscle repair in the mdx dystrophic mouse. **1994**, 17, 444-53	52
1592	Anionic phospholipids calcium binding sites in Duchenne and murine X-linked muscular dystrophy. **1994**, 17, 485-8	1
1591	Dystrophin and dystrophin-related protein in the brains of normal and mdx mice. **1994**, 17, 533-8	24
1590	Utilization of myoblasts from transgenic mice to evaluate the efficacy of myoblast transplantation. **1994**, 17, 975-80	45
1589	Ion channels in a skeletal muscle cell line from a Duchenne muscular dystrophy patient. **1994**, 17, 1021-8	13
1588	Time course of changes in plasma membrane permeability in the dystrophin-deficient mdx mouse. **1994**, 17, 1378-84	68
1587	Restoration of half the normal dystrophin sequence in a double-deletion Duchenne muscular dystrophy family. **1994**, 49, 323-7	12

1586 Abstracts-part VI (Continue in Part VII). **1994**, 1994, 301-350

1585 Enhanced urinary spontaneous luminescence in Duchenne muscular dystrophy. **1994**, 16, 851-3 5

1584 The emerging family of dystrophin-related proteins. **1994**, 4, 19-23 28

1583 Identification of disease genes by positional cloning. **1994**, 4, 97-102 1

1582 Dystrophin associated proteins fail in filling dystrophin's shoes. **1994**, 8, 311-2 7

1581 Dp71 can restore the dystrophin-associated glycoprotein complex in muscle but fails to prevent dystrophy. **1994**, 8, 333-9 150

1580 Migration of muscle cells. **1994**, 368, 406-7 59

1579 Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. **1994**, 21, 757-65 27

1578 Freeze-fracture analysis of muscle plasma membrane in Becker's muscular dystrophy. **1994**, 20, 487-94 4

1577 Dissociation of the complex of dystrophin and its associated proteins into several unique groups by n-octyl beta-D-glucoside. **1994**, 222, 1055-61 155

1576 Molecular Genetic Techniques for Prenatal Diagnosis*. **1994**, 34, 161-174

1575 Expression of NCAM and its polysialylated isoforms during mdx mouse muscle regeneration and in vitro myogenesis. **1994**, 4, 171-82 42

1574 A role for mast cells in the progression of Duchenne muscular dystrophy? Correlations in dystrophin-deficient humans, dogs, and mice. **1994**, 122, 44-56 94

1573 Autosomal recessive distal muscular dystrophy: normal expression of dystrophin, utrophin and dystrophin-associated proteins in muscle fibers. **1994**, 126, 70-6 11

1572 The pituitary-muscle axis in mdx dystrophic mice. **1994**, 123, 80-7 12

1571 Absence of dystrophin and spectrin in regenerating muscle fibers from Becker dystrophy patients. **1994**, 123, 88-94 7

1570 Contraction tension and kinetics of the peroneus longus muscle in golden retriever muscular dystrophy. **1994**, 123, 100-7 25

1569 Expression of myosin isoforms and of desmin, vimentin and titin in Tunisian Duchenne-like autosomal recessive muscular dystrophy. **1994**, 123, 114-21 4

1568	Lazaroids enhance skeletal myogenesis in primary cultures of dystrophin-deficient mdx mice. **1994**, 126, 138-45		11
1567	Molecular basis and diagnosis of neurogenetic disorders. **1994**, 124, 119-40		17
1566	PCR and immunoblot analyses of dystrophin in Becker muscular dystrophy. **1994**, 124, 225-9		4
1565	Does muscular dystrophy affect metabolic rate? A study in mdx mice. **1994**, 121, 203-7		15
1564	A role for dystrophin-associated glycoproteins and utrophin in agrin-induced AChR clustering. *Cell*, **1994**, 77, 663-74	56.2	348
1563	Characterization of the ocular phenotype of Duchenne and Becker muscular dystrophy. **1994**, 101, 856-65		75
1562	Expression of dystrophin-associated proteins in dystrophin-positive muscle fibers (revertants) in Duchenne muscular dystrophy. **1994**, 4, 115-20		26
1561	Deletion of the dystrophin muscle promoter in feline muscular dystrophy. **1994**, 4, 433-45		54
1560	Two patients with distal muscular dystrophy and autonomic nerve dysfunction. **1994**, 16, 65-70		5
1559	Cognitive impairment in Duchenne muscular dystrophy. **1994**, 4, 359-69		124
1558	Deletion analysis of the dystrophin-actin binding domain. **1994**, 344, 255-60		74
1557	Alpha-dystroglycan deficiency correlates with elevated serum creatine kinase and decreased muscle contraction tension in golden retriever muscular dystrophy. **1994**, 350, 173-6		12
1556	N-terminal domain of dystrophin. **1994**, 355, 49-53		17
1555	Myocyte-specific enhancer binding factor 2C expression in human brain development. **1994**, 63, 1067-79		78
1554	Deficiency of the 50 kDa dystrophin-associated glycoprotein and abnormal expression of utrophin in two south Asian cousins with variable expression of severe childhood autosomal recessive muscular dystrophy. **1994**, 4, 121-9		18
1553	Limb girdle muscular dystrophy: reappraisal of a rejected entity. **1994**, 96, 209-18		8
1552	Experimental regeneration in canine muscular dystrophy--2. Expression of myosin heavy chain isoforms. **1994**, 4, 25-37		15
1551	Neuromuscular disorders: gene location. **1994**, 4, 277-83		

1550	'Oil globules' in Duchenne muscular dystrophy--history, demonstration, and metabolic significance. **1994**, 43, 327-38	6
1549	A molecular survey of Israeli Duchenne and Becker muscular dystrophy patients. **1994**, 48, 359-64	1
1548	Dystrophin deficiency, altered cell signalling and fibre hypertrophy. **1994**, 4, 305-15	19
1547	Expression of the 43 kDa dystrophin-associated glycoprotein in human neuromuscular disease. **1994**, 4, 101-13	12
1546	Mdx mouse skeletal muscle: could a mitochondrial factor be responsible for the absence of progressive necrosis?. **1994**, 169, 97-100	7
1545	Expression and subcellular localization of dystrophin in skeletal, cardiac and smooth muscles during the human development. **1994**, 4, 419-32	17
1544	Neuromuscular disorders: Gene location?. **1994**, 4, 157-163	
1543	Neuromuscular disorders: Gene location?. **1994**, 4, 89-95	
1542	Calmodulin-activated phosphorylation of dystrophin. **1994**, 33, 5797-804	34
1541	Expression of dystrophin-associated glycoproteins and utrophin in carriers of Duchenne muscular dystrophy. **1994**, 4, 401-9	22
1540	Mechanosensitive ion channels in skeletal muscle from normal and dystrophic mice. **1994**, 481 (Pt 2), 299-309	112
1539	Agrin-induced clustering of acetylcholine receptors: a cytoskeletal link. **1994**, 126, 1-4	50
1538	Cloning of human basic A1, a distinct 59-kDa dystrophin-associated protein encoded on chromosome 8q23-24. **1994**, 91, 4446-50	117
1537	Defective muscle basement membrane and lack of M-laminin in the dystrophic dy/dy mouse. **1994**, 91, 5572-6	225
1536	Dystrophin, its gene, and the dystrophinopathies. **1995**, 33, 177-231	22
1535	Myoblast-based gene therapies. **1995**, 51, 123-37	59
1534	The genetic basis of paediatric heart disease. **1995**, 27, 289-300	22
1533	Inhibition of proliferation in 8-week-old mdx mouse muscle fibroblasts in vitro. **1995**, 59, 145-54	5

1532	Duchenne muscular dystrophy and myotonic dystrophy in the same patient. **1995**, 55, 342-8	5
1531	Somatic mosaicism for a DMD gene deletion. **1995**, 56, 80-6	12
1530	Absence of correlation between utrophin localization and quantity and the clinical severity in Duchenne/Becker dystrophies. **1995**, 58, 305-9	30
1529	Primary adhalin deficiency as a cause of muscular dystrophy in patients with normal dystrophin. **1995**, 38, 367-72	56
1528	Dystroglycan mRNA expression during normal and mdx mouse embryogenesis: a comparison with utrophin and the apo-dystrophins. **1995**, 204, 178-85	33
1527	Developmental studies of dystrophin and other cytoskeletal proteins in cultured muscle cells. **1995**, 30, 437-57	13
1526	Dystrophin expression in the developing conduction system of the human heart. **1995**, 30, 458-68	3
1525	Myoblast transfer and gene therapy in muscular dystrophies. **1995**, 30, 469-79	16
1524	Phenotype of dystrophinopathy in old mdx mice. **1995**, 242, 70-6	166
1523	Expression of heat-shock/stress proteins in Duchenne muscular dystrophy. **1995**, 18, 23-31	36
1522	Site and mechanics of failure in normal and dystrophin-deficient skeletal muscle. **1995**, 18, 216-23	31
1521	Evaluation of the cardiomyopathy in Becker muscular dystrophy. **1995**, 18, 283-91	105
1520	Pretreatment of myoblast cultures with basic fibroblast growth factor increases the efficacy of their transplantation in mdx mice. **1995**, 18, 834-41	57
1519	Altered distribution of beta-dystroglycan in sarcolemma of human dystrophic muscles: an immunohistochemical study. **1995**, 18, 910-3	5
1518	Quantification of normal dystrophin mRNA following myoblast transplantation in mdx mice. **1995**, 18, 980-6	15
1517	Age-related differences in regeneration of dystrophic (mdx) and normal muscle in the mouse. **1995**, 18, 1147-54	76
1516	Beneficial versus adverse effects of long-term use of clenbuterol in mdx mice. **1995**, 18, 1447-59	31
1515	Becker-like muscular dystrophy in sisters. **1995**, 245, 326-30	

1514	Observations of muscle plasma membrane undercoats in Duchenne and fukuyama muscula dystrophies. **1995**, 28, 102-110	1
1513	Immunohistological analyses of neutral glycosphingolipids and gangliosides in normal mouse skeletal muscle and in mice with neuromuscular diseases. **1995**, 12, 721-8	7
1512	Immunoblot analysis of sarcoplasmic calcium binding proteins in Duchenne muscular dystrophy. **1995**, 242, 82-6	6
1511	Visualization of the subsarcolemmal cytoskeleton network of mouse skeletal muscle cells by en face views and application to immunoelectron localization of dystrophin. **1995**, 16, 553-66	5
1510	Adenovirus-mediated gene transfer into striated muscles. **1995**, 73, 165-80	25
1509	The genetic contribution to the phenotype. **1995**, 95, 127-48	59
1508	Immunohistochemical study of calpain and its endogenous inhibitor in the skeletal muscle of muscular dystrophy. **1995**, 89, 399-403	30
1507	Fluorescence in situ hybridisation studies provide evidence for somatic mosaicism in de novo dystrophin gene deletions. **1995**, 95, 43-5	13
1506	Cytoplasmic body myopathy: familial cases with accumulation of desmin and dystrophin. An immunohistochemical, immunoelectron microscopic and biochemical study. **1995**, 90, 150-7	21
1505	Familial fetal akinesia deformation sequence with a skeletal muscle maturation defect. **1995**, 90, 176-83	7
1504	Importance of lower limb surgery in Duchenne muscular dystrophy. **1995**, 114, 106-11	27
1503	Normal pregnancy after preimplantation DNA diagnosis of a dystrophin gene deletion. **1995**, 15, 351-8	53
1502	The mouse dystonia musculorum gene is a neural isoform of bullous pemphigoid antigen 1. **1995**, 10, 301-6	228
1501	Beta-sarcoglycan: characterization and role in limb-girdle muscular dystrophy linked to 4q12. **1995**, 11, 257-65	433
1500	Beta-sarcoglycan (A3b) mutations cause autosomal recessive muscular dystrophy with loss of the sarcoglycan complex. **1995**, 11, 266-73	405
1499	Abnormal calcium homeostasis in Duchenne muscular dystrophy myotubes contracting in vitro. **1995**, 18, 177-86	72
1498	Toward a gene therapy for duchenne muscular dystrophy. **1995**, 1, 71-78	3
1497	Molecular genetics: cardiac disease and risk-related genes. **1995**, 18, IV13-9	5

1496	Progressive muscular dystrophy--Duchenne type. Controversies of the kinesitherapy treatment. **1995**, 113, 995-9	
1495	Successful histocompatible myoblast transplantation in dystrophin-deficient mdx mouse despite the production of antibodies against dystrophin. **1995**, 131, 975-88	82
1494	Immunohistochemical alterations of dystrophin in congenital muscular dystrophy. **1995**, 53, 416-23	1
1493	Cardiac Problems in Patients with Neurologic Disease. **1995**, 13, 179-208	20
1492	Perspectives and Molecular Diagnosis of Duchenne and Becker Muscular Dystrophies. **1995**, 15, 927-941	5
1491	Recombinant truncated dystrophin minigenes: construction, expression, and adenoviral delivery. **1995**, 6, 1477-85	25
1490	Myogenic Expression of Mesenchymal Stem Cells within Myotubes of mdx Mice in Vitro and in Vivo. **1995**, 1, 327-43	102
1489	Hypothyroidism prolongs and increases mdx muscle precursor proliferation and delays myotube formation in normal and dystrophic limb muscle. **1995**, 73, 181-90	34
1488	A novel dystrophin isoform is required for normal retinal electrophysiology. **1995**, 4, 837-42	209
1487	The childhood muscular dystrophies: diseases sharing a common pathogenesis of membrane instability. **1995**, 10, 150-9	37
1486	The neurobiology of infantile autism. **1995**, 18, 101-28	122
1485	Association of aciculin with dystrophin and utrophin. **1995**, 270, 6328-37	37
1484	Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm. **1995**, 13, 508-17	32
1483	Bone marrow transplantation versus chemotherapy in non-Hodgkin's lymphoma. **1995**, 333, 727; author reply 730	
1482	Transplantation of fetal mesencephalic tissue in Parkinson's disease. **1995**, 333, 730-1	15
1481	Ibuprofen in patients with cystic fibrosis. **1995**, 333, 731; author reply 732	1
1480	Serum antibodies to the deleted dystrophin sequence after cardiac transplantation in a patient with Becker's muscular dystrophy. **1995**, 333, 732-3	18
1479	Cost sharing in health insurance. **1995**, 333, 733-4	14

1478	More on smoking superheroes. **1995**, 333, 734	1
1477	Expression of deletion-containing dystrophins in mdx muscle: implications for gene therapy and dystrophin function. **1995**, 37, 693-700	11
1476	Muscular fatigue in Duchenne muscular dystrophy. **1995**, 45, 306-10	33
1475	Heart Hypertrophy and Failure. **1995**,	
1474	The prevention of neurogenetic disease. **1995**, 52, 356-62	8
1473	Non-muscle alpha-dystroglycan is involved in epithelial development. **1995**, 130, 79-91	176
1472	Mouse alpha 1- and beta 2-syntrophin gene structure, chromosome localization, and homology with a discs large domain. **1995**, 270, 25859-65	100
1471	Myoblast transfer in the treatment of Duchenne's muscular dystrophy. **1995**, 333, 832-8	453
1470	Absence of extraocular muscle pathology in Duchenne's muscular dystrophy: role for calcium homeostasis in extraocular muscle sparing. **1995**, 182, 467-75	120
1469	Myopathies. **1995**, 5, 275-288	1
1468	Interactions between dystrophin glycoprotein complex proteins. **1995**, 34, 12204-9	30
1467	Phospholipase A2 activity in dystrophinopathies. **1995**, 5, 193-9	41
1466	Sarcolemmal indentation in cardiomyopathy with mental retardation and vacuolar myopathy. **1995**, 5, 149-55	23
1465	Effect of voluntary wheel-running exercise on muscles of the mdx mouse. **1995**, 5, 323-32	77
1464	A severe muscular dystrophy patient with an internally deleted very short (110 kD) dystrophin: presence of the binding site for dystrophin-associated glycoprotein (DAG) may not be enough for physiological function of dystrophin. **1995**, 5, 429-38	14
1463	How does dystrophin deficiency lead to muscle degeneration?--evidence from the mdx mouse. **1995**, 5, 445-56	77
1462	Morphological and functional study of extensor digitorum longus muscle regeneration after iterative crush lesions in mdx mouse. **1995**, 5, 489-500	17
1461	Neuromuscular disorders: Gene location. **1995**, 5, I-VII	

1460	Analysis of peristaltic reflex in young mdx dystrophic mice. **1995**, 192, 57-60	22
1459	Architectural changes of the cortico-spinal system in the dystrophin defective mdx mouse. **1995**, 200, 53-6	42
1458	Basic fibroblast growth factor promotes in vivo muscle regeneration in murine muscular dystrophy. **1995**, 202, 121-4	74
1457	Muscular degeneration in Duchenne's dystrophy may be caused by a mitochondrial defect. **1995**, 44, 298-300	5
1456	Utrophin expression during human fetal development. **1995**, 13, 585-93	11
1455	Genetic mapping of the mouse neuromuscular mutation kyphoscoliosis. **1995**, 25, 207-13	9
1454	Modulation by prednisolone of calcium handling in skeletal muscle cells. **1995**, 116, 2811-6	38
1453	Cardiac dystrophin abnormalities in Becker muscular dystrophy assessed by endomyocardial biopsy. **1995**, 129, 702-7	22
1452	Mutational analysis of muscle and brain specific promoter regions of dystrophin gene in DMD/BMD Italian patients by denaturing gradient gel electrophoresis (DGGE). **1995**, 9, 441-6	4
1451	Purine and carnitine metabolism in muscle of patients with Duchenne muscular dystrophy. **1995**, 243, 151-64	17
1450	Full-length and short forms of utrophin, the dystrophin-related protein. **1995**, 358, 262-6	21
1449	Dystrophin-associated protein A0 is a homologue of the Torpedo 87K protein. **1995**, 367, 311-4	23
1448	Direct binding of Torpedo syntrophin to dystrophin and the 87 kDa dystrophin homologue. **1995**, 375, 91-4	42
1447	Down-regulation of mitochondrial mRNAs in the mdx mouse model for Duchenne muscular dystrophy. **1995**, 375, 268-72	27
1446	Connective tissue proliferation and growth factors in animal models of Duchenne muscular dystrophy. **1995**, 128, 36-44	30
1445	Limb-girdle muscular dystrophy: clinical and pathologic reevaluation. **1995**, 129, 15-20	19
1444	Dystrophin expression in skin biopsy immunohistochemical. Localisation of striated muscle type dystrophin. **1995**, 129, 29-33	13
1443	Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity. **1995**, 131, 1-7	14

1442	A new familial congenital myopathy in children with desmin and dystrophin reacting plaques. **1995**, 131, 88-95	20
1441	Is dystrophin always altered in Becker muscular dystrophy patients?. **1995**, 131, 99-104	9
1440	Ouabain sensitive Na+/K(+)-ATPase content is elevated in mdx mice: implications for the regulation of ions in dystrophic muscle. **1995**, 133, 11-5	20
1439	X-linked dilated cardiomyopathy. Novel mutation of the dystrophin gene. **1995**, 752, 470-91	40
1438	Increased deposition of extracellular matrix components in the thymus gland of MDX mouse: correlation with the muscular lesion. **1995**, 59, 9-18	11
1437	Mutations in the dystrophin-associated protein gamma-sarcoglycan in chromosome 13 muscular dystrophy. **1995**, 270, 819-22	469
1436	Antioxidant lazaroids enhance differentiation of C2 skeletal muscle cells. **1995**, 186, 177-80	3
1435	Type II diabetes: clinical aspects of molecular biological studies. **1995**, 44, 1-10	66
1434	Extraocular muscles: basic and clinical aspects of structure and function. **1995**, 39, 451-84	192
1433	Brain abnormalities in Duchenne muscular dystrophy: phosphorus-31 magnetic resonance spectroscopy and neuropsychological study. **1995**, 345, 1260-4	53
1432	Lymphocyte infiltration following allo- and xenomyoblast transplantation in mdx mice. **1995**, 18, 39-51	63
1431	mdx mice show progressive weakness and muscle deterioration with age. **1995**, 129, 97-105	283
1430	Myocyte-specific enhancer binding factor 2C expression in gerbil brain following global cerebral ischemia. **1996**, 70, 67-77	15
1429	Genetic aspects of dilated cardiomyopathy. **1996**, 6, 71-82	7
1428	Immunohistochemical localization of utrophin and other cytoskeletal proteins in skin smooth muscle in neuromuscular diseases. **1996**, 143, 156-60	14
1427	Recruitment of mast cells to muscle after mild damage. **1996**, 135, 10-7	45
1426	alpha-Sarcoglycan (adhalin) deficiency: complete deficiency patients are 5% of childhood-onset dystrophin-normal muscular dystrophy and most partial deficiency patients do not have gene mutations. **1996**, 140, 30-9	31
1425	Extraocular, limb and diaphragm muscle group-specific antioxidant enzyme activity patterns in control and mdx mice. **1996**, 139, 180-186	50

1424	An in vivo and in vitro H-magnetic resonance spectroscopy study of mdx mouse brain: abnormal development or neural necrosis?. **1996**, 141, 13-8	31
1423	Contractile properties of myocardium are altered in dystrophin-deficient mdx mice. **1996**, 142, 17-24	32
1422	Regulation of cytosolic calcium in skeletal muscle cells of the mdx mouse under conditions of stress. **1996**, 118, 611-6	68
1421	Expression of dystrophin Dp71 during PC12 cell differentiation. **1996**, 213, 107-10	19
1420	Early postnatal muscle contractile activity regulates the carbonic anhydrase phenotype of proprioceptive neurons in young and mature mice: evidence for a critical period in development. **1996**, 71, 787-95	6
1419	Dystrophin and the dystrophin-associated glycoprotein, beta-dystroglycan, co-localize in photoreceptor synaptic complexes of the human retina. **1996**, 73, 605-12	37
1418	Duchenne/Becker muscular dystrophy: from molecular diagnosis to gene therapy. **1996**, 18, 167-72	43
1417	Gene therapy in Duchenne muscular dystrophy. **1996**, 18, 357-61	16
1416	Muscular dystrophy, mental retardation and cardiomyopathy not associated with dystrophin deficiency. **1996**, 6, 167-72	1
1415	Hypoosmotic shocks induce elevation of resting calcium level in Duchenne muscular dystrophy myotubes contracting in vitro. **1996**, 6, 351-60	45
1414	Activation of protein phosphatase-1 isoforms and glycogen synthase kinase-3 beta in muscle from mdx mice. **1996**, 28, 13-22	24
1413	No alteration in gene expression of components of the ubiquitin-proteasome proteolytic pathway in dystrophin-deficient muscles. **1996**, 393, 292-6	36
1412	Skeletal muscle of patients with Duchenne's muscular dystrophy: evidence of a mitochondrial proteolytic factor responsible for calmitine deficiency. **1996**, 223, 31-5	5
1411	Nitric oxide synthase I (NOS-I) is deficient in the sarcolemma of striated muscle fibers in patients with Duchenne muscular dystrophy, suggesting an association with dystrophin. **1996**, 98, 61-9	57
1410	Autosomal recessive muscular dystrophy and mutations of the sarcoglycan complex. **1996**, 6, 475-82	39
1409	Neuromuscular disorders: Gene location. **1996**, 6, I-IX	
1408	Neuromuscular disorders: Gene Location. **1996**, 6, I-IX	
1407	Neuromuscular disorders: gene location. **1996**, 6, I-IX	

1406 Neuromuscular disorders: Gene location. **1996**, 6, I-X

1405 Neuromuscular disorders: Gene location. **1996**, 6, I-IX

1404 Neuromuscular disorders: Gene location. **1996**, 6, I-X 1

1403 Cognitive dysfunction as the major presenting feature of Becker's muscular dystrophy. **1996**, 46, 461-5 32

1402 Muscle Contraction. **1996**, 491, 121-132 1

1401 Oxidative damage to muscle protein in Duchenne muscular dystrophy. **1996**, 8, 357-61 110

1400 Quantitative estimation of dystrophin protein: a sensitive and convenient "two-antibody sandwich" ELISA. **1996**, 180, 57-63 4

1399 Childhood neuromuscular disorders: a decade's experience in Saudi Arabia. **1996**, 16, 271-80 11

1398 Defects in muscle-cytoskeleton interaction in diseased states. **1996**, 3, 107-131 1

1397 Costameric distribution of beta-dystroglycan (43 kDa dystrophin-associated glycoprotein) in normal and dystrophin-deficient human skeletal muscle. **1996**, 24, 501-6 5

1396 Understanding the heterogeneity of the limb-girdle muscular dystrophies. **1996**, 24, 489-96 3

1395 Neuronal nitric oxide synthase and dystrophin-deficient muscular dystrophy. **1996**, 93, 9142-7 309

1394 Mechanism of increasing dystrophin-positive myofibers by myoblast transplantation: study using mdx/beta-galactosidase transgenic mice. **1996**, 91, 489-93 25

1393 Immunohistochemical study of utrophin and dystrophin at the motor end-plate in myasthenia gravis. **1996**, 92, 14-8 8

1392 Differential susceptibility of human skeletal muscle proteins to free radical induced oxidative damage: a histochemical, immunocytochemical and electron microscopical study in vitro. **1996**, 92, 331-40 62

1391 Electron microscopic observations of triple immunogold labelling for dystrophin, beta-dystroglycan and adhalin in human skeletal myofibers. **1996**, 92, 569-75 10

1390 Congenital myopathy in Braunvieh x Brown Swiss calves. **1996**, 115, 23-34 5

1389 The genetic basis of pediatric cardiovascular disease. **1996**, 20, 564-76 20

1388	The Dawning of a New Era in the Molecular Biology of the Muscular Dystrophies. **1996**, 6, 17-17	2
1387	Dystrophin and its isoforms. **1996**, 6, 25-35	86
1386	Clinical and histopathological features of abnormalities of the dystrophin-based membrane cytoskeleton. **1996**, 6, 49-61	31
1385	Dystrophinopathies. **1996**, 3, 99-109	6
1384	Membrane abnormalities and Ca homeostasis in muscles of the mdx mouse, an animal model of the Duchenne muscular dystrophy: a review. **1996**, 156, 397-406	77
1383	Perchlorate differentially potentiates excitation-contraction coupling of diaphragm muscle from mdx and control mice. **1996**, 158, 287-94	3
1382	Congenital muscular dystrophy with primary laminin alpha2 (merosin) deficiency presenting as inflammatory myopathy. **1996**, 40, 782-91	105
1381	Genetic counseling of isolated carriers of Duchenne muscular dystrophy. **1996**, 63, 573-80	24
1380	X-linked mental retardation with thin habitus, osteoporosis, and kyphoscoliosis: linkage to Xp21.3-p22.12. **1996**, 64, 50-8	29
1379	Utrophin-dystroglycan complex in membranes of adherent cultured cells. **1996**, 33, 163-74	39
1378	Prenatal diagnosis of Duchenne and Becker muscular dystrophy. **1996**, 16, 1187-98	14
1377	Tenascin-C expression in dystrophin-related muscular dystrophy. **1996**, 19, 147-54	20
1376	Single channel evidence for a cytoskeletal defect involving acetylcholine receptors and calcium influx in cultured dystrophic (mdx) myotubes. **1996**, 19, 1116-26	10
1375	Acetylcholine receptor and calcium leakage activity in nondystrophic and dystrophic myotubes (MDX). **1996**, 19, 1258-67	10
1374	Leukemia inhibitory factor and interleukin-6 are produced by diseased and regenerating skeletal muscle. **1996**, 19, 1291-301	119
1373	The mdx-amplification-resistant mutation system assay, a simple and rapid polymerase chain reaction-based detection of the mdx allele. **1996**, 19, 1549-53	74
1372	Quantitative and qualitative alterations of dystrophin are expressed in muscle cell cultures of Xp21 muscular dystrophy patients (Duchenne and Becker type). **1996**, 26, 322-4	
1371	Increased expression of dystrophin, beta-dystroglycan and adhalin in denervated rat muscles. **1996**, 17, 523-32	20

1370	Severe dystrophinopathy in a patient with congenital hypotonia. **1996**, 12, 466-9	3
1369	Emerin deficiency at the nuclear membrane in patients with Emery-Dreifuss muscular dystrophy. **1996**, 12, 254-9	293
1368	The sarcoglycan complex in the six autosomal recessive limb-girdle muscular dystrophies. **1996**, 5, 1963-9	139
1367	Identification of a novel sarcoglycan gene at 5q33 encoding a sarcolemmal 35 kDa glycoprotein. **1996**, 5, 1179-86	138
1366	Genomic screening for beta-sarcoglycan gene mutations: missense mutations may cause severe limb-girdle muscular dystrophy type 2E (LGMD 2E). **1996**, 5, 1953-61	80
1365	The association of cardiac dystrophin with myofibrils/Z-disc regions in cardiac muscle suggests a novel role in the contractile apparatus. **1996**, 271, 12364-71	42
1364	Beta 1D integrin displaces the beta 1A isoform in striated muscles: localization at junctional structures and signaling potential in nonmuscle cells. **1996**, 132, 211-26	190
1363	Development of Cardiomyopathy in Female Carriers of Duchenne and Becker Muscular Dystrophies. **1996**, 275, 1335	127
1362	Myalgia and cramps: dystrophinopathy with wide-ranging laboratory findings. **1996**, 11, 21-4	23
1361	The Emery-Dreifuss muscular dystrophy protein, emerin, is a nuclear membrane protein. **1996**, 5, 801-8	292
1360	Cloning and characterization of the human homologue of a dystrophin related phosphoprotein found at the Torpedo electric organ post-synaptic membrane. **1996**, 5, 489-96	100
1359	Understanding Cardiac Development Through the Perspective of Gene Regulation and Gene Manipulation. **1996**, 16, 173-194	3
1358	Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA4Ig. **1996**, 7, 1455-63	56
1357	Impairment of force generation after adenovirus-mediated gene transfer to muscle is alleviated by adenoviral gene inactivation and host CD8+ T cell deficiency. **1996**, 7, 1813-26	31
1356	Characterization of delta-sarcoglycan, a novel component of the oligomeric sarcoglycan complex involved in limb-girdle muscular dystrophy. **1996**, 271, 32321-9	75
1355	? REVIEW : Postsynaptic Anchoring of Receptors: A Cellular Approach to Neuronal and Muscular Sensitivity. **1996**, 2, 100-108	13
1354	Brain metabolism is abnormal in the mdx model of Duchenne muscular dystrophy. **1996**, 119 (Pt 3), 1039-44	41
1353	Brief report: deficiency of a dystrophin-associated glycoprotein (adhalin) in a patient with muscular dystrophy and cardiomyopathy. **1996**, 334, 362-6	72

1352	Dystrophin deficient mdx muscle is not prone to MH susceptibility: an in vitro study. **1997**, 79, 125-7	5
1351	Skeletal Muscle Function. **1997**, 407-440	11
1350	Postsynaptic abnormalities at the neuromuscular junctions of utrophin-deficient mice. **1997**, 136, 883-94	201
1349	Identification of the Syrian hamster cardiomyopathy gene. **1997**, 6, 601-7	207
1348	LacZ gene transfer to skeletal muscle using a replication-defective herpes simplex virus type 1 mutant vector. **1997**, 8, 439-52	48
1347	Engineering Herpes Simplex. **1997**, 40, 103-136b	20
1346	Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. **1997**, 6, 1771-80	631
1345	Increased cerebral choline-compounds in Duchenne muscular dystrophy. **1997**, 8, 1435-7	17
1344	Functional morphology of serially linked skeletal muscle fibers. **1997**, 159, 99-107	26
1343	Gene therapy of Duchenne muscular dystrophy. **1997**, 35, 117-53	6
1342	Myoblast-MediatedEx VivoGene Transfer to Mature Muscle. **1997**, 3, 125-133	20
1341	Cysteine Proteases and Their Inhibitors. **1997**, 97, 133-172	626
1340	The clinical and molecular genetic approach to Duchenne and Becker muscular dystrophy: an updated protocol. **1997**, 34, 805-12	35
1339	2.1 kb 5'-flanking region of the brain type dystrophin gene directs the expression of lacZ in the cerebral cortex, but not in the hippocampus. **1997**, 147, 13-20	9
1338	Distribution of intramembranous particle size in the muscle plasma membrane of the mdx mouse. **1997**, 148, 147-51	6
1337	Human adenovirus vectors for gene transfer into mammalian cells. **1997**, 40, 137-206	142
1336	Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. **1997**, 139, 375-85	411
1335	A drug inhibits the mitochondrial protease inducing calmitine deficiency in skeletal muscle of patients with Duchenne's muscular dystrophy and dy/dy dystrophic mice. **1997**, 232, 559-61	

1334	Targeted disruption of exon 52 in the mouse dystrophin gene induced muscle degeneration similar to that observed in Duchenne muscular dystrophy. **1997**, 238, 492-7		96
1333	Dp140: alternatively spliced isoforms in brain and kidney. **1997**, 45, 132-9		31
1332	Neuromuscular disorders: gene location. **1997**, 7, I-XI		
1331	Strategies to accomplish targeted gene delivery to muscle cells employing tropism-modified adenoviral vectors. **1997**, 7, 284-98		20
1330	Gene transfer to muscle using herpes simplex virus-based vectors. **1997**, 7, 299-313		37
1329	Use of the dog model for Duchenne muscular dystrophy in gene therapy trials. **1997**, 7, 325-8		42
1328	Challenges in Duchenne muscular dystrophy. **1997**, 7, 482-6		25
1327	Dystrophin is replaced by utrophin in frog heart; implications for muscular dystrophy. **1997**, 7, 493-8		5
1326	Muscle fibers of mdx mice are more vulnerable to exercise than those of normal mice. **1997**, 7, 487-92		123
1325	Neuromuscular disorders: gene location. **1997**, 7, I-XI		2
1324	The molecular basis for cross-reaction of an anti-dystrophin antibody with alpha-actinin. **1997**, 1360, 169-76		5
1323	Efficient myoblast transplantation in mice immunosuppressed with monoclonal antibodies and CTLA4 Ig. **1997**, 29, 1932-4		13
1322	Skeletal and cardiac myopathies in mice lacking utrophin and dystrophin: a model for Duchenne muscular dystrophy. *Cell*, **1997**, 90, 729-38	56.2	535
1321	In vitro expressed dystrophin fragments do not associate with each other. **1997**, 410, 153-9		21
1320	Ochre suppressor transfer RNA restored dystrophin expression in mdx mice. **1997**, 61, PL 205-9		4
1319	Autonomic nervous system imbalance and left ventricular systolic dysfunction as potential candidates for arrhythmogenesis in Becker muscular dystrophy. **1997**, 59, 275-9		35
1318	Dystrophin in the retina. **1997**, 53, 547-60		40
1317	Effect of dystrophin antisense oligonucleotides on cultured human neurons. **1997**, 31, 447-57		12

1316	Dystrophin and its isoforms in a sympathetic ganglion of normal and dystrophic mdx mice: immunolocalization by electron microscopy and biochemical characterization. **1997**, 80, 613-24	23
1315	Skeletal muscle stem cells: function and potential role in therapy. **1997**, 75-98	2
1314	Acetylcholine receptors in innervated muscles of dystrophic mdx mice degrade as after denervation. **1997**, 17, 8194-200	61
1313	Persistence in muscle of an adenoviral vector that lacks all viral genes. **1997**, 94, 1645-50	260
1312	The importance of fresh frozen section in muscle biopsy for diagnostic purposes. **1997**, 6, 73	
1311	The HRX Proto-oncogene Product Is Widely Expressed in Human Tissues and Localizes to Nuclear Structures. **1997**, 89, 3361-3370	62
1310	Contractile properties of clenbuterol-treated mdx muscle are enhanced by low-intensity swimming. **1997**, 82, 435-9	33
1309	Subtle neuromuscular defects in utrophin-deficient mice. **1997**, 136, 871-82	191
1308	Early cardiac failure in a child with Becker muscular dystrophy is due to an abnormally low amount of dystrophin transcript lacking exon 13. **1997**, 39, 685-9	6
1307	DNA-fragmentation and expression of apoptosis-related proteins in muscular dystrophies. **1997**, 23, 331-338	60
1306	Detection of deletions within the dystrophin gene in Polish families affected with Duchenne/Becker muscular dystrophy. **1997**, 4, 138-42	1
1305	Sensorineural hearing loss in the mdx mouse: a model of Duchenne muscular dystrophy. **1997**, 107, 1053-6	15
1304	Utrophin muscles in on the action. **1997**, 3, 22-3	20
1303	The fate of individual myoblasts after transplantation into muscles of DMD patients. **1997**, 3, 970-7	270
1302	Gene table: the muscular dystrophies. **1997**, 1, 53-4	1
1301	Epilepsy in Duchenne and Becker muscular dystrophies. **1997**, 1, 115-9	26
1300	Serum levels of carboxyterminal propeptide of type I procollagen, aminoterminal propeptide of type III procollagen and laminin P1 in Duchenne muscular dystrophy. **1997**, 86, 377-80	3
1299	A splice variant of Dp71 lacking the syntrophin binding site is expressed in early stages of human neural development. **1997**, 103, 77-82	22

1298	Muscle satellite cells from dystrophic (mdx) mice have elevated levels of heparan sulphate proteoglycan receptors for fibroblast growth factor. **1998**, 19, 43-51	10
1297	The membrane-cytoskeleton interface: the role of dystrophin and utrophin. **1997**, 18, 617-29	71
1296	Reduced sarcolemmal dystrophin distribution and upregulation of utrophin in the cardiac and skeletal muscles of CHF-146 dystrophic hamsters. **1997**, 31, 187-206	3
1295	Dystrophin expression in heterozygous mdx/+ mice indicates imprinting of X chromosome inactivation by parent-of-origin-, tissue-, strain- and position-dependent factors. **1997**, 195, 175-82	20
1294	Immunogold and freeze etch electron microscopic studies of merosin localization in basal lamina of human skeletal muscle fibers. **1997**, 93, 34-42	2
1293	Exertional rhabdomyolysis and exercise intolerance revealing dystrophinopathies. **1997**, 94, 48-53	40
1292	Ultrastructural localization of alpha 1-syntrophin and neuronal nitric oxide synthase in normal skeletal myofiber, and their relation to each other and to dystrophin. **1997**, 94, 455-64	29
1291	A 900 bp genomic region from the mouse dystrophin promoter directs lacZ reporter expression only to the right heart of transgenic mice. **1997**, 39, 257-65	15
1290	Systematic use of dystrophin testing in muscle biopsies: results in 201 cases. **1997**, 27, 352-8	14
1289	Asymptomatic dystrophinopathy. **1997**, 69, 261-7	28
1288	Increase in fetal breech presentation in female carriers of Duchenne muscular dystrophy. **1997**, 73, 276-8	6
1287	Subcellular concentration of □dystroglycan in photoreceptors and glial cells of the chick retina. **1997**, 389, 668-678	36
1286	Age-related changes in muscle calcium content in dystrophin-deficient mdx mice. **1997**, 20, 357-60	18
1285	Myoblast implantation in Duchenne muscular dystrophy: the San Francisco study. **1997**, 20, 469-78	164
1284	Skeletal muscle fiber degeneration in mdx mice induced by electrical stimulation. **1997**, 20, 1422-32	10
1283	Limitations of nls beta-galactosidase as a marker for studying myogenic lineage or the efficacy of myoblast transfer. **1997**, 248, 40-50	17
1282	Respiratory muscle injury in animal models and humans. **1998**, 179, 63-80	46
1281	The molecular basis of activity-induced muscle injury in Duchenne muscular dystrophy. **1998**, 179, 111-23	136

1280	Molecular diagnosis of muscular dystrophies. **1998**, 18, 123-130	
1279	Ex vivo gene transfer using adenovirus-mediated full-length dystrophin delivery to dystrophic muscles. **1998**, 5, 19-30	80
1278	Adenovirus-mediated dystrophin minigene transfer improves muscle strength in adult dystrophic (MDX) mice. **1998**, 5, 369-79	59
1277	Mutations in the caveolin-3 gene cause autosomal dominant limb-girdle muscular dystrophy. **1998**, 18, 365-8	493
1276	Effects of iron deprivation on the pathology and stress protein expression in murine X-linked muscular dystrophy. **1998**, 56, 751-7	42
1275	What's in a name? Muscular dystrophy revisited. **1998**, 2, 279-84	2
1274	Muscle maturation: implications for gene therapy. **1998**, 4, 214-20	35
1273	Muscle fiber immaturity and inactivity reduce myonecrosis in Duchenne muscular dystrophy. **1998**, 44, 967-71	4
1272	A dystrophin missense mutation showing persistence of dystrophin and dystrophin-associated proteins yet a severe phenotype. **1998**, 44, 971-6	37
1271	Differential distribution of beta-dystroglycan in rabbit and rat retina. **1998**, 51, 735-47	31
1270	Absence of correlation between skewed X inactivation in blood and serum creatine-kinase levels in Duchenne/Becker female carriers. **1998**, 80, 356-361	24
1269	Transplantation of myoblasts from a transgenic mouse overexpressing dystrophin prduced only a relatively small increase of dystrophin-positive membrane. **1998**, 21, 91-103	37
1268	Aging normal and dystrophic mouse muscle: analysis of myogenicity in cultures of living single fibers. **1998**, 21, 173-83	97
1267	Disorganization of dystrophin costameric lattice in Becker muscular dystrophy. **1998**, 21, 211-6	11
1266	Prior culture with concanavalin A increases intramuscular migration of transplanted myoblast. **1998** , 21, 291-7	40
1265	Corticosteroid therapy does not alter the threshold for contraction-induced injury in dystrophic (mdx) mouse diaphragm. **1998**, 21, 394-7	14
1264	From dystrophinopathy to sarcoglycanopathy: evolution of a concept of muscular dystrophy. **1998**, 21, 421-38	165
1263	Force and stiffness of old dystrophic (mdx) mouse skeletal muscles. **1998**, 21, 536-9	15

1262 Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. **1998**, 21, 567-76 90

1261 Functional involvement of cerebral cortex in Duchenne muscular dystrophy. **1998**, 21, 662-4 25

1260 Dystrophinopathy in a young boy with Klinefelter's syndrome. **1998**, 21, 792-5 2

1259 Differences in both inositol 1,4,5-trisphosphate mass and inositol 1,4,5-trisphosphate receptors between normal and dystrophic skeletal muscle cell lines. **1998**, 21, 902-9 52

1258 Gamma irradiation can reduce muscle damage in mdx dystrophic mice. **1998**, 96, 564-8 9

1257 Subcellular localization of dystrophin and vinculin in cardiac muscle fibers and fibers of the conduction system of the chicken ventricle. **1998**, 294, 137-43 5

1256 Reversal of impaired oxidative phosphorylation and calcium overloading in the skeletal muscle mitochondria of CHF-146 dystrophic hamsters. **1998**, 34, 53-77 9

1255 Muscular dystrophy: centronucleation may reflect a compensatory activation of defective myonuclei. **1998**, 5, 54-61 2

1254 Dystrophin gene analysis on 130 patients with Duchenne muscular dystrophy with a special reference to muscle mRNA analysis. **1998**, 20, 165-8 20

1253 Spatial discrimination learning and CA1 hippocampal synaptic plasticity in mdx and mdx3cv mice lacking dystrophin gene products. **1998**, 86, 53-66 48

1252 C-myc is expressed in mouse skeletal muscle nuclei during post-natal maturation. **1998**, 30, 811-21 7

1251 Beta-sarcoglycan: genomic analysis and identification of a novel missense mutation in the LGMD2E Amish isolate. **1998**, 8, 30-8 38

1250 Sparing of mdx extraocular muscles from dystrophic pathology is not attributable to normalized concentration or distribution of neuronal nitric oxide synthase. **1998**, 8, 22-9 23

1249 Myoblast transplantation in non-dystrophic dog. **1998**, 8, 95-110 28

1248 Implications of maturation for viral gene delivery to skeletal muscle. **1998**, 8, 135-48 46

1247 Dystrophinopathy in a boy with Chediak-Higashi syndrome. **1998**, 8, 489-94

1246 Myotonic ADR-MDX mutant mice show less severe muscular dystrophy than MDX mice. **1998**, 8, 542-50 14

1245 Newborn screening for Duchenne muscular dystrophy. **1998**, 3, 27-34 28

1244	Functional rescue of the sarcoglycan complex in the BIO 14.6 hamster using delta-sarcoglycan gene transfer. **1998**, 1, 841-8	111
1243	Characterization of the tyrosine phosphorylation and distribution of dystrobrevin isoforms. **1998**, 432, 133-40	34
1242	The effects of myotonic dystrophy and Duchenne muscular dystrophy on the orofacial muscles and dentofacial morphology. **1998**, 56, 369-74	76
1241	Transplantation of dermal fibroblasts expressing MyoD1 in mouse muscles. **1998**, 248, 648-54	43
1240	Normal myoblast implantation in MDX mice prevents muscle damage by exercise. **1998**, 250, 321-7	31
1239	The dystrophinopathies: an alternative to the structural hypothesis. **1998**, 5, 3-15	70
1238	Expression of three calpain isoform genes in human skeletal muscles. **1998**, 155, 163-9	38
1237	Decade of the brain: neurological advances. **1998**, 158, 5-14	2
1236	Development of approaches to improve cell survival in myoblast transfer therapy. **1998**, 142, 1257-67	395
1235	Interaptin, an actin-binding protein of the alpha-actinin superfamily in Dictyostelium discoideum, is developmentally and cAMP-regulated and associates with intracellular membrane compartments. **1998**, 142, 735-50	43
1234	Molecular organization of sarcoglycan complex in mouse myotubes in culture. **1998**, 143, 2033-44	108
1233	mdx muscle pathology is independent of nNOS perturbation. **1998**, 7, 823-9	94
1232	Neonatal screening for Duchenne muscular dystrophy: a novel semiquantitative application of the bioluminescence test for creatine kinase in a pilot national program in Cyprus. **1998**, 2, 55-60	41
1231	Muscle type promoter and its first intron abnormalities in dystrophin gene in patients with Duchenne muscular dystrophy. **1998**, 13, 290-2	5
1230	Localization of dystrophin isoform Dp71 to the inner limiting membrane of the retina suggests a unique functional contribution of Dp71 in the retina. **1998**, 7, 1385-91	46
1229	The muscular dystrophies. **1998**, 317, 991-5	81
1228	Preimplantation diagnosis of non-deletion Duchenne muscular dystrophy (DMD) by linkage polymerase chain reaction analysis. **1998**, 4, 345-9	24
1227	Polarity and Development of The Cell Surface in Skeletal Muscle. **1998**, 157-199	

1226 Impaired metabolic modulation of alpha-adrenergic vasoconstriction in dystrophin-deficient skeletal muscle. **1998**, 95, 15090-5 320

1225 Isolation and characterization of lethal mutation near the unc-29 (LG I) region of Caenorhabditis elegans. **1998**, 2, 123-131

1224 Chapter 12 The molecular and cellular biology of skeletal muscle myogenesis. **1998**, 229-259

1223 Effects of aging and voluntary exercise on the function of dystrophic muscle from mdx mice. **1998**, 77, 20-7 64

1222 Differential protein oxidation in Duchenne and Becker muscular dystrophy. **1998**, 9, 2201-7 33

1221 Differential distribution of dystrophin in postsynaptic densities of spine synapses. **1998**, 9, 2249-51 18

1220 Effect of propylthiouracil-induced hypothyroidism on the onset of skeletal muscle necrosis in dystrophin-deficient mdx mice. **1998**, 95, 83-89 10

1219 Effect of propylthiouracil-induced hypothyroidism on the onset of skeletal muscle necrosis in dystrophin-deficient mdx mice. **1998**, 95, 83 6

1218 Respiratory muscles as a target for adenovirus-mediated gene therapy. **1998**, 11, 492-7 10

1217 The ubiquitin-proteasome pathway in distal myopathy with rimmed vacuoles. **1998**, 37, 722-3

1216 References. **1998**, 409-468

1215 The Role of Exercise in Neuromuscular Disease. **1998**, 9, 115-125 18

1214 Molecular Basis of Neuromuscular Disease. **1998**, 9, 49-81 12

1213 Contractile function and low-intensity exercise effects of old dystrophic (mdx) mice. **1998**, 274, C1138-44 62

1212 Hindlimb immobilization applied to 21-day-old mdx mice prevents the occurrence of muscle degeneration. **1999**, 86, 924-31 47

1211 Postmortem proteolysis and calpain/calpastatin activity in callipyge and normal lamb biceps femoris during extended postmortem storage. **1999**, 77, 1490-501 104

1210 Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. **1999**, 104, 375-81 414

1209 MECHANICAL PROPERTIES OF SMOOTH MUSCLE PORTAL VEIN IN NORMAL AND DYSTROPHIN-DEFICIENT (m d x) MICE. **1999**, 84, 929-940 4

1208	In utero fetal muscle biopsy: a precious aid for the prenatal diagnosis of Duchenne muscular dystrophy. **1999**, 14, 127-32	15
1207	Reduced cytosolic acidification during exercise suggests defective glycolytic activity in skeletal muscle of patients with Becker muscular dystrophy. An in vivo 31P magnetic resonance spectroscopy study. **1999**, 122 (Pt 1), 121-30	53
1206	The childhood muscular dystrophies: making order out of chaos. **1999**, 19, 9-23	9
1205	Outlook for therapy in the muscular dystrophies. **1999**, 19, 81-6	8
1204	Activation of utrophin promoter by heregulin via the ets-related transcription factor complex GA-binding protein alpha/beta. **1999**, 10, 2075-86	99
1203	Dysferlin is a plasma membrane protein and is expressed early in human development. **1999**, 8, 855-61	230
1202	The WW domain of dystrophin requires EF-hands region to interact with beta-dystroglycan. **1999**, 380, 431-42	89
1201	The genetic basis of cognition. **1999**, 122 (Pt 11), 2015-32	43
1200	Molecular therapy for genetic muscle diseases--status 1999. **1999**, 55, 1-8	12
1199	Unusual clinical expression of dystrophinopathy in a female, mimicking a congenital myopathy. **1999**, 42, 221-4	2
1198	Quantitative analysis of immunofluorescent signals for dystrophin, beta-dystroglycan and myosin skeletal muscle by epifluorescence microscopy. **1999**, 74, 92-7	1
1197	epsilon-sarcoglycan replaces alpha-sarcoglycan in smooth muscle to form a unique dystrophin-glycoprotein complex. **1999**, 274, 27989-96	100
1196	Membrane targeting and stabilization of sarcospan is mediated by the sarcoglycan subcomplex. **1999**, 145, 153-65	120
1195	Muscle: Part 2 muscle damage: its causes and investigation. **1999**, 13, 131-143	
1194	Mechanical Properties of Smooth Muscle Portal Vein in Normal and Dystrophin-Deficient (MDX) Mice. **1999**, 84, 929-940	1
1193	Increased calcium entry into dystrophin-deficient muscle fibres of MDX and ADR-MDX mice is reduced by ion channel blockers. **1999**, 515 (Pt 3), 859-68	110
1192	rAAV vector-mediated sarcogylcan gene transfer in a hamster model for limb girdle muscular dystrophy. **1999**, 6, 74-82	101
1191	Functional roles of dystrophin and of associated proteins. New insights for the sarcoglycans. **1999**, 20, 371-9	9

1190	Dystrophin and utrophin complexed with different associated proteins in cardiac Purkinje fibres. **1999**, 31, 425-32	30
1189	Differential distribution of dystrophin and beta-spectrin at the sarcolemma of fast twitch skeletal muscle fibers. **1999**, 20, 383-93	28
1188	Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse. **1999**, 20, 605-25	132
1187	Mechanisms of resistance to pathogenesis in muscular dystrophies. **1999**, 195, 155-67	21
1186	Creatine kinase, cell membrane and Duchenne muscular dystrophy. **1999**, 190, 143-151	49
1185	Localisation and quantification of dehydrogenase activities in single muscle fibers of mdx gastrocnemius. **1999**, 112, 427-36	14
1184	Fukuyama-type congenital muscular dystrophy: the first human disease to be caused by an ancient retrotransposal integration. **1999**, 77, 816-23	14
1183	[Current diagnosis in muscular dystrophies. New developments, methods of examination and case examples]. **1999**, 70, 89-100	4
1182	Variable histological expression of dystrophinopathy in two females. **1999**, 97, 657-60	5
1181	Recruitment of bone-marrow-derived cells by skeletal and cardiac muscle in adult dystrophic mdx mice. **1999**, 199, 391-6	330
1180	Phosphorylation of dystrophin and alpha-syntrophin by Ca(2+)-calmodulin dependent protein kinase II. **1999**, 1434, 260-74	25
1179	The muscular dystrophies. **1999**, 3, 137-9	
1178	New aspect of the research on limb-girdle muscular dystrophy 2A: a molecular biologic and biochemical approach to pathology. **1999**, 9, 114-8	12
1177	Quantitative magnetic resonance imaging of the mdx mouse model of Duchenne muscular dystrophy. **1999**, 22, 1367-71	44
1176	A new three allele polymorphism at distal 21q22.3, a region relatively devoid of polymorphic markers. Mutations in brief no. 212. Online. **1999**, 13, 170	15
1175	Facilitated NMDA receptor-mediated synaptic plasticity in the hippocampal CA1 area of dystrophin-deficient mice. **1999**, 33, 59-70	30
1174	Computerised dystrophic muscle simulator: prospecting potential therapeutic strategies for muscle dystrophies using a virtual experimental Model. **1999**, 1, 43-55	1
1173	Herpes simplex virus vector-mediated dystrophin gene transfer and expression in MDX mouse skeletal muscle. **1999**, 1, 280-9	62

1172	Extended tropism of an adenoviral vector does not circumvent the maturation-dependent transducibility of mouse skeletal muscle. **1999**, 1, 393-9	26
1171	Management of neuromuscular scoliosis. **1999**, 30, 435-49, viii	100
1170	Inherited skeletal muscle disorders. **1999**, 26, 507-25	2
1169	Correlation of muscle fiber type measurements with clinical and molecular genetic data in Duchenne muscular dystrophy. **1999**, 9, 150-8	17
1168	Behavioral characterization of mdx3cv mice deficient in C-terminal dystrophins. **1999**, 9, 296-304	36
1167	Muscular dystrophies: alterations in a limited number of cellular pathways?. **1999**, 9, 275-82	20
1166	Molecular control of muscle development: specification, determination and differentiation in the amniote embryo. **1999**, 4, 79-91	
1165	The effect of methylprednisolone on intracellular calcium of normal and dystrophic human skeletal muscle cells. **1999**, 269, 110-4	21
1164	GSH system in relation to redox state in dystrophic skin fibroblasts. **1999**, 81, 1025-9	11
1163	Characteristics of skeletal muscle in mdx mutant mice. **1999**, 191, 99-148	79
1162	Cardiomyopathy in Dystrophin-Deficient Hypertrophic Feline Muscular Dystrophy. **1999**, 13, 346-356	39
1161	Multifocal glial nodules in a case of Duchenne muscular dystrophy with severe mental retardation. **1999**, 19, 322-327	8
1160	The role of gene therapy. Fact or fiction?. **1999**, 18, 223-39, vii-viii	11
1159	Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease. **1999**, 341, 1715-24	1026
1158	Counting muscular dystrophies in the post-molecular census. **1999**, 164, 3-6	9
1157	Sarcoglycanopathies are responsible for 68% of severe autosomal recessive limb-girdle muscular dystrophy in the Brazilian population. **1999**, 164, 44-9	71
1156	Immunocytochemical studies of aquaporin 4 in the skeletal muscle of mdx mouse. **1999**, 164, 24-8	41
1155	Contraction force generated by tarsal joint flexion and extension in dogs with golden retriever muscular dystrophy. **1999**, 166, 115-21	52

1154	The 2.0 A structure of the second calponin homology domain from the actin-binding region of the dystrophin homologue utrophin. **1999**, 285, 1257-64	42
1153	Effects of dystrophin isoforms on signal transduction through neural retina: genotype-phenotype analysis of duchenne muscular dystrophy mouse mutants. **1999**, 66, 100-10	50
1152	Dystrophin and the retina. **1999**, 68, 304-9	30
1151	Nitric oxide and l-arginine cause an accumulation of utrophin at the sarcolemma: a possible compensation for dystrophin loss in Duchenne muscular dystrophy. **1999**, 6, 499-507	51
1150	Increased number of caveolae and caveolin-3 overexpression in Duchenne muscular dystrophy. **1999**, 261, 547-50	85
1149	Role of EMG in the evaluation of presumed myopathies in the era of DNA analysis. **2000**, 53, 133-8	
1148	Cardiac involvement of female carrier of Duchenne muscular dystrophy. **2000**, 39, 2-3	6
1147	A female carrier of Duchenne muscular dystrophy complicated with cardiomyopathy. **2000**, 39, 34-8	9
1146	Why do cultured transplanted myoblasts die in vivo? DNA quantification shows enhanced survival of donor male myoblasts in host mice depleted of CD4+ and CD8+ cells or Nk1.1+ cells. **2000**, 9, 489-502	131
1145	Enhancement of adult muscle regeneration by primary myoblast transplantation. **2000**, 9, 369-77	18
1144	Thymic myoid cells as a source of cells for myoblast transfer. **2000**, 9, 531-8	17
1143	Myoblast transplantation in whole muscle of nonhuman primates. **2000**, 59, 197-206	67
1142	Dissociation of the dystroglycan complex in caveolin-3-deficient limb girdle muscular dystrophy. **2000**, 9, 2335-40	124
1141	Limb-girdle muscular dystrophy: one gene with different phenotypes, one phenotype with different genes. **2000**, 13, 511-7	78
1140	Introduction to muscular dystrophy. **2000**, 48, 127-30	4
1139	Plasma membrane cytoskeleton of muscle: a fine structural analysis. **2000**, 48, 131-41	21
1138	Dystrophin and utrophin: genetic analyses of their role in skeletal muscle. **2000**, 48, 155-66	23
1137	Progress in myoblast transplantation: a potential treatment of dystrophies. **2000**, 48, 213-22	63

1136	Delay of muscle degeneration and necrosis in mdx mice by calpain inhibition. **2000**, 23, 106-11	90
1135	Enhanced migration and fusion of donor myoblasts in dystrophic and normal host muscle. **2000**, 23, 560-74	20
1134	Membrane skeleton of innervated and denervated fast- and slow-twitch muscle. **2000**, 23, 590-9	16
1133	Leukemia inhibitory factor ameliorates muscle fiber degeneration in the mdx mouse. **2000**, 23, 1700-5	36
1132	Muscular dystrophy. **2000**, 20 Suppl, S34-41	9
1131	Overcoming adeno-associated virus vector size limitation through viral DNA heterodimerization. **2000**, 6, 599-602	203
1130	IGF-II ameliorates the dystrophic phenotype and coordinately down-regulates programmed cell death. **2000**, 7, 1109-18	24
1129	Matching host muscle and donor myoblasts for myosin heavy chain improves myoblast transfer therapy. **2000**, 7, 428-37	54
1128	Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice. **2000**, 7, 1447-57	44
1127	T-cell-dependent fibrosis in the mdx dystrophic mouse. **2000**, 80, 881-91	100
1126	The structure of the N-terminal actin-binding domain of human dystrophin and how mutations in this domain may cause Duchenne or Becker muscular dystrophy. **2000**, 8, 481-91	132
1125	Prospects for gene therapy for inherited cardiomyopathies. **2000**, 12, 133-145	7
1124	Synthesis of proteoglycans is augmented in dystrophic mdx mouse skeletal muscle. **2000**, 79, 173-81	58
1123	Testing of SHIRPA, a mouse phenotypic assessment protocol, on Dmd(mdx) and Dmd(mdx3cv) dystrophin-deficient mice. **2000**, 11, 725-8	66
1122	Differential expression of dystrophin, utrophin, and dystrophin-associated proteins in human muscle culture. **2000**, 300, 447-57	30
1121	Proteasome expression in the skeletal muscles of patients with muscular dystrophy. **2000**, 100, 595-602	57
1120	Aciculin and its relation to dystrophin: immunocytochemical studies in human normal and Duchenne dystrophy quadriceps muscles. **2000**, 99, 654-62	4
1119	Sarcoglycanopathies in Dutch patients with autosomal recessive limb girdle muscular dystrophy. **2000**, 247, 524-9	40

1118	Structural comparison of actin binding in utrophin and dystrophin. **2000**, 21, S929-37	15
1117	Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. **2000**, 80, 1215-65	657
1116	Maternal contamination at fetal muscle biopsy. **2000**, 15, 118-21	3
1115	Differential effects of dystrophin and utrophin gene transfer in immunocompetent muscular dystrophy (mdx) mice. **2000**, 3, 133-44	50
1114	Contraction-induced injury to single permeabilized muscle fibers from mdx, transgenic mdx, and control mice. **2000**, 279, C1290-4	104
1113	MYOBLAST THERAPY. **2000**, 739-748	2
1112	Novel Approaches to Therapeutics of the Muscular Dystrophies. **2000**, 18, 1-11	
1111	The dystrophin-associated glycoprotein complex: what parts can you do without?. **2000**, 97, 13464-6	18
1110	Sarcospan-deficient mice maintain normal muscle function. **2000**, 20, 1669-77	59
1109	Rescue of dystrophin expression in mdx mouse muscle by RNA/DNA oligonucleotides. **2000**, 97, 5363-8	143
1108	Myogenic stem cell function is impaired in mice lacking the forkhead/winged helix protein MNF. **2000**, 97, 5416-21	132
1107	Gamma1- and gamma2-syntrophins, two novel dystrophin-binding proteins localized in neuronal cells. **2000**, 275, 15851-60	104
1106	Modulation of Starling forces and muscle fiber maturity permits adenovirus-mediated gene transfer to adult dystrophic (mdx) mice by the intravascular route. **2000**, 11, 701-14	38
1105	Immunobiology and the future of myoblast transfer therapy. **2000**, 1, 304-13	68
1104	The molecular neuropathology of the muscular dystrophies: a review and update. **2000**, 59, 1019-30	8
1103	Klinischer Nutzen genetischer Untersuchungen in der Neurologie. **2000**, 27, 365-375	
1102	Severe mechanical dysfunction in pharyngeal muscle from adult mdx mice. **2000**, 162, 278-81	21
1101	The use of adeno-associated virus to circumvent the maturation-dependent viral transduction of muscle fibers. **2000**, 11, 521-36	79

1100	A novel means of drug delivery: myoblast-mediated gene therapy and regulatable retroviral vectors. **2000**, 40, 295-317	34
1099	Animal models for muscular dystrophy: valuable tools for the development of therapies. **2000**, 9, 2459-67	112
1098	Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. **2000**, 148, 985-96	163
1097	Caveolin-3 deficiency causes muscle degeneration in mice. **2000**, 9, 3047-54	130
1096	Clonal isolation of muscle-derived cells capable of enhancing muscle regeneration and bone healing. **2000**, 150, 1085-100	537
1095	Functional muscle ischemia in neuronal nitric oxide synthase-deficient skeletal muscle of children with Duchenne muscular dystrophy. **2000**, 97, 13818-23	352
1094	Adeno-associated virus vector carrying human minidystrophin genes effectively ameliorates muscular dystrophy in mdx mouse model. **2000**, 97, 13714-9	374
1093	Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. **2000**, 151, 1321-36	414
1092	The small leucine-rich repeat proteoglycan biglycan binds to alpha-dystroglycan and is upregulated in dystrophic muscle. **2000**, 148, 801-10	131
1091	Vertebrate Eye Development. **2000**,	1
1090	Filamin 2 (FLN2): A muscle-specific sarcoglycan interacting protein. **2000**, 148, 115-26	227
1089	Therapies in muscular dystrophy: current concepts and future prospects. **2000**, 43, 127-32	9
1088	Calcium influx through calcium leak channels is responsible for the elevated levels of calcium-dependent proteolysis in dystrophic myotubes. **2000**, 275, 9452-60	142
1087	Caveolin-3 directly interacts with the C-terminal tail of beta -dystroglycan. Identification of a central WW-like domain within caveolin family members. **2000**, 275, 38048-58	149
1086	Diagnosis of pediatric neuromuscular disorders in the era of DNA analysis. **2000**, 23, 289-300	39
1085	Maturation and maintenance of the neuromuscular synapse: genetic evidence for roles of the dystrophin--glycoprotein complex. **2000**, 25, 279-93	240
1084	Large-scale analysis of differential gene expression in the hindlimb muscles and diaphragm of mdx mouse. **2000**, 1500, 17-30	64
1083	Immunohistochemical staining of dystrophin on formalin-fixed paraffin-embedded sections in Duchenne/Becker muscular dystrophy and manifesting carriers of Duchenne muscular dystrophy. **2000**, 10, 425-9	12

1082	Pre-clinical screening of drugs using the mdx mouse. **2000**, 10, 235-9		126
1081	Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. **2000**, 5, 141-51		167
1080	The NO way to increase muscular utrophin expression?. **2000**, 323, 735-40		14
1079	Neural Science. *Cell*, **2000**, 100, 1-55	56.2	61
1078	Biosynthesis of dystroglycan: processing of a precursor propeptide. **2000**, 468, 79-83		133
1077	From the sarcomere to the nucleus: role of genetics and signaling in structural heart disease. **2000**, 1, 179-223		56
1076	Identification of genes that are differentially expressed in extraocular and limb muscle. **2000**, 179, 76-84		15
1075	The emergence of modern neuroscience: some implications for neurology and psychiatry. **2000**, 23, 343-91		84
1074	Novel approaches to treat muscular dystrophies. **2001**, 10, 695-707		4
1073	Scale-up of a myoblast culture process. **2001**, 91, 63-74		24
1072	Evaluaci□ y tratamiento de las enfermedades neuromusculares. **2001**, 22, 1-11		
1071	Dystrophin in adult zebrafish muscle. **2001**, 286, 478-83		33
1070	Helper (CD4(+)) and cytotoxic (CD8(+)) T cells promote the pathology of dystrophin-deficient muscle. **2001**, 98, 235-43		199
1069	Structural diversity despite strong evolutionary conservation in the 5'-untranslated region of the P-type dystrophin transcript. **2001**, 17, 500-13		5
1068	Differential distribution of the members of the dystrophin glycoprotein complex in mouse retina: effect of the mdx(3Cv) mutation. **2001**, 17, 908-20		33
1067	Dystrophin and muscular dystrophy: past, present, and future. **2001**, 74, 75-88		83
1066	Differential regulation of transcripts for dystrophin Isoforms, dystroglycan, and alpha3AChR subunit in mouse sympathetic ganglia following postganglionic nerve crush. **2001**, 8, 513-24		8
1065	Paradoxical weight loss with extra energy expenditure at brown adipose tissue in adolescent patients with Duchenne muscular dystrophy. **2001**, 50, 1181-5		13

1064	Biochemical and histochemical analysis of 71 kDa dystrophin isoform (Dp71f) in rat brain. **2001**, 103, 209-24	50
1063	Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain). **2001**, 1527, 54-60	40
1062	Expression of dystrophin in the mouse myenteric neurones. **2001**, 300, 120-4	9
1061	Molecular pathophysiology and targeted therapeutics for muscular dystrophy. **2001**, 22, 465-70	61
1060	Isolation of a mouse brain cDNA expressed in developing neuroblasts and mature neurons. **2001**, 86, 153-67	13
1059	Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1. **2001**, 1, 717-24	590
1058	Fukuyama muscular dystrophy associated with lack of C-terminal domain of dystrophin. **2001**, 24, 373-8	2
1057	Mast cell proliferation and alterations in bFGF amount and localization are involved in the response of muscle to dystrophin deficiency in hypertrophic feline dystrophy. **2001**, 11, 56-71	6
1056	Cationic channels in normal and dystrophic human myotubes. **2001**, 11, 72-9	37
1055	Identification of altered gene expression in skeletal muscles from Duchenne muscular dystrophy patients. **2001**, 11, 269-77	43
1054	Gene Mutation. **2001**, 11, 104-120	1
1053	Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. **2001**, 11, 703-12	107
1052	[Muscle and heart]. **2001**, 116, 18-9	2
1051	Increased calcium influx is responsible for the sustained mechanical tone in colon from dystrophic (mdx) mice. **2001**, 120, 1430-7	13
1050	Fracturas en la distrofia muscular de duchenne. **2001**, 35, 302-306	
1049	Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. **2001**, 98, 42-47	324
1048	Tyrosine phosphorylation of beta-dystroglycan at its WW domain binding motif, PPxY, recruits SH2 domain containing proteins. **2001**, 40, 14585-92	82
1047	Molecular Diagnosis and Genetic Counseling of the Manifesting Carrier of Duchenne Muscular Dystrophy. **2001**, 173-188	

1046	Stretch-activated cation channels in skeletal muscle myotubes from sarcoglycan-deficient hamsters. **2001**, 281, C690-9	48
1045	Cytoskeletal protein contents before and after hindlimb suspension in a fast and slow rat skeletal muscle. **2001**, 280, R323-30	54
1044	La transplantation de myoblastes normaux ou g□□iquement modifi□ pour le traitement de maladies h□□itaires ou acquises. **2001**, 195, 29-37	4
1043	Combined immunosuppression of mycophenolate mofetil and FK506 for myoblast transplantation in mdx mice. **2001**, 72, 38-44	24
1042	Human gene therapy: are we still expecting too much, too soon?. **2001**, 94, 337-9	
1041	Chapter 15 Clinical Trials in Muscle Disorders. **2001**, 25, 311-325	1
1040	Serum Creatine Kinase in Progressive Muscular Dystrophies. **2001**, 31-49	2
1039	Pharmacologic and genetic therapy for childhood muscular dystrophies. **2001**, 1, 168-74	13
1038	Progress in gene therapy for Duchenne muscular dystrophy. **2001**, 1, 89-96	5
1037	Apoptosis of skeletal muscle cells and the pathogenesis of myositis: a perspective. **2001**, 3, 325-33	14
1036	Changes of skeletal muscle in young dystrophin-deficient cats: a morphological and morphometric study. **2001**, 101, 591-600	21
1035	Most apoptotic cells in mdx diaphragm muscle contain accumulated lipofuscin. **2001**, 115, 205-14	17
1034	Voltage-gated sodium channel (SkM1) content in dystrophin-deficient muscle. **2001**, 441, 746-55	20
1033	Stretch-induced cell damage in sarcoglycan-deficient myotubes. **2001**, 442, 161-70	17
1032	Desmin-related myopathies in mice and man. **2001**, 171, 341-8	55
1031	Harnessing the potential of dystrophin-related proteins for ameliorating Duchenne's muscular dystrophy. **2001**, 171, 349-58	17
1030	Muscle training in muscular dystrophies. **2001**, 171, 359-66	42
1029	Immunolocalisation of neuronal nitric oxide synthase at the neuromuscular junction of MDX mice: a confocal microscopy study. **2001**, 198, 663-71	15

1028	Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle. **2000**, 74, 70-80	45
1027	Altered electrical activity in colonic smooth muscle cells from dystrophic (mdx) mice. **2001**, 13, 169-75	27
1026	Identification of myogenesis-dependent transcriptional enhancers in promoter region of mouse gamma-sarcoglycan gene. **2001**, 268, 948-57	19
1025	Skeletal muscle necrosis and regeneration after injection of Thalassophryne nattereri (niquim) fish venom in mice. **2001**, 82, 55-64	43
1024	Alterations in dystrophin and utrophin expression parallel the reorganization of GABAergic synapses in a mouse model of temporal lobe epilepsy. **2001**, 13, 1113-24	59
1023	Abnormal lipid profile of dystrophic cardiac tissue as demonstrated by one- and two-dimensional magic-angle spinning (1)H NMR spectroscopy. **2001**, 46, 249-55	91
1022	Response to high-intensity eccentric muscle contractions in persons with myopathic disease. **2001**, 24, 1181-7	26
1021	Confocal analysis of the dystrophin protein complex in muscular dystrophy. **2001**, 24, 262-72	16
1020	Acetylcholine receptors and neuronal nitric oxide synthase distribution at the neuromuscular junction of regenerated muscle fibers. **2001**, 24, 410-6	20
1019	Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice. **2001**, 24, 428-32	62
1018	A novel splice site mutation (3157+1G>T) in the dystrophin gene causing total exon skipping and DMD phenotype. **2001**, 17, 239	4
1017	Comparative analysis of PCR-deletion detection and immunohistochemistry in Brazilian Duchenne and Becker muscular dystrophy patients. **2001**, 103, 115-20	15
1016	Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. **2001**, 49, 706-711	201
1015	Multiple applications for replication-defective herpes simplex virus vectors. **2001**, 19, 358-77	59
1014	Tibialis anterior muscles in mdx mice are highly susceptible to contraction-induced injury. **2001**, 22, 467-75	156
1013	The Current State and Prospects of the Gene Therapy of Duchenne Muscular Dystrophy Worldwide and in Russia. **2001**, 37, 868-875	2
1012	Dystrophin-associated proteins in obliquely striated muscle of the leech Pontobdella muricata (Annelida, Hirudinea). **2001**, 33, 135-9	2
1011	Comparative evolution of muscular dystrophy in diaphragm, gastrocnemius and masseter muscles from old male mdx mice. **2001**, 22, 133-9	60

1010	Muscle plasma membrane changes in dystrophin gene exon 52 knockout mouse. **2001**, 197, 441-7	4
1009	Cell invasion is affected by differential expression of the urokinase plasminogen activator/urokinase plasminogen activator receptor system in muscle satellite cells from normal and dystrophic patients. **2001**, 81, 27-39	45
1008	Transplanted primary neonatal myoblasts can give rise to functional satellite cells as identified using the Myf5nlacZl+ mouse. **2001**, 8, 778-83	86
1007	Electrotransfer of naked DNA in the skeletal muscles of animal models of muscular dystrophies. **2001**, 8, 1097-107	94
1006	Calcium currents and transients in co-cultured contracting normal and Duchenne muscular dystrophy human myotubes. **2001**, 534, 343-55	30
1005	Caveolae and the caveolins in human disease. **2001**, 49, 325-35	19
1004	Carrier detection and prenatal molecular diagnosis in a Duchenne muscular dystrophy family without any affected relative available. **2001**, 44, 149-53	7
1003	The organisation of spinal projecting brainstem neurons in an animal model of muscular dystrophy. A retrograde tracing study on mdx mutant mice. **2001**, 895, 213-22	26
1002	Calcium homeostasis and cell death in Sol8 dystrophin-deficient cell line in culture. **2001**, 29, 85-96	15
1001	Problems and solutions in myoblast transfer therapy. **2001**, 5, 33-47	62
1000	Syncoilin, a novel member of the intermediate filament superfamily that interacts with alpha-dystrobrevin in skeletal muscle. **2001**, 276, 6645-55	100
999	A nitric oxide synthase transgene ameliorates muscular dystrophy in mdx mice. **2001**, 155, 123-31	426
998	In vivo requirement of the alpha-syntrophin PDZ domain for the sarcolemmal localization of nNOS and aquaporin-4. **2001**, 155, 113-22	154
997	Antisense-induced exon skipping restores dystrophin expression in DMD patient derived muscle cells. **2001**, 10, 1547-54	214
996	Dystrophin-deficient cardiomyocytes are abnormally vulnerable to mechanical stress-induced contractile failure and injury. **2001**, 15, 1655-7	146
995	gamma-Sarcoglycanopathy in two Palestinian-American siblings. **2001**, 40, 115-7	
994	Intraarterial injection of muscle-derived CD34(+)Sca-1(+) stem cells restores dystrophin in mdx mice. **2001**, 152, 335-48	232
993	Decreased mitochondrial oxygen consumption and antioxidant enzyme activities in skeletal muscle of dystrophic mice after low-intensity exercise. **2001**, 45, 58-66	28

992	Dystrophin-deficient myocardium is vulnerable to pressure overload in vivo. **2001**, 50, 509-15	61
991	Alteration in calcium handling at the subcellular level in mdx myotubes. **2001**, 276, 4647-51	118
990	Novel gene mutations in patients with left ventricular noncompaction or Barth syndrome. **2001**, 103, 1256-63	426
989	Muscular Dystrophy. **2001**,	4
988	Identification of a neuronal nitric oxide synthase in isolated cardiac mitochondria using electrochemical detection. **2001**, 98, 14126-31	298
987	Overexpression of gamma-sarcoglycan induces severe muscular dystrophy. Implications for the regulation of Sarcoglycan assembly. **2001**, 276, 21785-90	42
986	Variations in dystrophin complex in red and white caudal muscles from Torpedo marmorata. **2001**, 49, 857-65	2
985	Dystrophin muscle enhancer 1 is implicated in the activation of non-muscle isoforms in the skeletal muscle of patients with X-linked dilated cardiomyopathy. **2001**, 10, 2627-35	24
984	In Vitro and In Vivo Tetracycline-Controlled Myogenic Conversion of NIH-3T3 Cells: Evidence of Programmed Cell Death after Muscle Cell Transplantation. **2001**, 10, 209-221	8
983	[Progressive limb-girdle muscular dystrophy]. **2001**, 126, 655-8	
982	Molecular genetics of left ventricular dysfunction. **2001**, 1, 81-90	37
981	Forced myofiber regeneration promotes dystrophin gene transfer and improved muscle function despite advanced disease in old dystrophic mice. **2001**, 4, 499-507	14
980	Effect of injecting primary myoblasts versus putative muscle-derived stem cells on mass and force generation in mdx mice. **2002**, 13, 1081-90	43
979	Ultrasound Increases Plasmid-Mediated Gene Transfer to Dystrophic Muscles without Collateral Damage. **2002**, 6, 687-693	1
978	Gene therapy of muscular dystrophy. **2002**, 11, 2355-62	93
977	Overexpression of a calpastatin transgene in mdx muscle reduces dystrophic pathology. **2002**, 11, 2645-55	130
976	Association of syncoilin and desmin: linking intermediate filament proteins to the dystrophin-associated protein complex. **2002**, 277, 3433-9	62
975	A- and B-utrophin have different expression patterns and are differentially up-regulated in mdx muscle. **2002**, 277, 45285-90	96

974	Adeno-associated virus vector-mediated minidystrophin gene therapy improves dystrophic muscle contractile function in mdx mice. **2002**, 13, 1451-60	118
973	Altered aquaporin-4 expression in human muscular dystrophies: a common feature?. **2002**, 16, 1120-2	56
972	Involvement of TRPC in the abnormal calcium influx observed in dystrophic (mdx) mouse skeletal muscle fibers. **2002**, 158, 1089-96	276
971	A chronic inflammatory response dominates the skeletal muscle molecular signature in dystrophin-deficient mdx mice. **2002**, 11, 263-72	322
970	Skeletal myopathy in transgenic mice carrying human prototype c-Ha-ras gene. **2002**, 30, 501-6	5
969	Utrophin binds laterally along actin filaments and can couple costameric actin with sarcolemma when overexpressed in dystrophin-deficient muscle. **2002**, 13, 1512-21	88
968	Growth factor-dependent proliferation and invasion of muscle satellite cells require the cell-associated fibrinolytic system. **2002**, 383, 127-36	19
967	Reduced aquaporin 4 expression in the muscle plasma membrane of patients with Duchenne muscular dystrophy. **2002**, 59, 431-7	52
966	Autotransplantation in mdx Mice of mdx Myoblasts Genetically Corrected by an HSV-1 Amplicon Vector. **2002**, 11, 759-767	20
965	Molecular diagnosis of myocardial disease. **2002**, 2, 587-602	13
964	The molecular biology of dilated cardiomyopathy. **2002**, 4, I2-I7	3
963	Duchenne muscular dystrophy--parental perceptions. **2002**, 41, 105-9	37
962	Spectrin-like repeats from dystrophin and alpha-actinin-2 are not functionally interchangeable. **2002**, 11, 1807-15	29
961	Calsarcin-3, a novel skeletal muscle-specific member of the calsarcin family, interacts with multiple Z-disc proteins. **2002**, 277, 13998-4004	134
960	Cardiomyopathy is independent of skeletal muscle disease in muscular dystrophy. **2002**, 16, 1096-8	19
959	Dystrophin-deficient muscular dystrophy in a Labrador retriever. **2002**, 38, 255-61	42
958	Adeno-associated virus vector gene transfer and sarcolemmal expression of a 144 kDa micro-dystrophin effectively restores the dystrophin-associated protein complex and inhibits myofibre degeneration in nude/mdx mice. **2002**, 11, 733-41	74
957	Regenerated mdx mouse skeletal muscle shows differential mRNA expression. **2002**, 93, 537-45	95

956	Ultrasound Increases Plasmid-Mediated Gene Transfer to Dystrophic Muscles without Collateral Damage. **2002**, 6, 687-693	53
955	The Role of the Calpain System in Neuromuscular Disease. **2002**, 63-73	1
954	Costameres: repeating structures at the sarcolemma of skeletal muscle. **2002**, S203-10	53
953	Duchenne muscular dystrophy: current knowledge, treatment, and future prospects. **2002**, 88-106	37
952	Genetically dystrophic mdx/mdx mice exhibit decreased response to nicotine in passive avoidance. **2002**, 13, 1219-22	10
951	Case report: a young boy with painful leg swelling. **2002**, 14, 731-4	0
950	Nutrition and neurological disorders: in the absence of a cure, what can we offer?. **2002**, 5, 597-9	
949	Interactions between muscle and the immune system during modified musculoskeletal loading. **2002**, S100-9	42
948	Molecular pathophysiology of myofiber injury in deficiencies of the dystrophin-glycoprotein complex. **2002**, 81, S162-74	75
947	Syntrophins and dystrobrevins: defining the dystrophin scaffold at synapses. **2002**, 11, 123-9	72
946	Dilated cardiomyopathy: concepts derived from gene deficient and transgenic animal models. **2002** , 66, 219-24	26
945	Gene delivery using herpes simplex virus vectors. **2002**, 21, 915-36	75
944	A subpopulation of murine bone marrow cells fully differentiates along the myogenic pathway and participates in muscle repair in the mdx dystrophic mouse. **2002**, 277, 74-85	64
943	A novel muscle-specific enhancer identified within the deletion overlap region of two XLDC patients lacking muscle exon 1 of the human dystrophin gene. **2002**, 80, 614-20	8
942	Dystrophin stabilizes alpha 3- but not alpha 7-containing nicotinic acetylcholine receptor subtypes at the postsynaptic apparatus in the mouse superior cervical ganglion. **2002**, 10, 54-66	22
941	Sp1 and the ets-related transcription factor complex GABP alpha/beta functionally cooperate to activate the utrophin promoter. **2002**, 197, 27-35	21
940	Striated muscle cytoarchitecture: an intricate web of form and function. **2002**, 18, 637-706	479
939	Cardiomyopathies and Myofibril Abnormalities. **2002**, 237-263	

938	Herpes simplex virus type 1 amplicon vector-mediated gene transfer to muscle. **2002**, 13, 261-73	27
937	The Feline Genome Project. **2002**, 36, 657-86	55
936	Neurogenetics. **2002**,	
935	The muscular dystrophies. **2002**, 359, 687-95	1086
934	Metabolic profiles of dystrophin and utrophin expression in mouse models of Duchenne muscular dystrophy. **2002**, 530, 109-16	30
933	Ca(2+) influx and opening of Ca(2+)-activated K(+) channels in muscle fibers from control and mdx mice. **2002**, 82, 3012-21	18
932	Muscle lesions associated with dystrophin deficiency in neonatal golden retriever puppies. **2002**, 126, 100-8	76
931	Function and genetics of dystrophin and dystrophin-related proteins in muscle. **2002**, 82, 291-329	882
930	Eccentric contraction injury in dystrophic canine muscle. **2002**, 83, 1572-8	46
929	Dystrophin isoform Dp71 is present in lamellipodia and focal complexes in human astrocytoma cells U-373 MG. **2002**, 104, 245-54	16
928	Becker muscular dystrophy-related cardiomyopathy: a favorable response to medical therapy. **2002** , 21, 496-8	14
927	Expression of dystrophin-associated proteins during neuronal differentiation of P19 embryonal carcinoma cells. **2002**, 12, 36-48	13
926	A quantitative study of bioenergetics in skeletal muscle lacking utrophin and dystrophin. **2002**, 12, 247-57	43
925	DMD(mdx3Cv) and DMD(mdx4Cv) dystrophin mutations in mice: rapid polymerase chain reaction genotyping. **2002**, 12, 366-70	4
924	Muscular dystrophy into the new millennium. **2002**, 12, 343-9	75
923	Neuromuscular disorders: gene location. **2002**, 12, 82-100	
922	Na(+)/Ca(2+) exchange in human myotubes: intracellular calcium rises in response to external sodium depletion are enhanced in DMD. **2002**, 12, 665-73	27
921	Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. **2002**, 12, 828-35	48

920	Gene transfer studies in animals: what do they really tell us about the prospects for gene therapy in DMD?. **2002**, 12 Suppl 1, S11-22	27
919	Viral vectors for gene transfer of micro-, mini-, or full-length dystrophin. **2002**, 12 Suppl 1, S23-9	67
918	Current protocol of a research phase I clinical trial of full-length dystrophin plasmid DNA in Duchenne/Becker muscular dystrophies. Part I: rationale. **2002**, 12 Suppl 1, S49-51	17
917	Screening for antisense modulation of dystrophin pre-mRNA splicing. **2002**, 12 Suppl 1, S67-70	20
916	Targeted exon skipping as a potential gene correction therapy for Duchenne muscular dystrophy. **2002**, 12 Suppl 1, S71-7	135
915	Expression profiling in stably regenerating skeletal muscle of dystrophin-deficient mdx mice. **2002**, 12 Suppl 1, S118-24	30
914	Pharmacological control of cellular calcium handling in dystrophic skeletal muscle. **2002**, 12 Suppl 1, S155-61	55
913	Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models. **2002**, 12, 349-61	361
912	Muscular dystrophies and other inherited myopathies. **2002**, 32, 103-24	51
911	Molecular diversity of the dystrophin-like protein complex in the developing and adult avian retina. **2002**, 111, 259-73	26
910	Changes in the distribution and density of caveolin 3 molecules at the plasma membrane of mdx mouse skeletal muscles: a fracture-label electron microscopic study. **2002**, 325, 171-4	10
909	Genetic diseases of muscle. **2002**, 20, 645-78	33
908	Clarifying the boundaries between the inflammatory and dystrophic myopathies: insights from molecular diagnostics and microarrays. **2002**, 28, 743-57	42
907	Pulsed Doppler tissue imaging in dystrophinopathic cardiomyopathy. **2002**, 15, 891-9	33
906	A biologia molecular contribuindo para a compreens□ e a preven□ das doen□s hereditⷠias. **2002**, 7, 85-99	1
905	Functional characteristics of dystrophic skeletal muscle: insights from animal models. **2002**, 93, 407-17	86
904	Global/temporal gene expression in diaphragm and hindlimb muscles of dystrophin-deficient (mdx) mice. **2002**, 283, C773-84	47
903	The Wayne State experience. **2002**, 17, 321-30	2

902	Analysis of Dystrophin Gene Deletions by Multiplex PCR in Moroccan Patients. **2002**, 2, 158-160	21
901	The zebrafish as a model for human disease. **2002**, 7, d1439-1453	1
900	Green tea extract decreases muscle necrosis in mdx mice and protects against reactive oxygen species. **2002**, 75, 749-53	112
899	Sarcolemmal proteins and the spectrum of limb-girdle muscular dystrophies. **2002**, 9, 81-99	26
898	Muscular nitric oxide synthase (muNOS) and utrophin. **2002**, 96, 43-52	28
897	Altered regional brain glucose metabolism in Duchenne muscular dystrophy: a pet study. **2002**, 26, 506-12	55
896	Adenovirus mediated gene transfer to skeletal muscle. **2002**, 58, 45-51	13
895	Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. **2002**, 4, 644-54	118
894	New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies. **2002**, 171, 99-104	3
893	Cardiovascular Complications of Neuromuscular Disorders. **2002**, 4, 171-179	19
892	Dilated cardiomyopathies as a cause of congestive heart failure. **2002**, 27, 113-34	21
891	Localization of alpha 7 integrins and dystrophin suggests potential for both lateral and longitudinal transmission of tension in large mammalian muscles. **2002**, 308, 255-65	37
890	Cytoskeletal derangements in hereditary myopathy with a desmin L345P mutation. **2002**, 104, 493-504	22
889	Gingival eruption cysts induced by cyclosporine administration to neonatal dogs. **2002**, 29, 507-13	6
888	Gutless Adenoviral Vectors Promising Tools for Gene Therapy. **2002**, 34, 95-100	2
887	Increased vulnerability to kainate-induced seizures in utrophin-knockout mice. **2002**, 15, 1474-84	13
886	Spontaneous mechanical activity and evoked responses in isolated gastric preparations from normal and dystrophic (mdx) mice. **2002**, 14, 667-75	22
885	Increased vulnerability of auditory system to noise exposure in mdx mice. **2002**, 112, 520-5	10

884	Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. **2002**, 418, 417-22	667
883	Functional improvement of dystrophic muscle by myostatin blockade. **2002**, 420, 418-21	675
882	The failing heart. **2002**, 415, 227-33	433
881	Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. **2002**, 8, 253-61	446
880	Early onset of lipofuscin accumulation in dystrophin-deficient skeletal muscles of DMD patients and mdx mice. **2004**, 35, 489-99	39
879	A study of short utrophin isoforms in mice deficient for full-length utrophin. **2003**, 14, 47-60	14
878	Merosin (laminin-2) localization in basal lamina of normal skeletal muscle fibers and changes in plasma membrane of merosin-deficient skeletal muscle fibers. **2003**, 36, 213-20	10
877	Novel therapies for Duchenne muscular dystrophy. **2003**, 2, 299-310	60
876	Cortical and brainstem neurons containing calcium-binding proteins in a murine model of Duchenne's muscular dystrophy: selective changes in the sensorimotor cortex. **2003**, 456, 48-59	25
875	Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. **2003**, 5, 518-27	35
874	Nuclear envelope proteins and neuromuscular diseases. **2003**, 27, 393-406	61
873	Acetylcholine receptor distribution and synapse elimination at the developing neuromuscular junction of mdx mice. **2003**, 28, 561-9	19
872	Ventilatory dysfunction in mdx mice: impact of tumor necrosis factor-alpha deletion. **2003**, 28, 336-43	66
871	Muscle-derived stem cells: potential for muscle regeneration. **2003**, 69, 230-7	74
870	Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study. **2003**, 21, 145-53	75
869	Duodenal contractile activity in dystrophic (mdx) mice: reduction of nitric oxide influence. **2003**, 15, 559-65	15
868	Duchenne's muscular dystrophy: animal models used to investigate pathogenesis and develop therapeutic strategies. **2003**, 84, 165-72	131
867	Proteomic analysis of mdx skeletal muscle: Great reduction of adenylate kinase 1 expression and enzymatic activity. **2003**, 3, 1895-903	72

866	Fukuyama-type congenital muscular dystrophy (FCMD) and alpha-dystroglycanopathy. **2003**, 43, 97-104	42
865	Muscle stem cells differentiate into haematopoietic lineages but retain myogenic potential. **2003**, 5, 640-6	213
864	Skipping to new gene therapies for muscular dystrophy. **2003**, 9, 997-8	9
863	Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. **2003**, 9, 1009-14	332
862	Pharmacological strategies for muscular dystrophy. **2003**, 2, 379-90	167
861	Advances in Duchenne muscular dystrophy gene therapy. **2003**, 4, 774-83	168
860	The changing role of pediatric electrodiagnosis. **2003**, 14, 435-43	1
859	A noninvasive means of detecting preclinical cardiomyopathy in Duchenne muscular dystrophy?. **2003**, 42, 317-8	10
858	Skeletal muscle stem cells. **2003**, 1, 101	89
857	Localization of phospho-beta-dystroglycan (pY892) to an intracellular vesicular compartment in cultured cells and skeletal muscle fibers in vivo. **2003**, 42, 7110-23	43
856	Down-regulation of a novel actin-binding molecule, skeletrophin, in malignant melanoma. **2003**, 163, 1395-404	18
855	Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. **2003**, 163, 1663-75	104
854	Cytoskeletal defects in cardiomyopathy. **2003**, 35, 231-41	22
853	Sast124, a novel splice variant of syntrophin-associated serine/threonine kinase (SAST), is specifically localized in the restricted brain regions. **2003**, 117, 373-81	6
852	Muscular dystrophies: genes to pathogenesis. **2003**, 13, 231-8	165
851	Human melanoma/NG2 chondroitin sulfate proteoglycan is expressed in the sarcolemma of postnatal human skeletal myofibers. Abnormal expression in merosin-negative and Duchenne muscular dystrophies. **2003**, 23, 219-31	24
850	Persistent over-expression of specific CC class chemokines correlates with macrophage and T-cell recruitment in mdx skeletal muscle. **2003**, 13, 223-35	72
849	Consequence of parvalbumin deficiency in the mdx mouse: histological, biochemical and mechanical phenotype of a new double mutant. **2003**, 13, 376-87	35

848	Deficiency of the syntrophins and alpha-dystrobrevin in patients with inherited myopathy. **2003**, 13, 456-67	23
847	Extrajunctional resting Ca2+ influx is not increased in a severely dystrophic expiratory muscle (triangularis sterni) of the mdx mouse. **2003**, 14, 229-39	15
846	Mental retardation and early onset of weakness in a girl with a dystrophinopathy and a large Xp21-23 deletion. **2003**, 18, 79-81	15
845	Chapter 18 Pediatric electromyography and neurography. **2003**, 389-406	
844	Myopathies. **2003**, 14, 403-34, x	7
843	Identification of a putative pathway for the muscle homing of stem cells in a muscular dystrophy model. **2003**, 162, 511-20	55
842	Molecular Diagnosis of Genetic Diseases. **2003**,	
841	Chapter 21 Dystrophinopathies. **2003**, 2, 429-441	
840	Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. **2003**, 12, 1449-59	98
839	Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. **2003**, 12, 907-14	199
838	Skeletal muscle repair by adult human mesenchymal stem cells from synovial membrane. **2003**, 160, 909-18	558
837	The new frontier in muscular dystrophy research: booster genes. **2003**, 17, 1579-84	80
836	The dystrophin associated protein complex in zebrafish. **2003**, 12, 601-615	85
835	Archvillin, a muscle-specific isoform of supervillin, is an early expressed component of the costameric membrane skeleton. **2003**, 116, 2261-75	45
834	Vasomodulation by skeletal muscle-derived nitric oxide requires alpha-syntrophin-mediated sarcolemmal localization of neuronal Nitric oxide synthase. **2003**, 92, 554-60	115
833	Dystrophin delivery in dystrophin-deficient DMDmdx skeletal muscle by isogenic muscle-derived stem cell transplantation. **2003**, 14, 1535-46	28
832	Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. **2003**, 12, 1801-11	166
831	Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. **2003**, 12, 1813-21	101

830	Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy. **2003**, 8, 274-83	7
829	Comprehensive expression profiling by muscle tissue class and identification of the molecular niche of extraocular muscle. **2003**, 17, 1370-2	27
828	Constitutive properties, not molecular adaptations, mediate extraocular muscle sparing in dystrophic mdx mice. **2003**, 17, 893-5	57
827	Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy. **2003**, 17, 386-96	221
826	Dystrophin-glycoprotein complex: post-translational processing and dystroglycan function. **2003**, 278, 15457-60	330
825	Interaction of dystrophin rod domain with membrane phospholipids. Evidence of a close proximity between tryptophan residues and lipids. **2003**, 278, 5993-6001	33
824	Duchenne and Becker muscular dystrophy. **2004**, 92, 311-41	
823	Klassifikation und Benennung von Myopathien. **2003**, 29, 86-93	
822	Gene therapy for muscular dystrophy - a review of promising progress. **2003**, 3, 803-14	21
821	The molecular era of myology. **2003**, 62, 1203-10	3
820	New molecular research technologies in the study of muscle disease. **2003**, 15, 698-707	8
819	Fetoscopic surgery. **2003**, 46, 76-91	4
818	References. 601-868	
817	Dystrophin and Dystrophin-Associated Proteins. **2003**, 67-69	0
816	Global Genomic Analyses of Cardiovascular Disease: A Potential Map or Blind Alley?. 27-44	
815	Plasmin generation dependent on alpha-enolase-type plasminogen receptor is required for myogenesis. **2003**, 90, 724-33	34
814	Cytoskeletal and cellular adhesion proteins in zebrafish (Danio rerio) myogenesis. **2003**, 36, 1117-20	14
813	MUSCULAR DYSTROPHIES. **2003**, 1142-1167	

812	Protein defects in neuromuscular diseases. **2003**, 36, 543-55	18
811	[Current aspects of myopathology]. **2003**, 60, 413-7	
810	Depolarization-induced contraction and SR function in mechanically skinned muscle fibers from dystrophic mdx mice. **2003**, 285, C522-8	22
809	Therapeutic gene transfer to dystrophic diaphragm by an adenoviral vector deleted of all viral genes. **2004**, 287, L569-76	20
808	Functional status and muscle strength in people with Duchenne muscular dystrophy living in the community. **2004**, 36, 124-9	33
807	Stem cell therapy for muscular dystrophy. **2004**, 4, 1-9	35
806	Sustained improvement of muscle function one year after full-length dystrophin gene transfer into mdx mice by a gutted helper-dependent adenoviral vector. **2004**, 15, 145-56	59
805	Genetics of inherited cardiomyopathies. **2004**, 2, 683-97	20
804	Loss of dystrophin causes aberrant mechanotransduction in skeletal muscle fibers. **2004**, 18, 102-13	131
803	Purinoceptor expression in regenerating skeletal muscle in the mdx mouse model of muscular dystrophy and in satellite cell cultures. **2004**, 18, 1404-6	43
802	Temporal gene expression profiling of dystrophin-deficient (mdx) mouse diaphragm identifies conserved and muscle group-specific mechanisms in the pathogenesis of muscular dystrophy. **2004**, 13, 257-69	100
801	Severe proliferative retinopathy in a patient with advanced muscular dystrophy. **2004**, 88, 1604-5	10
800	The mouse dystrophin muscle enhancer-1 imparts skeletal muscle, but not cardiac muscle, expression onto the dystrophin Purkinje promoter in transgenic mice. **2004**, 13, 2853-62	6
799	Antisense derivatives of U7 and other small nuclear RNAs as tools to modify pre-mRNA splicing patterns. **2004**, 2, 321-349	10
798	Multiple pathogenetic mechanisms in X linked dilated cardiomyopathy. **2004**, 90, 835-41	58
797	Evaluation of sarcoglycans, vinculin-talin-integrin system and filamin2 in □and □sarcoglycanopathy: An immunohistochemical study. **2004**, 14, 989	1
796	Systemic delivery of human microdystrophin to regenerating mouse dystrophic muscle by muscle progenitor cells. **2004**, 101, 3581-6	122
795	Heregulin ameliorates the dystrophic phenotype in mdx mice. **2004**, 101, 13856-60	103

794	The potassium channel Kir4.1 associates with the dystrophin-glycoprotein complex via alpha-syntrophin in glia. **2004**, 279, 28387-92	148
793	Targeted exon skipping in transgenic hDMD mice: A model for direct preclinical screening of human-specific antisense oligonucleotides. **2004**, 10, 232-40	102
792	The congenital and limb-girdle muscular dystrophies: sharpening the focus, blurring the boundaries. **2004**, 61, 189-99	52
791	Regenerative capacity of the dystrophic (mdx) diaphragm after induced injury. **2004**, 287, R961-8	25
790	Full-length dystrophin expression in half of the heart cells ameliorates beta-isoproterenol-induced cardiomyopathy in mdx mice. **2004**, 13, 1669-75	56
789	Rocuronium 0.3 mg x kg-1 (ED95) induces a normal peak effect but an altered time course of neuromuscular block in patients with Duchenne's muscular dystrophy. **2006**, 16, 840-5	14
788	Role of contraction-induced injury in the mechanisms of muscle damage in muscular dystrophy. **2004**, 31, 557-61	38
787	Skeletal muscle function: role of ionic changes in fatigue, damage and disease. **2004**, 31, 485-93	95
786	Restoration of dystrophin expression in mdx mice by intravascular injection of naked DNA containing full-length dystrophin cDNA. **2004**, 11, 901-8	57
785	Comparative analysis of antisense oligonucleotide analogs for targeted DMD exon 46 skipping in muscle cells. **2004**, 11, 1391-8	109
784	CTLA4Ig delivered by high-capacity adenoviral vector induces stable expression of dystrophin in mdx mouse muscle. **2004**, 11, 1453-61	22
783	Mini-dystrophin restores L-type calcium currents in skeletal muscle of transgenic mdx mice. **2004**, 555, 251-65	47
782	The action potential-evoked sarcoplasmic reticulum calcium release is impaired in mdx mouse muscle fibres. **2004**, 557, 59-75	86
781	Novel Duchenne muscular dystrophy treatment through myoblast transplantation tolerance with anti-CD45RB, anti-CD154 and mixed chimerism. **2004**, 4, 1255-65	31
780	Dysferlin and the plasma membrane repair in muscular dystrophy. **2004**, 14, 206-13	236
779	Spatial analysis reveals alterations of parvalbumin- and calbindin-positive local circuit neurons in the cerebral cortex of mutant mdx mice. **2004**, 1016, 1-11	28
778	Function induced modifications of gene expression: an alternative approach to gene therapy of Duchenne muscular dystrophy. **2004**, 25, 187-92	2
777	Longitudinal pathologic study of the gastrocnemius muscle group in mdx mice. **2004**, 107, 27-34	28

776	Evolution of pathological changes in the gastrocnemius of the mdx mice correlate with utrophin and beta-dystroglycan expression. **2004**, 108, 443-52	23
775	The relationship between clinical stage, prognosis and myocardial damage in patients with Duchenne-type muscular dystrophy: five-year follow-up study. **2004**, 18, 203-8	9
774	Therapeutics for Duchenne muscular dystrophy: current approaches and future directions. **2004**, 82, 102-15	80
773	Orthodontic treatment of a case of Becker muscular dystrophy. **2004**, 7, 55-62	7
772	Gene therapy in orthopaedic surgery: the current status. **2004**, 74, 46-54	13
771	Distribution of calcitonin gene-related peptide at the neuromuscular junction of mdx mice. **2004**, 279, 798-803	1
770	Differential expression of the skeletal muscle proteome in mdx mice at different ages. **2004**, 25, 2576-85	38
769	Laminin-induced aggregation of the inwardly rectifying potassium channel, Kir4.1, and the water-permeable channel, AQP4, via a dystroglycan-containing complex in astrocytes. **2004**, 47, 138-49	99
768	DGGE-based whole-gene mutation scanning of the dystrophin gene in Duchenne and Becker muscular dystrophy patients. **2004**, 23, 57-66	45
767	Specific assembly pathway of sarcoglycans is dependent on beta- and delta-sarcoglycan. **2004**, 29, 409-19	48
766	Effects of exercise and steroid on skeletal muscle apoptosis in the mdx mouse. **2004**, 30, 456-62	37
765	Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle. **2004**, 30, 645-53	102
764	Effects of prednisone in canine muscular dystrophy. **2004**, 30, 767-73	42
763	Ex vivo gene transfer to mature skeletal muscle by using adenovirus helper cells. **2004**, 6, 155-65	
762	Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. **2004**, 6, 1149-58	23
761	Reduced expression of aquaporin 4 in human muscles with amyotrophic lateral sclerosis and other neurogenic atrophies. **2004**, 200, 203-9	17
760	Role of caveolae and caveolins in health and disease. **2004**, 84, 1341-79	693
759	Molecular normalization of dystrophin in the failing left and right ventricle of patients treated with either pulsatile or continuous flow-type ventricular assist devices. **2004**, 43, 811-7	76

758	Glucocorticoid corticosteroids for Duchenne muscular dystrophy. **2004**, CD003725	70
757	Muscular dystrophy with truncated dystrophin in a family of Japanese Spitz dogs. **2004**, 217, 143-9	38
756	Evolving therapeutic strategies for Duchenne muscular dystrophy: targeting downstream events. **2004**, 56, 831-41	80
755	beta-Dystroglycan can be revealed in microsomes from mdx mouse muscle by detergent treatment. **2004**, 572, 216-20	10
754	Characterization and identification of the inhibitory domain of GDF-8 propeptide. **2004**, 315, 525-31	97
753	Expression of a NOS transgene in dystrophin-deficient muscle reduces muscle membrane damage without increasing the expression of membrane-associated cytoskeletal proteins. **2004**, 82, 312-20	49
752	A-utrophin up-regulation in mdx skeletal muscle is independent of regeneration. **2004**, 14, 19-23	40
751	The PKA-p38MAPK-NFAT5-Organic Osmolytes Pathway in Duchenne Muscular Dystrophy: From Essential Player in Osmotic Homeostasis, Inflammation and Skeletal Muscle Regeneration to Therapeutic Target. **2021**, 9,	0
750	Targeted genome editing in vivo corrects a Dmd duplication restoring wild-type dystrophin expression. **2021**, 13, e13228	3
749	Standard of care versus new-wave corticosteroids in the treatment of Duchenne muscular dystrophy: Can we do better?. **2021**, 16, 117	8
748	Whole exome sequencing reveals a homozygous SGCB variant in a Pakhtun family with limb girdle muscular dystrophy (LGMDR4) phenotype. **2021**, 22, 101014	
747	Cardiomyocyte depolarization triggers NOS-dependent NO transient after calcium release, reducing the subsequent calcium transient. **2021**, 116, 18	3
746	Targeted addition of mini-dystrophin into rDNA locus of Duchenne muscular dystrophy patient-derived iPSCs. **2021**, 545, 40-45	0
745	Short-term treatment of golden retriever muscular dystrophy (GRMD) dogs with rAAVrh74.MHCK7.GALGT2 induces muscle glycosylation and utrophin expression but has no significant effect on muscle strength. **2021**, 16, e0248721	1
744	Tetrahydrobiopterin synthesis and metabolism is impaired in dystrophin-deficient mdx mice and humans. **2021**, 231, e13627	0
743	Essential roles of the dystrophin-glycoprotein complex in different cardiac pathologies. **2021**, 66, 52-71	1
742	Some dystrophy phenotypes of dystrophin-deficient mdx mice are exacerbated by mild, repetitive daily stress. **2021**, 35, e21489	1
741	Treatment with a triazole inhibitor of the mitochondrial permeability transition pore fully corrects the pathology of sapje zebrafish lacking dystrophin. **2021**, 165, 105421	5

740	Correlations Between Dark-Adapted Rod Threshold Elevations and ERG Response Deficits in Duchenne Muscular Dystrophy. **2021**, 62, 29	0
739	Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. **2021**, 7,	29
738	Empowering Muscle Stem Cells for the Treatment of Duchenne Muscular Dystrophy. **2021**, 1-14	7
737	Partial resistance to HDAC inhibitors in FAPs of dystrophic muscles at late stages of disease is associated to epigenetic and transcriptional features of cellular senescence.	
736	Immortalized Canine Dystrophic Myoblast Cell Lines for Development of Peptide-Conjugated Splice-Switching Oligonucleotides. **2021**, 31, 172-181	4
735	Improved Bone Quality and Bone Healing of Dystrophic Mice by Parabiosis. **2021**, 11,	2
734	Diaphragm muscle fibrosis involves changes in collagen organization with mechanical implications in Duchenne Muscular Dystrophy.	0
733	Polypurine Reverse-Hoogsteen Hairpins as a Tool for Exon Skipping at the Genomic Level in Mammalian Cells. **2021**, 22,	1
732	Pharmacological activation of SERCA ameliorates dystrophic phenotypes in dystrophin-deficient mdx mice. **2021**, 30, 1006-1019	7
731	Muscular dystrophy: Experimental animal models and therapeutic approaches (Review). **2021**, 21, 610	1
730	Therapeutic Approaches for Duchenne Muscular Dystrophy: Old and New. **2021**, 37, 100877	8
729	Evolving Roles of Muscle-Resident Fibro-Adipogenic Progenitors in Health, Regeneration, Neuromuscular Disorders, and Aging. **2021**, 12, 673404	17
728	More than movement: the proprioceptive system as a new regulator of musculoskeletal biology. **2021**, 20, 77-89	4
727	CRISPR technologies for the treatment of Duchenne muscular dystrophy. **2021**, 29, 3179-3191	6
726	Highly sensitive screening of antisense sequences for different types of DMD mutations in patients' urine-derived cells. **2021**, 423, 117337	1
725	CRISPR Genome Editing Technology and its Application in Genetic Diseases: A Review. **2021**, 22, 468-479	0
724	Maternal Genetic Disorders That Affect Fetal Health. **2021**, 1120-1157	
723	Early Inflammation in Muscular Dystrophy Differs between Limb and Respiratory Muscles and Increases with Dystrophic Severity. **2021**, 191, 730-747	3

722	A stromal progenitor and ILC2 niche promotes muscle eosinophilia and fibrosis-associated gene expression. **2021**, 35, 108997	8
721	Dose-Dependent Microdystrophin Expression Enhancement in Cardiac Muscle by a Cardiac-Specific Regulatory Element. **2021**, 32, 1138-1146	1
720	Altered visual processing in the mdx52 mouse model of Duchenne muscular dystrophy. **2021**, 152, 105288	2
719	Metformin ncreases arcolemma ntegrity and meliorates euromuscular eficits in a urine odel of Duchenne uscular ystrophy. **2021**, 12, 642908	9
718	Cardioprotective Effect of Whole Body Periodic Acceleration in Dystrophic Phenotype Rodent. **2021**, 12, 658042	2
717	Increasing LRP4 diminishes neuromuscular deficits in a mouse model of Duchenne muscular dystrophy. **2021**, 30, 1579-1590	1
716	Persistent NF-B activation in muscle stem cells induces proliferation-independent telomere shortening. **2021**, 35, 109098	6
715	Decreased Global Strains of LV in Asymptomatic Female Duchenne Muscular Dystrophy Gene Carriers Using CMR-FT. **2021**, 14, 1070-1072	4
714	Bayesian adaptive design for clinical trials in Duchenne muscular dystrophy. **2021**, 40, 4167-4184	3
713	Striated muscle activator of Rho signalling (STARS) overexpression in the mdx mouse enhances muscle functional capacity and regulates the actin cytoskeleton and oxidative phosphorylation pathways. **2021**, 106, 1597-1611	
712	Long-term effect of human mini-dystrophin in transgenic mdx mice improves muscle physiological function. **2021**, 35, e21628	1
711	Low human dystrophin levels prevent cardiac electrophysiological and structural remodelling in a Duchenne mouse model. **2021**, 11, 9779	0
710	Postcontractile blood oxygenation level-dependent (BOLD) response in Duchenne muscular dystrophy. **2021**, 131, 83-94	
709	LTBP4 in Health and Disease. **2021**, 12,	4
708	Prenatal diagnosis of de novo DMD duplication by multiplex ligation-dependent probe amplification (MLPA) after noninvasive prenatal screening (NIPS) at 11 gestational weeks. **2021**, 60, 570-573	
707	A muscle fatigue-like contractile decline was recapitulated using skeletal myotubes from Duchenne muscular dystrophy patient-derived iPSCs. **2021**, 2, 100298	1
706	Early ambulatory Duchenne muscular dystrophy: First symptomatic stage of ambulation - A case report. **2021**, 33, 100349	
705	E3 ligase MKRN3 is a tumor suppressor regulating PABPC1 ubiquitination in non-small cell lung cancer. **2021**, 218,	5

704	Theragnosis for Duchenne Muscular Dystrophy. **2021**, 12, 648390	1
703	Altered Ca Handling and Oxidative Stress Underlie Mitochondrial Damage and Skeletal Muscle Dysfunction in Aging and Disease. **2021**, 11,	5
702	Automatic and unbiased segmentation and quantification of myofibers in skeletal muscle. **2021**, 11, 11793	6
701	Emerging Oligonucleotide Therapeutics for Rare Neuromuscular Diseases. **2021**, 8, 869-884	4
700	The Minimal Clinical Important Difference (MCID) in Annual Rate of Change of Timed Function Tests in Boys with DMD. **2021**, 8, 939-948	1
699	Advanced Fiber Type-Specific Protein Profiles Derived from Adult Murine Skeletal Muscle. **2021**, 9,	5
698	Efficient precise in vivo base editing in adult dystrophic mice. **2021**, 12, 3719	8
697	Application of CRISPR-Cas9 gene editing for congenital heart disease. **2021**, 64, 269-279	4
696	Dystrophin deficiency impairs vascular structure and function in the canine model of Duchenne muscular dystrophy. **2021**, 254, 589-605	4
695	Utrophin modulator drugs as potential therapies for Duchenne and Becker muscular dystrophies. **2021**, 47, 711-723	7
694	Clinical and genetic spectra in patients with dystrophinopathy in Korea: A single-center study. **2021**, 16, e0255011	1
693	Longitudinal motor function in proximal versus distal DMD pathogenic variants. **2021**, 64, 467-473	
692	Evaluation of the Lipid-binding Properties of Recombinant Dystrophin Spectrin-like Repeat Domains R1-3. **2021**, 8, 489-494	0
691	COVID-19 in advanced Duchenne/Becker muscular dystrophy patients. **2021**, 31, 607-611	4
690	Cardiomyocyte-produced miR-339-5p mediates pathology in Duchenne muscular dystrophy cardiomyopathy. **2021**, 30, 2347-2361	0
689	Pathological alterations in the gastrointestinal tract of a porcine model of DMD. **2021**, 11, 131	1
688	Transcriptomic analysis of mdx mouse muscles reveals a signature of early human Duchenne muscular dystrophy.	0
687	A symptomatic male carrier of Duchenne muscular dystrophy with Klinefelter's syndrome mimicking Becker muscular dystrophy. **2021**, 31, 666-672	

686 Filopodia powered by class X myosin promote fusion of mammalian myoblasts.

685 Indices of Defective Autophagy in Whole Muscle and Lysosome Enriched Fractions From Aged D2-mdx Mice. **2021**, 12, 691245 0

684 A video game based hand grip system for measuring muscle force in children. **2021**, 18, 113 2

683 Molecular and cellular basis of genetically inherited skeletal muscle disorders. **2021**, 22, 713-732 11

682 New diagnostic and therapeutic modalities in neuromuscular disorders in children. **2021**, 51, 101033 1

681 Influence of Different Types of Corticosteroids on Heart Rate Variability of Individuals with Duchenne Muscular Dystrophy-A Pilot Cross Sectional Study. **2021**, 11, 2

680 The Interplay of Mitophagy and Inflammation in Duchenne Muscular Dystrophy. **2021**, 11, 3

679 Ifetroban reduces coronary artery dysfunction in a mouse model of Duchenne muscular dystrophy. **2021**, 321, H52-H58 0

678 Targeting HDAC8 to ameliorate skeletal muscle differentiation in Duchenne muscular dystrophy. **2021**, 170, 105750 2

677 Mechanics of dystrophin deficient skeletal muscles in very young mice and effects of age. **2021**, 321, C230-C246 1

676 Serum Antibodies to N-Glycolylneuraminic Acid Are Elevated in Duchenne Muscular Dystrophy and Correlate with Increased Disease Pathology in Cmahmdx Mice. **2021**, 191, 1474-1486

675 Musculoskeletal magnetic resonance imaging in the DE50-MD dog model of Duchenne muscular dystrophy. **2021**, 31, 736-751 2

674 IRE1/XBP1 signaling promotes skeletal muscle regeneration through a cell non-autonomous mechanism.

673 Myogenic Cell Transplantation in Genetic and Acquired Diseases of Skeletal Muscle. **2021**, 12, 702547 3

672 Murine models of Duchenne muscular dystrophy: is there a best model?. **2021**, 321, C409-C412 1

671 Morphological Changes in the Myotendinous Junction of mdx Mice. **2021**, 1-5 2

670 Dystrophin modulates focal adhesion tension and YAP-mediated mechanotransduction.

669 A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. **2021**, 1

668	Cardiac CIP protein regulates dystrophic cardiomyopathy. **2021**,	2
667	Restoration of dystrophin expression in mice by suppressing a nonsense mutation through the incorporation of unnatural amino acids. **2021**,	5
666	Intrafamilial phenotypic heterogeneity related to a new DMD splice site variant. **2021**, 31, 788-797	0
665	Plasma membrane disruption (PMD) formation and repair in mechanosensitive tissues. **2021**, 149, 115970	1
664	Functional interrogation and therapeutic targeting of protein tyrosine phosphatases. **2021**, 49, 1723-1734	1
663	Filopodia powered by class x myosin promote fusion of mammalian myoblasts. **2021**, 10,	2
662	Duchenne muscular dystrophy cell culture models created by CRISPR/Cas9 gene editing and their application in drug screening. **2021**, 11, 18188	0
661	Contractile Activity of Myotubes Derived from Human Induced Pluripotent Stem Cells: A Model of Duchenne Muscular Dystrophy. **2021**, 10,	1
660	LncRNAs as a new regulator of chronic musculoskeletal disorder. **2021**, 54, e13113	2
659	Complexity of skeletal muscle degeneration: multi-systems pathophysiology and organ crosstalk in dystrophinopathy. **2021**, 473, 1813-1839	8
658	Interrogation of Dystrophin and Dystroglycan Complex Protein Turnover After Exon Skipping Therapy. **2021**, 8, S383-S402	0
657	Characterizing Expiratory Respiratory Muscle Degeneration in Duchenne Muscular Dystrophy Using MRI. **2021**,	1
656	The Satellite Cell at 60: The Foundation Years. **2021**, 8, S183-S203	1
655	Anti-latent TGF□binding protein 4 antibody improves muscle function and reduces muscle fibrosis in muscular dystrophy. **2021**, 13, eabf0376	3
654	Evaluating longitudinal therapy effects via the North Star Ambulatory Assessment. **2021**, 64, 614-619	0
653	miRNome profiling in Duchenne muscular dystrophy; identification of asymptomatic and manifesting female carriers. **2021**, 41,	
652	Sarcospan increases laminin binding capacity of □dystroglycan to ameliorate DMD independent of Galgt2. **2021**,	1
651	Identification of Common genes and proteins in Alzheimer□ Disease, Multiple Sclerosis and Duchenne Muscular Dystrophy using in-silico methods.	

650 Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy. **2021**, 8, S369-S381

649 A consolidated AAV system for single-cut CRISPR correction of a common Duchenne muscular dystrophy mutation. **2021**, 22, 122-132 4

648 IRE1 regulates skeletal muscle regeneration through Myostatin mRNA decay. **2021**, 0

647 Flexible Conditional Borrowing Approaches for Leveraging Historical Data in the Bayesian Design of Superiority Trials. 1

646 A preview of selected articles. **2021**, 10, 1361-1364 78

645 Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency.

644 Development of a novel startle response task in Duchenne muscular dystrophy. 0

643 Steroid switching in dystrophinopathy treatment: a US chart review of patient characteristics and clinical outcomes. **2021**, 10, 1065-1078 2

642 Genome editing in large animal models. **2021**, 29, 3140-3152 2

641 CRISPR/Cas correction of muscular dystrophies. **2021**, 408, 112844 1

640 Shared and distinct mechanisms of skeletal muscle atrophy: A narrative review. **2021**, 71, 101463 1

639 Treatment and Management of Muscular Dystrophies. **2022**, 492-527

638 Palliative Care in Patients with Neuromuscular Diseases. **2021**, 231-253

637 C-X-C motif chemokine ligand 12: a potential therapeutic target in Duchenne muscular dystrophy. **2021**, 12, 5428-5439 0

636 Mss51 deletion increases endurance and ameliorates histopathology in the mdx mouse model of Duchenne muscular dystrophy. **2021**, 35, e21276 3

635 Molecular Basis of Neurological Disorders. **2021**, 1-13

634 Epigenetic modifications in muscle regeneration and progression of Duchenne muscular dystrophy. **2021**, 13, 13 6

633 Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing. **2021** , 18, 1048-1062 6

632	Genetics of Muscle Disease. 39-67	1
631	Skeletal Muscle Adaptations to Disease States. **2006**, 315-360	2
630	The Cardiac Sodium Channel and Its Protein Partners. **2018**, 246, 73-99	10
629	Inflammatory cardiomyopathy: there is a specific matrix destruction in the course of the disease. **2006**, 219-50	8
628	Muscular Dystrophies and Protein Mutations. **2007**, 391-407	1
627	Animal Models for Inherited Muscle Diseases. **2010**, 1-21	1
626	Human Genome Initiative. **1994**, 305-330	1
625	Cloning of the Duchenne/Becker muscular dystrophy locus. **1988**, 17, 61-98	41
624	A Molecular Approach to Autosomal Dominant Polycystic Kidney Disease. **1990**, 221-246	1
623	Models of Cardiac Disease in the Mouse. **2001**, 335-352	1
622	Familial Dilated Cardiomyopathy. **2000**, 195-218	1
621	Free radicals and trials of antioxidant therapy in muscle diseases. **1990**, 264, 485-91	18
620	Practical aspects of myoblast implantation: investigations on two inherited myopathies in animals. **1990**, 280, 89-94; discussion 95-6	7
619	Regeneration of skeletal muscle induced by satellite cell grafts. **1990**, 280, 159-65; discussion 165-6	4
618	Plausible structural/functional/behavioral/biochemical transformations following myoblast transfer therapy. **1990**, 280, 241-9; discussion 249-50	3
617	Mdx mouse as therapeutic model system: development and implementation of phenotypic monitoring. **1990**, 280, 251-63; discussion 263-5	8
616	Detection of truncated dystrophin in fetal DMD myotubes. **1990**, 280, 17-23	2
615	The physiological evaluation of gene therapies of dystrophin-deficient muscles. **1998**, 453, 411-6; discussion 417	5

614	The Essentials of Molecular Genetics. **1992**, 103-127	1
613	Nonisotopic in Situ Hybridization. **1994**, 187-255	14
612	Evolution and Revolution in Psychiatric Genetics. **1996**, 5-28	3
611	PMO Delivery System Using Bubble Liposomes and Ultrasound Exposure for Duchenne Muscular Dystrophy Treatment. **2018**, 1687, 185-192	6
610	Flow Cytometry-Defined CD49d Expression in Circulating T-Lymphocytes Is a Biomarker for Disease Progression in Duchenne Muscular Dystrophy. **2018**, 1687, 219-227	3
609	Genome-Wide Association Studies in Muscle Physiology and Disease. **2019**, 9-30	0
608	Electroporation of corrective nucleic acids (CNA) in vivo to promote gene correction in dystrophic muscle. **2008**, 423, 405-19	1
607	Gene delivery to dystrophic muscle. **2008**, 423, 421-31	7
606	The Domestic Cat, Felis catus, as a Model of Hereditary and Infectious Disease. **2008**, 221-232	3
605	Animal Models for Muscle Disease and Muscle Gene Therapy. **2019**, 41-63	1
604	Genetically Engineered Large Animals in Biomedicine. **2018**, 169-214	1
603	Roles of the extracellular matrix in retinal development and maintenance. **2000**, 31, 115-40	11
602	Muscular Dystrophies and Myopathies in Arab Populations. **2010**, 145-179	6
601	Antisense Technology: From Unique Laboratory Tool to Novel Anticancer Treatments. **2012**, 145-189	2
600	Reactive Oxygen Species and Muscular Dystrophy. **2014**, 3055-3079	3
599	Das Herz bei prim□en Muskelkrankheiten. **2000**, 1477-1531	0
598	Muskeldystrophien. **2002**, 621-637	0
597	The transmission of contractility through cell adhesion. **2000**, 25, 21-35	1

596	Gene Transfer of a Murine Dystrophin Minigene Construct. **1992**, 158-166	1
595	Skeletal Muscle. **2012**, 449-460	2
594	Skeletal Muscle Collagen: Age, Injury and Disease. **2011**, 159-172	3
593	Tissue engineering: Cartilage, bone and muscle. **1996**, 235-245	2
592	Molecular mechanisms of muscle damage. **1993**, 3, 257-82	4
591	Myoblast transplantation in inherited myopathies. **1993**, 3, 303-31	5
590	Molecular genetics and genetic counselling for Duchenne/Becker muscular dystrophy. **1993**, 3, 37-84	16
589	Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. **1993**, 3, 139-66	40
588	PCR analysis of muscular dystrophy in mdx mice. **1993**, 3, 167-89	8
587	Therapeutic Potential of Skeletal Muscle Plasticity and Slow Muscle Programming for Muscular Dystrophy and Related Muscle Conditions. **2017**, 277-292	4
586	Calmodulin-Binding Proteins of the Cytoskeleton. **1998**, 347-396	2
585	Neuromuscular Disorders and Malignant Hyperthermia. **2010**, 1171-1195	10
584	Immunohistochemistry Applications in Pathology. **2008**, 493-515	1
583	Prediction and prevention in Huntington's disease. **1991**, 281-297	0
582	Experimental Observations of Creatine Phosphate and Creatine Metabolism. **1996**, 33-50	3
581	Muscle Cell Transplants. **2007**, 289-302	1
580	Immunologicalization and Structural Configuration of Membrane and Cytoskeletal Proteins Involved in Excitation-Contraction Coupling of Cardiac Muscle. **1997**, 1-32	1
579	Muscular Dystrophies. **2012**, 1570-1606	1

578	Funktionspathologien und Untersuchung des Skelettmuskels. **2016**, 27-54	0
577	Therapeutic Gene Editing with CRISPR: A Laboratory Medicine Perspective. **2020**, 40, 205-219	3
576	Association of utrophin and multiple dystrophin short forms with the mammalian M(r) 58,000 dystrophin-associated protein (syntrophin).. **1994**, 269, 2870-2876	120
575	Identification of a chromosome 6-encoded dystrophin-related protein.. **1990**, 265, 16717-16720	157
574	Association of the Mr 58,000 postsynaptic protein of electric tissue with Torpedo dystrophin and the Mr 87,000 postsynaptic protein.. **1992**, 267, 6213-6218	67
573	Molecular cloning and expression of a mouse muscle cDNA encoding adenylosuccinate synthetase.. **1991**, 266, 22582-22587	30
572	Ca2+-independent F-actin Capping Proteins. **1989**, 264, 12639-12647	50
571	Molecular cloning of cDNAs from human kidney coding for two alternatively spliced products of the cardiac Ca2+-ATPase gene.. **1988**, 263, 15024-15031	273
570	Evidence for the association of dystrophin with the transverse tubular system in skeletal muscle.. **1988**, 263, 8480-8484	54
569	Dystrophin in Electric Organ of Torpedo californica Homologous to That in Human Muscle. **1989**, 264, 20831-20834	48
568	Full-length sequence of the cDNA for human erythroid beta-spectrin.. **1990**, 265, 11827-11832	175
567	Identification of dystrophin-binding protein(s) in membranes from Torpedo electrocyte and rat muscle. **1993**, 268, 13019-13022	22
566	Muscle creatine kinase isoenzyme expression in adult human brain.. **1990**, 265, 6403-6409	27
565	Detailed analysis of the repeat domain of dystrophin reveals four potential hinge segments that may confer flexibility.. **1990**, 265, 4560-4566	262
564	RESPIRATORY DYSFUNCTION IN MUSCULAR DYSTROPHY AND OTHER MYOPATHIES. **1994**, 15, 661-674	34
563	Regulation of ligand-gated ion channels by protein phosphorylation. **1999**, 33, 49-78	253
562	Chapter 11:Drug Discovery Approaches for Rare Neuromuscular Diseases. **2014**, 257-343	3
561	From diagnosis to therapy in Duchenne muscular dystrophy. **2020**, 48, 813-821	10

560	Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. **2001**, 98, 42-7	182
559	Hydrodynamic limb vein injection of AAV8 canine myostatin propeptide gene in normal dogs enhances muscle growth. **2008**, 081015093227032	2
558	Nerve Growth Factor Improves the Muscle Regeneration Capacity of Muscle Stem Cells in Dystrophic Muscle. **2006**, 060123080936002	2
557	Gastrointestinal disorders in muscular dystrophies. **1997**, 25 Suppl 1, S20-1	5
556	Immunosuppression with monoclonal antibodies and CTLA4-Ig after myoblast transplantation in mice. **1996**, 62, 962-7	19
555	Successful myoblast transplantation in fibrotic muscles: no increased impairment by the connective tissue. **1999**, 67, 1618-22	13
554	The sarcoglycan complex in limb-girdle muscular dystrophy. **1998**, 11, 443-52	106
553	Transplantation of Muscle Stem Cell Mitochondria Rejuvenates the Bioenergetic Function of Dystrophic Muscle.	1
552	Myogenesis modelled by human pluripotent stem cells uncovers Duchenne muscular dystrophy phenotypes prior to skeletal muscle commitment.	1
551	Multiplex in situ hybridization within a single transcript: RNAscope reveals dystrophin mRNA dynamics.	3
550	Gadolinium reduces short-term stretch-induced muscle damage in isolated mdx mouse muscle fibres. **2003**, 552, 449-58	70
549	The basal lamina is a physical barrier to herpes simplex virus-mediated gene delivery to mature muscle fibers. **1996**, 70, 8117-23	64
548	Combinatorial blockade of calcineurin and CD28 signaling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles. **1998**, 72, 4601-9	37
547	The GLI gene encodes a nuclear protein which binds specific sequences in the human genome. **1990** , 10, 634-642	209
546	mXBP/CRE-BP2 and c-Jun form a complex which binds to the cyclic AMP, but not to the 12-O-tetradecanoylphorbol-13-acetate, response element. **1990**, 10, 1609-1621	103
545	Suite of clinically relevant functional assays to address therapeutic efficacy and disease mechanism in the dystrophic mouse. **2017**, 122, 593-602	3
544	Myocardial involvement is very frequent among patients affected with subclinical Becker's muscular dystrophy. **1996**, 94, 3168-75	137
543	Evidence for a dystrophin missense mutation as a cause of X-linked dilated cardiomyopathy. **1997**, 95, 2434-40	129

542	S-nitrosylation of connexin43 hemichannels elicits cardiac stress-induced arrhythmias in Duchenne muscular dystrophy mice. **2019**, 4,	23
541	Glucocorticoids counteract hypertrophic effects of myostatin inhibition in dystrophic muscle. **2020**, 5,	9
540	Lack of miR-378 attenuates muscular dystrophy in mdx mice. **2020**, 5,	11
539	TGF-□driven muscle degeneration and failed regeneration underlie disease onset in a DMD mouse model. **2020**, 5,	32
538	Disease-modifying effects of orally bioavailable NF-B inhibitors in dystrophin-deficient muscle. **2016**, 1, e90341	35
537	Efficient exon skipping of SGCG mutations mediated by phosphorodiamidate morpholino oligomers. **2018**, 3,	11
536	Complementary DNA probes for the Duchenne muscular dystrophy locus demonstrate a previously undetectable deletion in a patient with dystrophic myopathy, glycerol kinase deficiency, and congenital adrenal hypoplasia. **1989**, 83, 95-9	46
535	Improved diagnosis of Duchenne/Becker muscular dystrophy. **1990**, 85, 613-9	54
534	Lysis of myotubes by alloreactive cytotoxic T cells and natural killer cells. Relevance to myoblast transplantation. **1990**, 86, 370-4	33
533	Are cysteine-rich and COOH-terminal domains of dystrophin critical for sarcolemmal localization?. **1992**, 89, 712-6	42
532	Deficiency of dystrophin-associated proteins in Duchenne muscular dystrophy patients lacking COOH-terminal domains of dystrophin. **1993**, 92, 866-71	57
531	Dystrophin: the long and short of it. **1994**, 93, 4	2
530	Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin. **1994**, 93, 99-105	35
529	Abnormal expression of laminin suggests disturbance of sarcolemma-extracellular matrix interaction in Japanese patients with autosomal recessive muscular dystrophy deficient in adhalin. **1994**, 94, 601-6	20
528	Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. **1995**, 96, 1137-44	227
527	Myonuclear apoptosis in dystrophic mdx muscle occurs by perforin-mediated cytotoxicity. **1997**, 99, 2745-51	125
526	Genetic correction of dystrophin deficiency and skeletal muscle remodeling in adult MDX mouse via transplantation of retroviral producer cells. **1997**, 100, 620-8	28
525	Prevention of connexin-43 remodeling protects against Duchenne muscular dystrophy cardiomyopathy. **2020**, 130, 1713-1727	24

524	Stem cell therapy for muscular dystrophies. **2020**, 130, 5652-5664	25
523	Dysferlin-mediated membrane repair protects the heart from stress-induced left ventricular injury. **2007**, 117, 1805-13	132
522	Chronic administration of membrane sealant prevents severe cardiac injury and ventricular dilatation in dystrophic dogs. **2010**, 120, 1140-50	90
521	microRNA-206 promotes skeletal muscle regeneration and delays progression of Duchenne muscular dystrophy in mice. **2012**, 122, 2054-65	229
520	Improved regenerative myogenesis and muscular dystrophy in mice lacking Mkp5. **2013**, 123, 2064-77	37
519	Inhibition of Coxsackievirus-associated dystrophin cleavage prevents cardiomyopathy. **2013**, 123, 5146-51	32
518	TRAF6 regulates satellite stem cell self-renewal and function during regenerative myogenesis. **2016**, 126, 151-68	42
517	COUP-TFII regulates satellite cell function and muscular dystrophy. **2016**, 126, 3929-3941	24
516	Mutations in the human delta-sarcoglycan gene in familial and sporadic dilated cardiomyopathy. **2000**, 106, 655-62	252
515	Mechanical factors tune the sensitivity of mdx muscle to eccentric strength loss and its protection by antioxidant and calcium modulators. **2020**, 10, 3	16
514	Wheat kernel ingestion protects from progression of muscle weakness in mdx mice, an animal model of Duchenne muscular dystrophy. **1996**, 40, 444-9	17
513	Modeling disease trajectory in Duchenne muscular dystrophy. **2020**, 94, e1622-e1633	21
512	Induction of dystrophin localization in cultured Xenopus muscle cells by latex beads. **1992**, 103, 551-563	12
511	Loss of cytoplasmic basic fibroblast growth factor from physiologically wounded myofibers of normal and dystrophic muscle. **1993**, 106, 121-133	145
510	Talin, vinculin and DRP (utrophin) concentrations are increased at mdx myotendinous junctions following onset of necrosis. **1994**, 107, 1477-1483	68
509	Interaction of chromosome-6-encoded dystrophin related protein with the extracellular matrix. **1995**, 108, 173-185	22
508	Dermal fibroblasts convert to a myogenic lineage in mdx mouse muscle. **1995**, 108, 207-214	61
507	Apoptosis precedes necrosis of dystrophin-deficient muscle. **1995**, 108, 2197-2204	161

506	Na,K-ATPase in skeletal muscle: two populations of beta-spectrin control localization in the sarcolemma but not partitioning between the sarcolemma and the transverse tubules. **2001**, 114, 751-762	42
505	Immunolocalization of caveolin-1 and caveolin-3 in monkey skeletal, cardiac and uterine smooth muscles. **2002**, 27, 375-82	32
504	Plasmalemma Function Is Rapidly Restored in Mdx Muscle after Eccentric Contractions. **2020**, 52, 354-361	14
503	Sequencing data from Massachusetts General Hospital shows Cas9 integration into the genome, highlighting a serious hazard in gene-editing therapeutics. 8, 1846	6
502	Chemical crosslinking analysis of □dystroglycan in dystrophin-deficient skeletal muscle.. **2018**, 1, 17	1
501	Chemical crosslinking analysis of □dystroglycan in dystrophin-deficient skeletal muscle. 1, 17	1
500	The effects of glucocorticoid and voluntary exercise treatment on the development of thoracolumbar kyphosis in dystrophin-deficient mice. **2012**, 4, e4ffdff160de8b	4
499	Collective Statement Regarding Patient Access to Approved Therapies from the Center Directors of Parent Project Muscular Dystrophy's Certified Duchenne Care Centers. **2018**, 10,	1
498	The 6-minute walk test and person-reported outcomes in boys with duchenne muscular dystrophy and typically developing controls: longitudinal comparisons and clinically-meaningful changes over one year. **2013**, 5,	62
497	Generation of embryonic stem cells and mice for duchenne research. **2013**, 5,	7
496	Effects of Dantrolene Therapy on Disease Phenotype in Dystrophin Deficient mdx Mice. **2013**, 5,	6
495	Reprogramming efficiency and quality of induced Pluripotent Stem Cells (iPSCs) generated from muscle-derived fibroblasts of mdx mice at different ages. **2011**, 3, RRN1274	50
494	Voluntary wheel running in dystrophin-deficient (mdx) mice: Relationships between exercise parameters and exacerbation of the dystrophic phenotype. **2011**, 3, RRN1295	16
493	L-type Ca2+ channel function is linked to dystrophin expression in mammalian muscle. **2008**, 3, e1762	32
492	Skeletal muscle-specific ablation of gamma(cyto)-actin does not exacerbate the mdx phenotype. **2008**, 3, e2419	19
491	Inhibitory control over Ca(2+) sparks via mechanosensitive channels is disrupted in dystrophin deficient muscle but restored by mini-dystrophin expression. **2008**, 3, e3644	38
490	Arginine metabolism by macrophages promotes cardiac and muscle fibrosis in mdx muscular dystrophy. **2010**, 5, e10763	91
489	□1-syntrophin modulation by miR-222 in mdx mice. **2010**, 5, e12098	15

488	Chronic hypoxia impairs muscle function in the Drosophila model of Duchenne's muscular dystrophy (DMD). **2010**, 5, e13450	14
487	Myogenin regulates exercise capacity but is dispensable for skeletal muscle regeneration in adult mdx mice. **2011**, 6, e16184	22
486	Contribution of human muscle-derived cells to skeletal muscle regeneration in dystrophic host mice. **2011**, 6, e17454	56
485	Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development. **2011**, 6, e19906	16
484	Differential requirement for utrophin in the induced pluripotent stem cell correction of muscle versus fat in muscular dystrophy mice. **2011**, 6, e20065	6
483	Chronic losartan administration reduces mortality and preserves cardiac but not skeletal muscle function in dystrophic mice. **2011**, 6, e20856	47
482	Translational regulation of utrophin by miRNAs. **2011**, 6, e29376	37
481	Granulocyte-colony stimulating factor improves MDX mouse response to peripheral nerve injury. **2012**, 7, e42803	4
480	Dystrophin deficiency compromises force production of the extensor carpi ulnaris muscle in the canine model of Duchenne muscular dystrophy. **2012**, 7, e44438	23
479	In vitro modeling of paraxial mesodermal progenitors derived from induced pluripotent stem cells. **2012**, 7, e47078	47
478	Requirement of plasminogen binding to its cell-surface receptor □enolase for efficient regeneration of normal and dystrophic skeletal muscle. **2012**, 7, e50477	8
477	Interplay between DMD point mutations and splicing signals in Dystrophinopathy phenotypes. **2013**, 8, e59916	29
476	Assessment of RT-qPCR normalization strategies for accurate quantification of extracellular microRNAs in murine serum. **2014**, 9, e89237	82
475	Role of dystrophin in airway smooth muscle phenotype, contraction and lung function. **2014**, 9, e102737	17
474	Defects in mitochondrial ATP synthesis in dystrophin-deficient mdx skeletal muscles may be caused by complex I insufficiency. **2014**, 9, e115763	76
473	Differential Gene Expression Profiling of Dystrophic Dog Muscle after MuStem Cell Transplantation. **2015**, 10, e0123336	14
472	Profiles of Steroid Hormones in Canine X-Linked Muscular Dystrophy via Stable Isotope Dilution LC-MS/MS. **2015**, 10, e0126585	7
471	Mest but Not MiR-335 Affects Skeletal Muscle Growth and Regeneration. **2015**, 10, e0130436	18

470	Cis-Acting Sequence Elements and Upstream Open Reading Frame in Mouse Utrophin-A 5'-UTR Repress Cap-Dependent Translation. **2015**, 10, e0134809	7
469	The Regulation of Muscle Structure and Metabolism by Mio/dChREBP in Drosophila. **2015**, 10, e0136504	3
468	Novel Nuclear Protein Complexes of Dystrophin 71 Isoforms in Rat Cultured Hippocampal GABAergic and Glutamatergic Neurons. **2015**, 10, e0137328	12
467	Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy. **2015**, 10, e0141240	40
466	The Effects of Experimental Sleep Apnea on Cardiac and Respiratory Functions in 6 and 18 Month Old Dystrophic (mdx) Mice. **2016**, 11, e0147640	3
465	Resting Energy Expenditure in Adults with Becker's Muscular Dystrophy. **2017**, 12, e0169848	7
464	Short (16-mer) locked nucleic acid splice-switching oligonucleotides restore dystrophin production in Duchenne Muscular Dystrophy myotubes. **2017**, 12, e0181065	6
463	Functional improvement of dystrophic muscle by repression of utrophin: let-7c interaction. **2017**, 12, e0182676	16
462	Multiplex in situ hybridization within a single transcript: RNAscope reveals dystrophin mRNA dynamics. **2020**, 15, e0239467	3
461	Cellular dynamics of myogenic cell migration: molecular mechanisms and implications for skeletal muscle cell therapies. **2020**, 12, e12357	7
460	Immunoreactivity of Antibodies Raised Against Synthetic Peptide Fragments Predicted from Cysteine-rich and Carboxy-terminal Domains of Dystrophin cDNA. **1992**, 4, 141-150	2
459	Dystrophin hydrophobic regions in the pathogenesis of Duchenne and Becker muscular dystrophies. **2015**, 15, 42-9	3
458	Reliability and validity of the turkish translation of pedsqlTM multidimensional Fatigue scale in Duchenne Muscular Dystrophy. **2019**, 24, 302-310	2
457	Decreased Dp71 expression is associated with gastric adenocarcinoma prognosis. **2016**, 7, 53702-53711	13
456	Diffusion tensor imaging study in Duchenne muscular dystrophy. **2016**, 4, 109	8
455	The diagnosis and orthopaedic treatment of inherited muscular diseases of childhood. **1993**, 75, 439-54	46
454	Possible orthopaedic applications of gene therapy. **1995**, 77, 1103-14	162
453	Evaluation of a program for long-term treatment of Duchenne muscular dystrophy. Experience at the University Hospitals of Cleveland. **1996**, 78, 1844-52	65

452	Proliferative Retinopathy Developed in a Duchenne Muscular Dystrophy Patient with Normal Cardiac Function. **2019**, 4, 36-39	1
451	Comparative Genomics of X-linked Muscular Dystrophies: The Golden Retriever Model. **2013**, 14, 330-42	23
450	Repurposing Pathogenic Variants of Gene and its Isoforms for DMD Exon Skipping Intervention. **2019**, 20, 519-530	8
449	Mitochondrial Dysfunction in Skeletal Muscle Pathologies. **2019**, 20, 536-546	23
448	Ryanodine receptor patents. **2012**, 6, 157-66	8
447	Poloxamer 188 (p188) as a membrane resealing reagent in biomedical applications. **2012**, 6, 200-11	77
446	Vamorolone targets dual nuclear receptors to treat inflammation and dystrophic cardiomyopathy. **2019**, 2,	28
445	The advances and challenges of Gene Therapy for Duchenne Muscular Dystrophy. **2017**, 1, 019-036	3
444	Hereditary neuromuscular diseases. Part 1. Muscular dystrophies: dystrophinopathy emerinopathy and facio-scapulo-humeral forms. **2020**, 24, 4-13	1
443	Decision-Making And Selection Bias in Four Observational Studies on Duchenne and Becker Muscular Dystrophy. **2020**, 7, 433-442	3
442	Existence of Apoptosis Related Proteins in the Mdx Mouse Masseter Muscle. **2005**, 10, 1-7	3
441	The diagnosis of muscular dystrophy. **2005**, 34, 525-30	7
440	The heart in muscular dystrophy. **2005**, 34, 531-5	13
439	Diminution in sperm quantity and quality in mouse models of Duchenne Muscular Dystrophy induced by a myostatin-based muscle growth-promoting intervention. **2020**, 30, 8904	3
438	Diminution in sperm quantity and quality in mouse models of Duchenne Muscular Dystrophy induced by a myostatin-based muscle growth-promoting intervention. **2020**, 30, 276-285	1
437	Retrospective cohort study comparing the efficacy of prednisolone and deflazacort in children with muscular dystrophy: A 6 years' experience in a South Indian teaching hospital. **2016**, 50, 551-557	3
436	Evaluation of multiplex ligation-dependent probe amplification analysis versus multiplex polymerase chain reaction assays in the detection of dystrophin gene rearrangements in an Iranian population subset. **2014**, 3, 72	9
435	Recent Advances in Antisense Oligonucleotide Therapy in Genetic Neuromuscular Diseases. **2018**, 21, 3-8	19

434	Neuromuscular diseases: Recent advances in antisense oligonucleotide therapy. **2018**, 5, 81	1
433	Global muscular dystrophy research: A 25-year bibliometric perspective. **2017**, 65, 993-1000	3
432	Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. **2012**, Suppl 7,	27
431	A Perspective on the Potential of Human iPS Cell-Based Therapies for Muscular Dystrophies: Advancements so far and Hurdles to Overcome. **2013**, 3,	5
430	Engraftment of ES-Derived Myogenic Progenitors in a Severe Mouse Model of Muscular Dystrophy. **2012**, 10,	23
429	Cardiac involvement in Duchenne and Becker muscular dystrophy. **2015**, 7, 410-4	41
428	Female Carriers of Duchenne Muscular Dystrophy. **2013**, 10, 94-98	7
427	Muscular dystrophy: identification and use of genes for diagnostics and therapeutics. **1999**, 123, 1050-2	14
426	Molecular and genetic aspects of Duchenne muscular dystrophy. **1995**, 11, 5-23	1
425	Transcriptional landscape of myogenesis from human pluripotent stem cells reveals a key role of TWIST1 in maintenance of skeletal muscle progenitors. **2020**, 9,	13
424	Mesenchymal stem cells derived from human induced pluripotent stem cells improve the engraftment of myogenic cells by secreting urokinase-type plasminogen activator receptor (uPAR). **2021**, 12, 532	2
423	Clinical Management of DMD-Associated Cardiomyopathy.	
422	Partial Ablation of Non-Myogenic Progenitor Cells as a Therapeutic Approach to Duchenne Muscular Dystrophy. **2021**, 11,	0
421	Molecular Characterization of Skeletal Muscle Dysfunction in Sigmar1 Knockout Mice. **2021**,	1
420	The Use of Different Vectors and Strategies for Gene Transfer to the Musculoskeletal System. **2000**, 15-40	
419	Muskeldystrophien. **2000**, 3-30	
418	Cardiac Disease in Duchenne and Becker Muscular Dystrophies: The Dystrophinopathies. **2000**, 251-266	
417	Calcium and Muscle Disease: Pathophysiology of Calpains and Limb-Girdle Muscular Dystrophy Type 2A (LGMD2A). **2000**, 443-464	1

416 Stem Cell Culture. **2002**, 439-453

415 Hereditary Myopathies. **2002**, 1265-1370 4

414 De la clinique □la g□□ique mol□ulaire : le nouveau panorama des dystrophies musculaires h□□itaires. **2002**, 186, 1035-1049

413 Can 1H NMR Derived Metabolic Profiles Contribute to Proteomic Analyses?. **2003**, 39-68

412 Muscular Dystrophy: Limb□Girdle, Becker's, and Duchenne's. **2003**, 292-303

411 Erkrankungen der Skelettmuskulatur. **2003**, 1391-1401

410 Dilated Cardiomyopathies and Congestive Heart Failure. **2003**, 35-65

409 Animal Models for Muscular Disorders. **2004**, 225-239

408 Duchenne And Becker Muscular Dystrophies. **2005**, 126-152

407 The Interrelation of DNA Analysis with Clinical Neurophysiology in the Diagnosis of Chronic Neuromuscular Disorder of Childhood. **2006**, 781-795

406 The Structure and Function of D ystrophin. **2006**, 32-52

405 Medical Management of Duchenne Muscular Dystrophy. **2006**, 151-176

404 Cellular Mediated Delivery: The Intersection Between Regenerative Medicine and Genetic Therapy. **2006**, 323-346

403 Cardiac Involvement in Skeletal Myopathies and Neuromuscular Disorders. **2007**, 2385-2407

402 Neuromuscular Diseases. **2007**, 87-96

401 References. **2007**, 557-594

400 Muscle Repair after Injury and Disease. **2008**, 459-480

399 Neuromuscular Disorders. **2008**, 1499-1527

398 Neuromuscular Diseases. **2009**, 85-94

397 Myocardial Disease. **2009**, 665-716

396 Molecular genetics of cardiomyopathies and myocarditis. **2010**, 91-156

395 Defective Glycosylation of Dystroglycan in Muscular Dystrophy and Cancer. **2011**, 119-143

394 Molecular Genetics and Prenatal Diagnosis. 380-444

393 Role of Myostatin in Skeletal Muscle Growth and Development: Implications for Sarcopenia. **2011**, 419-447

392 Invasive Procedures for Antenatal Diagnosis. **2011**, 143-159.e4

391 Le muscle myopathique. **2011**, 141-168

390 Cardiomyopathies in Infants and Children. **2011**, 718-733

389 The Present and Future of the Research on Neurological Disorders. **2011**, 16, 52-56

388 Surgical treatment of the fetus. **2011**, 189-214

387 Direct myocardial implantation of human embryonic stem cells in a dog model of Duchenne cardiomyopathy reveals poor cell survival in dystrophic tissue. **2011**, 7, 80-6

386 Phenotypes of the Drosophila melanogaster caused by dysfunction of dystrophin and dystroglycan. **2011**, 27, 423-431 2

385 Innovations in Twenty-First Century Cardiovascular Medicine. **2012**, 509-523

384 Inherited Diseases. **2012**, 1239-1292

383 Muskeldystrophien. **2012**, 689-718

382 Normal Muscle. **2012**, 1463-1481

381 New Approach for Antisense Oligonucleotide-Mediated Exon Skipping in Duchenne Muscular Dystrophy. **2012**, 16, 521-526

380 Introduction to Neurobiotechnology. **2013**, 1-5

379 Gene Therapy of Neurological Disorders. **2013**, 383-476 1

378 Neuromuscular Disorders. **2013**, 1335-1361.e5

377 Muscular Dystrophies and Allied Disorders I. **2013**, 250-275

376 Nanoparticles to Deliver Antisense Oligonucleotides Aimed at Exon Skipping Therapies. **2013**, 43-66

375 Dystrophinopathies. **2014**, 1207-1229

374 Gene Therapy for Duchenne Muscular Dystrophy.

373 Synthesis and Exon-Skipping Activity of Chemically Modified RNAs. **2014**, 497-510

372 Structure and Development of the Photoreceptor Ribbon Synapse. **2014**, 199-215 1

371 Dystroglycan: An Extracellular Matrix Receptor That Links to the Cytoskeleton. **2014**, 1-7

370 Stem Cells in Dystrophic Animal Models: From Preclinical to Clinical Studies. **2014**, 3-30

369 Prenatal Diagnosis of Duchenne Muscular Dystrophy: A Three-year Experience in a Rapidly Evolving Field. **1989**, 174-190

368 Advances in Genetic Prediction and Diagnosis. **1989**, 23-35

367 The Electronic Properties of Dystrophic Muscle Membrane Systems. **1989**, 115-127

366 Molecular Biology of Neuroreceptors: Implications for Clinical Neuroscience. **1989**, 645-659

365 Mouse chimeras and genetic rescue of mosaic muscle. **1990**, 280, 173-85

364 Genetics of Vitamin-D-Resistant Rickets. **1990**, 167-176

363 Myogenic conversion of human non-muscle cells for the diagnosis and therapy of neuromuscular diseases. **1990**, 280, 205-10 1

362 Present approaches in DNA-diagnosis of hereditary diseases. **1990**, 6, 5-12

361 Erkrankungen der Skelettmuskulatur. **1991**, 882-889

360 The DNA Map. **1991**, 25-33

359 Comparative Studies on Chicken Skeletal and Smooth Muscle Dystrophins. **1991**, 151-159

358 Molecular Biology of Contractile and Cytoskeletal Proteins. **1992**, 129-150 2

357 Prevention of Mental Retardation (Genetics). **1992**, 140-148 2

356 Dominant Olivopontocerebellar Atrophy Mapping to Human Chromosome 6p. **1992**, 425-441

355 Dystrophin mRNA Processing in the Canine Homologue of Duchenne Muscular Dystrophy: An Authentic Model for Gene Therapy. **1992**, 146-157

354 Duchenne and Becker Muscular Dystrophy: Current Diagnostics. **1993**, 187-200

353 Human dystrophin gene transfer: genetic correction of dystrophin deficiency. **1993**, 3, 283-302 2

352 Molecular human genetics and the Duchenne/Becker muscular dystrophy gene. **1993**, 3, 1-11 2

351 Polymorphism of pERT locus of dystrophin gene in families with high risk of muscular Duchenne dystrophy and within healthy women from Ukraine. **1993**, 9, 105-108 1

350 The Molecular and Cellular Biology of Heart Failure. **1994**, 17-53

349 Fetal-Like Slow Na+ Channels in Duchenne Muscular Dystrophy. **1994**, 123-132

348 Skeletal Muscle: Structure, Chemistry, and Function. **1994**, 85-101 1

347 Retroviral-Mediated Gene Transfer and Duchenne Muscular Dystrophy. **1994**, 391-410 1

346 Einflu der mitochondrialen Radikalproduktion des Skelettmuskels auf die Pathogenese der Duchenne-Muskeldystrophie (mdx-Maus Modell) unter Ber ksichtigung der Auswirkungen einer submaximalen physischen Belastung. **1995**, 229-244

345 Erkrankungen der Skelettmuskulatur. **1995**, 1097-1105

344	Genetically Determined Cardiomyopathies in Neuromuscular Diseases. **1995**, 27-38	
343	Applications of Recent Advances in DNA Techniques to Diagnosis in the Fetus. **1995**, 24-42	
342	Duchenne muscular dystrophy. **1995**, 5, 261-80	1
341	Molecular medicine makes its way to the bedside. **1995**, 162, 567-568	
340	Genetic Control of Muscle Function and Molecular Basis of Muscle Diseases. **1996**, 959-968	
339	Review of Gene Mapping and Molecular Genetic Studies of Schizophrenia. **1997**, 27, 279-284	1
338	Muscular Dystrophies. **1998**, 859-863	
337	Therapeutic trials of antioxidants in muscle diseases. **1998**, 327-333	2
336	Erkrankungen der Skelettmuskulatur. **1999**, 1249-1257	
335	An Overview of Mouse Models in Neuroscience Research. **1999**, 1-24	
334	Creatine kinase, cell membrane and Duchenne muscular dystrophy. **1999**, 143-151	2
333	Herz. **1999**, 103-276	1
332	Mendelsche Erbgänge und monogene Erkrankungen. **1999**, 97-142	
331	Dystroglycan: Extracellular Matrix Receptor that Links to Cytoskeleton. **2015**, 1245-1251	
330	An Overview of Methods Used in Neurogenomics and Their Applications. **2015**, 1-59	
329	Personalized Management of Genetic Disorders. **2015**, 529-549	
328	Stem Cell Transplantation for Degenerative Muscle Diseases. **2016**, 85-108	1
327	Neuromuscular Diseases. **2016**, 127-138	

326 Therapeutic Approach of iPS Cell Technology for Treating Muscular Dystrophy. **2016**, 137-151

325 Dystrophinopathies. **2016**, 1-14

324 Changes in cytosolic Ca2+ dynamics in the sarcoplasmic reticulum associated with the pathology of Duchenne muscular dystrophy. **2016**, 5, 309-312

323 Neuromuscular Cardiomyopathies. **2017**, 175-196

322 Biological Role of TRPC1 in Myogenesis, Regeneration, and Disease. **2017**, 211-230

321 Perturbation of PTEN-PI3K/AKT Signalling Impaired Autophagy Modulation in Dystrophin-Deficient Myoblasts.

320 Interleukins 4 and 13 Induce Exon Skipping of Mutant Dystrophin Pre-mRNA to Restore Dystrophin Production.

319 Single-cell quantitative analysis of skeletal muscle cell population dynamics during regeneration and ageing. 1

318 Dystroglycan proteolysis is conformationally-regulated and disrupted by disease-associated mutations. 2

317 Benfotiamine reduces pathology and improves muscle function in mdx mice.

316 Low dose resveratrol promotes hypertrophy in wildtype skeletal muscle and reduces damage in skeletal muscle of exercised mdx mice.

315 Exercise exacerbates decline in the musculature of an animal model of Duchenne muscular dystrophy.

314 High-resolution mass spectrometry-based non-targeted metabolomic discovery of disease and glucocorticoid biomarkers in an animal model of muscular dystrophy.

313 Novel signaling hub of insulin receptor, dystrophin glycoprotein complex and plakoglobin regulates muscle size.

312 [The pathogenesis of Duchenne muscular dystrophy]. **2019**, 119, 79-81 1

311 Loss of function of the RNA export factor, Nxt1, in Drosophila causes muscle degeneration and reduced expression of genes with long introns.

310 Can photobiomodulation therapy be an alternative to pharmacological therapies in decreasing the progression of skeletal muscle impairments of mdx mice?. **2019**,

309 A novel drug-combination screen in zebrafish identifies epigenetic small molecule candidates for Duchenne muscular dystrophy.

308	The microRNA, miR-133b, functions to slow Duchenne muscular dystrophy pathogenesis.	1
307	Engineered extracellular vesicle decoy receptor-mediated modulation of the IL6 trans-signalling pathway in muscle.	
306	Prenatal molecular diagnosis and carrier detection of Duchenne muscular dystrophy in Korea. **2020**, 17, 27-33	
305	PTEN Inhibition Ameliorates Muscle Degeneration and Improves Muscle Function in a Mouse Model of Duchenne Muscular Dystrophy.	
304	Perturbation of PI3K/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts. **2021**, 19, 105	0
303	Knee Strength and Ankle Range of Motion Impacts on Timed Function Tests in Duchenne Muscular Dystrophy: In the Era of Glucocorticoids. **2021**,	0
302	Orai1-STIM1 Regulates Increased Ca Mobilization, Leading to Contractile Duchenne Muscular Dystrophy Phenotypes in Patient-Derived Induced Pluripotent Stem Cells. **2021**, 9,	1
301	Strain-Specific Liver Metabolite Profiles in Medaka. **2021**, 11,	1
300	Mutation in histone deacetylase HDA-3 leads to shortened locomotor healthspan in. **2020**, 12, 23525-23547	1
299	Duchenne Muscular Dystrophy (DMD) Treatment: Past and Present Perspectives.	
298	Roles for RNA export factor, Nxt1, in ensuring muscle integrity and normal RNA expression in Drosophila. **2021**, 11,	0
297	Personalized Management of Genetic Disorders. **2021**, 343-362	
296	Lack of dystrophin influences muscle inflammation but not myogenic regulatory factors after eccentric exercise in mdx mice. **2020**, 26,	0
295	[Therapeutic drug screening with zebrafish models]. **2021**, 156, 355-358	0
294	Class I histone deacetylase HDA-3 is required for full maintenance of locomotor ability in Caenorhabditis elegans.	
293	Anesthesia Management of a Child with Duchenne's Muscular Dystrophy Posted for Skin Grafting. **2021**, 5, 13-14	
292	Hereditary and Acquired Myopathies. **2020**, 1281-1349	1
291	Splicing and Alternative Splicing and the Impact of Mechanics. **2020**, 509-593	

290	Duchenne Muscular Dystrophy Cell Culture Models Created By CRISPR/Cas 9 Gene Editing And Their Application To Drug Screening.	
289	Mr Imaging and Spectroscopy for Biomarker Characterization in Golden Retriever Muscular Dystrophy Tissue Samples. **2020**,	
288	Defining and Identifying Satellite Cell-opathies within Muscular Dystrophies and Myopathies. **2021**, 112906	7
287	The Donnan-dominated resting state of skeletal muscle fibers contributes to resilience and longevity in dystrophic fibers. **2022**, 154,	
286	Dystrophin and mini-dystrophin quantification by mass spectrometry in skeletal muscle for gene therapy development in Duchenne muscular dystrophy. **2021**,	1
285	Genetic correction strategies for Duchenne Muscular Dystrophy and their impact on the heart.. **2021**, 63, 101460-101460	0
284	Natural History of Serum Enzyme Levels in Duchenne Muscular Dystrophy and Implications for Clinical Practice. **2020**, 99, 1121-1128	2
283	A Historic Recapitulation of Myoblast Transplantation. **2006**, 61-79	
282	Erkrankungen der Skelettmuskulatur. **2005**, 1461-1471	
281	Muscular Dystrophies. **2006**, 1080-1087	
280	Skeletal Muscle Plasticity. **2008**, 16-36	1
279	Dystrophinopathies. **2006**, 331-337	
278	Nanoparticles to Deliver Antisense Oligonucleotides Aimed at Exon Skipping Therapies. **2013**, 43-66	0
277	Update on Genetics and Mental Retardation. **1989**, 19, 197-204	
276	MDX mouse myopathy I: Presence or absence of sarcolemmal lesions in tibialis anterior muscles from mice of different ages. **1989**, 47, 1070-1071	
275	Deleterious impacts of inactivity and beneficial impacts of neuromuscular electrical stimulation on muscle structure and function in the zebrafish model of Duchenne Muscular Dystrophy.	
274	Expression profile analysis to predict potential biomarkers for glaucoma: BMP1, DMD and GEM. **2020**, 8, e9462	0
273	Microutrophin expression in dystrophic mice displays myofiber type differences in therapeutic effects. **2020**, 16, e1009179	2

272	Mast cells in the pathophysiology of Duchenne muscular dystrophy in Golden Retriever dogs. **2020**, 40, 791-797	
271	Molecular basis of hypertrophic and dilated cardiomyopathy. **1994**, 21, 6-15	16
270	Molecular analysis of X-autosome translocations in females with Duchenne muscular dystrophy. **1991**, 10, 3931-9	10
269	Localization of the mdx mutation within the mouse dystrophin gene. **1988**, 7, 3017-21	39
268	The chicken dystrophin cDNA: striking conservation of the C-terminal coding and 3' untranslated regions between man and chicken. **1988**, 7, 4157-62	29
267	A model to estimate the expression of the dystrophin gene in muscle from female Becker muscular dystrophy carriers. **1992**, 29, 476-9	2
266	Diagnosing duchenne muscular dystrophy. **1989**, 150, 575	
265	Exon skipping and translation in patients with frameshift deletions in the dystrophin gene. **1993**, 53, 1007-15	62
264	Mild deficiency of dystrophin-associated proteins in Becker muscular dystrophy patients having in-frame deletions in the rod domain of dystrophin. **1993**, 53, 409-16	23
263	Somatic reversion/suppression in Duchenne muscular dystrophy (DMD): evidence supporting a frame-restoring mechanism in rare dystrophin-positive fibers. **1992**, 50, 950-9	94
262	Dystrophin in frameshift deletion patients with Becker muscular dystrophy. **1992**, 51, 562-70	53
261	Fluorescent multiplex linkage analysis and carrier detection for Duchenne/Becker muscular dystrophy. **1992**, 51, 721-9	40
260	Rapid detection of CA polymorphisms in cloned DNA: application to the 5' region of the dystrophin gene. **1991**, 48, 621-7	108
259	Differentiation of Duchenne and Becker muscular dystrophy phenotypes with amino- and carboxy-terminal antisera specific for dystrophin. **1991**, 48, 295-304	66
258	Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. **1991**, 49, 54-67	281
257	Brother/sister pairs affected with early-onset, progressive muscular dystrophy: molecular studies reveal etiologic heterogeneity. **1989**, 45, 63-72	14
256	Dystrophin analysis in duchenne muscular dystrophy: use in fetal diagnosis and in genetic counseling. **1989**, 45, 362-7	28
255	RFLPs for Duchenne muscular dystrophy cDNA clones 9 and 10. **1990**, 46, 1090-4	3

254	A truncated dystrophin lacking the C-terminal domains is localized at the muscle membrane. **1992**, 50, 508-14	53
253	Myopathy in complex glycerol kinase deficiency patients is due to 3' deletions of the dystrophin gene. **1988**, 43, 126-30	23
252	Normal human genomic restriction-fragment patterns and polymorphisms revealed by hybridization with the entire dystrophin cDNA. **1988**, 43, 612-9	40
251	Intragenic deletions in 21 Duchenne muscular dystrophy (DMD)/Becker muscular dystrophy (BMD) families studied with the dystrophin cDNA: location of breakpoints on HindIII and BglII exon-containing fragment maps, meiotic and mitotic origin of the mutations. **1988**, 43, 620-9	139
250	Dystrophin analysis in clonal myoblasts derived from a Duchenne muscular dystrophy carrier. **1989**, 44, 820-6	23
249	ERG phenotype of a dystrophin mutation in heterozygous female carriers of Duchenne muscular dystrophy. **1999**, 36, 316-22	3
248	Sequence analysis of the breakpoint regions of an X;5 translocation in a female with Duchenne muscular dystrophy. **1995**, 57, 329-36	12
247	Sarcoglycan complex is selectively lost in dystrophic hamster muscle. **1995**, 146, 530-6	36
246	Ultrastructural localization of the C-terminus of the 43-kd dystrophin-associated glycoprotein and its relation to dystrophin in normal murine skeletal myofiber. **1995**, 146, 189-96	10
245	Development of Duchenne-type cardiomyopathy. Morphologic studies in a canine model. **1989**, 135, 671-8	58
244	Feline muscular dystrophy with dystrophin deficiency. **1989**, 135, 909-19	123
243	Dystrophin is expressed in mdx skeletal muscle fibers after normal myoblast implantation. **1989**, 135, 27-32	167
242	Immunocytochemical study of dystrophin in muscle cultures from patients with Duchenne muscular dystrophy and unaffected control patients. **1988**, 132, 410-6	71
241	Normal and dystrophin-deficient muscle fibers in carriers of the gene for Duchenne muscular dystrophy. **1988**, 133, 440-5	58
240	Dystrophin is required for normal thin filament-membrane associations at myotendinous junctions. **1991**, 138, 17-21	46
239	Xp21 dystrophin and 6q dystrophin-related protein. Comparative immunolocalization using multiple antibodies. **1991**, 139, 969-76	31
238	Dystrophin deficiency is associated with myotendinous junction defects in prenecrotic and fully regenerated skeletal muscle. **1993**, 142, 1513-23	38
237	Expression of transforming growth factor-beta 1 and its relation to endomysial fibrosis in progressive muscular dystrophy. **1994**, 144, 221-6	67

236	The Evolving Genome Project: current and future impact. **1994**, 54, 129-36	15
235	Detection of new paternal dystrophin gene mutations in isolated cases of dystrophinopathy in females. **1994**, 54, 989-1003	91
234	A new nonsyndromic X-linked sensorineural hearing impairment linked to Xp21.2. **1994**, 55, 685-94	35
233	Refined mapping of a gene responsible for Fukuyama-type congenital muscular dystrophy: evidence for strong linkage disequilibrium. **1994**, 55, 946-50	37
232	Vasodilation of intramuscular arterioles under shear stress in dystrophin-deficient skeletal muscle is impaired through decreased nNOS expression. **2008**, 27, 30-6	21
231	Optimizing exon skipping therapies for DMD. **2007**, 26, 179-84	48
230	Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies. **2011**, 32, 129-34	21
229	Symptomatic therapy of Duchenne muscular dystrophy (DMD). **2012**, 31, 2-3	
228	Improvement of survival in Duchenne Muscular Dystrophy: retrospective analysis of 835 patients. **2012**, 31, 121-5	195
227	The muscular dystrophies: from genes to therapies. **2005**, 85, 1372-88	26
226	Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials. **2016**, 8, 2471-89	55
225	Gastrocnemius medialis muscle architecture and physiological cross sectional area in adult males with Duchenne muscular dystrophy. **2015**, 15, 154-60	11
224	Atopy and genetics. A review. **1990**, 24, 159-60	
223	Genetic diagnosis as a tool for personalized treatment of Duchenne muscular dystrophy. **2016**, 35, 122-127	18
222	Muscular response to the first three months of deflazacort treatment in boys with Duchenne muscular dystrophy. **2017**, 17, 8-18	5
221	Changes in Muscle Metabolism are Associated with Phenotypic Variability in Golden Retriever Muscular Dystrophy. **2017**, 90, 351-360	8
220	A Mutation in Dystrophin Causing Muscular Dystrophy in a Female Patient. **2017**, 130, 2273-2278	
219	Multi-slice MRI reveals heterogeneity in disease distribution along the length of muscle in Duchenne muscular dystrophy. **2017**, 36, 151-162	19

218	Antisense oligonucleotides for the treatment of cardiomyopathy in Duchenne muscular dystrophy. **2019**, 11, 1202-1218	17
217	Coagulation disorders in Duchenne muscular dystrophy? Results of a registry-based online survey. **2020**, 39, 2-12	2
216	Effect of AAV9-hIGF-1 on inflammatory reaction in mdx mice and its mechanism. **2020**, 12, 4488-4497	1
215	Giovanni Nigro and the Naples's school: historical contribution to the knowledge of heart involvement in Duchenne/Becker muscular dystrophies. **2020**, 39, 187-190	
214	Read-through approach for stop mutations in Duchenne muscular dystrophy. An update. **2021**, 40, 43-50	1
213	Emotional behavior and brain anatomy of the mdx52 mouse model of Duchenne muscular dystrophy. **2021**, 14,	
212	Co-Occurrence of Fragile X Syndrome with a Second Genetic Condition: Three Independent Cases of Double Diagnosis.. **2021**, 12,	
211	Skeletal Ryanodine Receptors Are Involved in Impaired Myogenic Differentiation in Duchenne Muscular Dystrophy Patients. **2021**, 22,	2
210	One in five patients with Duchenne muscular dystrophy dies from other causes than cardiac or respiratory failure. **2021**, 1	0
209	Effects of muscle damage on phosphorus magnetic resonance spectroscopy indices of energetic status and sarcolemma integrity in young mdx mice. **2021**, e4659	0
208	Natural History of a Mouse Model Overexpressing the Dp71 Dystrophin Isoform. **2021**, 22,	
207	CRISPR-Cas9-Mediated Gene Therapy in Neurological Disorders. **2021**, 1	4
206	Sensitivity to behavioral stress impacts disease pathogenesis in dystrophin-deficient mice. **2021**, 35, e22034	0
205	A Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. **2021**, 22,	2
204	Efficacy and Safety of Vamorolone in Duchenne Muscular Dystrophy: A 30-Month Nonrandomized Controlled Open-Label Extension Trial.. **2022**, 5, e2144178	3
203	Nanomedicine, a valuable tool for skeletal muscle disorders: Challenges, promises, and limitations.. **2022**, e1777	1
202	NOX4 inhibition promotes the remodeling of dystrophic muscle.	
201	Structural and Ultrastructural Changes in the Tongue of Mice.. **2022**, 1-8	1

200	Peak Cough Flow Reliability Versus Other Pulmonary Function Tests in Children with Duchenne Muscular Dystrophy.	
199	CRISPR/Cas9 editing of directly reprogrammed myogenic progenitors restores dystrophin expression in a mouse model of muscular dystrophy.. **2021**,	3
198	Evaluation of the GSP Creatine Kinase-MM Assay and Assessment of CK-MM Stability in Newborn, Patient, and Contrived Dried Blood Spots for Newborn Screening for Duchenne Muscular Dystrophy.. **2022**, 8,	1
197	Two novel RNA-binding proteins identification through computational prediction and experimental validation.. **2021**, 114, 149-160	
196	Therapeutic Application of Extracellular Vesicles-Capsulated Adeno-Associated Virus Vector via , Satellite, and Immune Cells in Duchenne Muscular Dystrophy.. **2022**, 23,	0
195	Human MuStem cells repress T-cell proliferation and cytotoxicity through both paracrine and contact-dependent pathways.. **2022**, 13, 7	
194	Lipidomic Analyses Reveal Specific Alterations of Phosphatidylcholine in Dystrophic Muscle.. **2021**, 12, 698166	0
193	PPMO-mediated exon skipping induces uniform sarcolemmal dystrophin rescue with dose-dependent restoration of circulating microRNA biomarkers and muscle biophysical properties.	
192	Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD.	
191	Diaphragm muscle fibrosis involves changes in collagen organization with mechanical implications in Duchenne Muscular Dystrophy.. **2022**,	2
190	scTenifoldKnk: An efficient virtual knockout tool for gene function predictions via single-cell gene regulatory network perturbation.. **2022**, 3, 100434	0
189	Evaluation of the dystrophin carboxy-terminal domain for micro-dystrophin gene therapy in cardiac and skeletal muscles in the DMD rat model.. **2022**,	2
188	Dystrophin-deficient muscular dystrophy in a Toy Poodle with a single base pair insertion in exon 45 of the Duchenne muscular dystrophy gene.. **2022**, 84,	
187	Hepatic Steatosis Assessment as a New Strategy for the Metabolic and Nutritional Management of Duchenne Muscular Dystrophy.. **2022**, 14,	0
186	CRISPR Therapeutics for Duchenne Muscular Dystrophy.. **2022**, 23,	2
185	Startle responses in Duchenne muscular dystrophy: a novel biomarker of brain dystrophin deficiency.. **2022**,	1
184	Injectable hydrogel microspheres for sustained gene delivery of antisense oligonucleotides to restore the expression of dystrophin protein in duchenne muscular dystrophy. **2022**, 166, 111038	0
183	Paeonia lactiflora extract improves the muscle function of mdx mice, an animal model of Duchenne muscular dystrophy, via downregulating the high mobility group box 1 protein.. **2022**, 289, 115079	

182	Comprehensive assessment of physical activity correlated with muscle function in canine Duchenne muscular dystrophy. **2021**, 101611	
181	Creatine kinase, cell membrane and Duchenne muscular dystrophy. **1999**, 190, 143-51	21
180	Dystrophic Cardiomyopathy and the Need for Cardiovascular Care.. **2022**,	1
179	TLR4 is a regulator of trained immunity in a murine model of Duchenne muscular dystrophy.. **2022**, 13, 879	1
178	Ultrasonographic assessment of lower limb muscle architecture in children with early-stage Duchenne muscular dystrophy.. **2022**,	
177	The jam session between muscle stem cells and the extracellular matrix in the tissue microenvironment.. **2022**, 7, 16	0
176	Natural History of Histopathologic Changes in Cardiomyopathy of Golden Retriever Muscular Dystrophy.. **2021**, 8, 759585	
175	A User-Friendly Approach for Routine Histopathological and Morphometric Analysis of Skeletal Muscle Using CellProfiler Software.. **2022**, 12,	0
174	Development of DG9 peptide-conjugated single- and multi-exon skipping therapies for the treatment of Duchenne muscular dystrophy.. **2022**, 119,	5
173	Tuning the Consonance of Microscopic Neuro-Cardiac Interactions Allows the Heart Beats to Play Countless Genres.. **2022**, 13, 841740	0
172	CD38-NADase is a new major contributor to Duchenne muscular dystrophic phenotype.. **2022**, e12860	0
171	Transiently expressed CRISPR/Cas9 induces wild-type dystrophin in vitro in DMD patient myoblasts carrying duplications.. **2022**, 12, 3756	0
170	Involvement of muscle satellite cell dysfunction in neuromuscular disorders: Expanding the portfolio of satellite cell-opathies.. **2022**,	2
169	A Comparison of Caregiver and Patient Preferences for Treating Duchenne Muscular Dystrophy.. **2022**, 1	0
168	Treating Duchenne Muscular Dystrophy: The Promise of Stem Cells, Artificial Intelligence, and Multi-Omics.. **2022**, 9, 851491	0
167	Pathogenesis of Multiple Organ Failure: The Impact of Systemic Damage to Plasma Membranes.. **2022**, 9, 806462	0
166	The 2022 On-site Padua Days on Muscle and Mobility Medicine hosts the University of Florida Institute of Myology and the Wellstone Center, March 30 - April 3, 2022 at the University of Padua and Thermae of Euganean Hills, Padua, Italy: The collection of abstracts.. **2022**,	0
165	A Longitudinal Study of Quantitative Muscle Strength and Functional Motor Ability in Ambulatory Boys with Duchenne Muscular Dystrophy.. **2021**,	

164	Non-Invasive Optical Motion Tracking Allows Monitoring of Respiratory Dynamics in Dystrophin-Deficient Mice.. **2022**, 11,	0
163	Spatial transcriptomics reveal markers of histopathological changes in Duchenne muscular dystrophy mouse models.	
162	Generation of a Dystrophin Mutant in Dog by Nuclear Transfer Using CRISPR/Cas9-Mediated Somatic Cells: A Preliminary Study.. **2022**, 23,	0
161	Circulating small RNA signatures differentiate accurately the subtypes of muscular dystrophies: small-RNA next-generation sequencing analytics and functional insights.. **2022**, 19, 507-518	1
160	Determinants of epigenetic resistance to HDAC inhibitors in dystrophic fibro-adipogenic progenitors.. **2022**, e54721	1
159	Biomarkers in Duchenne Muscular Dystrophy.. **2022**,	0
158	Long-term maintenance of dystrophin expression and resistance to injury of skeletal muscle in gene edited DMD mice.. **2022**, 28, 154-167	2
157	Synaptic alterations as a neurodevelopmental trait of Duchenne muscular dystrophy.. **2022**, 168, 105718	1
156	Combining Protein Expression and Molecular Data Improves Mutation Characterization of Dystrophinopathies.. **2021**, 12, 718396	
155	Pharmacological Profile of Viltolarsen for the Treatment of Duchenne Muscular Dystrophy: A Japanese Experience.. **2021**, 13, 235-242	1
154	Fibro-adipogenic progenitors in skeletal muscle homeostasis, regeneration and diseases. **2021**, 11, 210110	3
153	Lessons learned from developing an oligonucleotide drug for a rare disease. **2022**, 121-137	
152	The role of protein glycosylation in muscle diseases.. **2022**, 1	0
151	Development of a novel startle response task in Duchenne muscular dystrophy.. **2022**, 17, e0264091	0
150	WT-PE: Prime editing with nuclease wild-type Cas9 enables versatile large-scale genome editing.. **2022**, 7, 108	1
149	The Role of Oxidative Stress in Skeletal Muscle Myogenesis and Muscle Disease.. **2022**, 11,	1
148	Wound Healing and Cell Therapy for Muscle Repair. 270-289	
147	Data_Sheet_1.DOCX. **2019**,	

146 Image_1.TIF. **2019**,

145 Image_2.TIF. **2019**,

144 Image_3.TIF. **2019**,

143 Video_1.MOV. **2019**,

142 Video_2.AVI. **2019**,

141 Video_3.MOV. **2019**,

140 Video_4.AVI. **2019**,

139 Video_5.AVI. **2019**,

138 Video_6.MOV. **2019**,

137 Video_7.MOV. **2019**,

136 Video_8.MOV. **2019**,

135 Video_9.MOV. **2019**,

134 Image_1.TIF. **2018**,

133 Image_2.TIF. **2018**,

132 Image_1.TIFF. **2020**,

131 Image_2.TIFF. **2020**,

130 Image_3.TIFF. **2020**,

129 Image_4.TIFF. **2020**,

128	Table_1.DOC. **2020**,	
127	Table_2.DOC. **2020**,	
126	Table_3.DOC. **2020**,	
125	Table_4.XLSX. **2020**,	
124	Data_Sheet_1.pdf. **2020**,	
123	Image_1.TIF. **2018**,	
122	Image_2.TIF. **2018**,	
121	Image_3.TIF. **2018**,	
120	Image_4.TIF. **2018**,	
119	Table_1.docx. **2018**,	
118	Advanced Gene-Targeting Therapies for Motor Neuron Diseases and Muscular Dystrophies.. **2022**, 23,	1
117	Application of Droplet Digital PCR Technology in Muscular Dystrophies Research.. **2022**, 23,	1
116	Metabolic, Fibrotic, and Splicing Pathways Are All Altered in Emery-Dreifuss Muscular Dystrophy Spectrum Patients to Differing Degrees.	
115	Does the Pathogenic Sequence of Skeletal Muscle Degeneration in Duchenne Muscular Dystrophy Begin and End with Unrestrained Satellite Cell Activation?. **2022**, 1, 75-81	0
114	Historical Perspectives of Regenerative Rehabilitation: Recovering and Restoring Functional Capacity. **2022**, 1-38	
113	Regenerative Rehabilitation for Nonlethal Muscular Dystrophies. **2022**, 61-84	
112	Regenerative Rehabilitation for Duchenne Muscular Dystrophy. **2022**, 85-119	0
111	Brain Dp140 alters glutamatergic transmission and social behaviour in the mdx52 mouse model of Duchenne muscular dystrophy. **2022**, 102288	1

110	Advances in CRISPR-Based Functional Genomics and Nucleic Acid Detection in Pigs. 13,	
109	Forced activation of dystrophin transcription by CRISPR/dCas9 reduced arrhythmia susceptibility via restoring membrane Nav1.5 distribution.	
108	Development of Therapeutic RNA Manipulation for Muscular Dystrophy. 4,	
107	Long-Term Functional Efficacy and Safety of Viltolarsen in Patients with Duchenne Muscular Dystrophy. **2022**, 1-9	4
106	Therapeutic opportunities and clinical outcome measures in Duchenne muscular dystrophy.	0
105	Pain characteristics among individuals with Duchenne muscular dystrophy according to their clinical stage. **2022**, 23,	
104	The neurocognitive profile of adults with Becker muscular dystrophy in the Netherlands. **2022**, 1-11	
103	Dystrophin missense mutations alter focal adhesion tension and mechanotransduction. **2022**, 119,	1
102	Insulin receptor turnover in fasting is dependent on NAGLU-mediated □dystroglycan deglycosylation.	
101	Incidence of Duchenne muscular dystrophy in the modern era; an Australian study.	2
100	Factors associated with the health-related quality of life among people with Duchenne muscular dystrophy: a study using the Health Utilities Index (HUI). **2022**, 20,	0
99	MicroRNAs in Dystrophinopathy. **2022**, 23, 7785	2
98	Proteins implicated in muscular dystrophy and cancer are functional constituents of the centrosome. **2022**, 5, e202201367	
97	The Many Roles of Macrophages in Skeletal Muscle Injury and Repair. 10,	0
96	Smad8 Is Increased in Duchenne Muscular Dystrophy and Suppresses miR-1, miR-133a, and miR-133b. **2022**, 23, 7515	1
95	Comparative genomic analyses of multiple backcross mouse populations suggest SGCG as a novel potential obesity-modifier gene.	0
94	Current Outline of Exon Skipping Trials in Duchenne Muscular Dystrophy. **2022**, 13, 1241	4
93	Comparison of Quantitative Ultrasound Methods to Classify Dystrophic and Obese Models of Skeletal Muscle. **2022**,	0

92	Determining neurodevelopmental manifestations in Duchenne muscular dystrophy using a battery of brief tests. **2022**, 440, 120340	1
91	Temporal regulation of TAK1 to counteract muscular dystrophy.	1
90	Drug development progress in duchenne muscular dystrophy. 13,	1
89	Multi-omics analysis of sarcospan overexpression in mdx skeletal muscle reveals compensatory remodeling of cytoskeleton-matrix interactions that promote mechanotransduction pathways.	
88	Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. **2022**,	1
87	Myoblast Therapies Constitute a Safe and Efficacious Platform Technology of Regenerative Medicine for the Human Health Industry. **2022**, 1-66	0
86	Translation termination codons in protein synthesis and disease. **2022**,	1
85	Computerized working memory training in males with Duchenne muscular dystrophy: A single case experimental design study. 1-24	
84	CRISPR applications for Duchenne muscular dystrophy: From animal models to potential therapies.	0
83	Regulatory T cells in skeletal muscle repair and regeneration: recent insights. **2022**, 13,	0
82	Postdevelopmental knockout of Orai1 improves muscle pathology in a mouse model of Duchenne muscular dystrophy. **2022**, 154,	4
81	Diagnostic experiences of Duchenne families and their preferences for newborn screening: A mixed-methods study.	
80	Characterisation of Progressive Skeletal Muscle Fibrosis in the Mdx Mouse Model of Duchenne Muscular Dystrophy: An In Vivo and In Vitro Study. **2022**, 23, 8735	1
79	PPMO-mediated exon skipping induces uniform sarcolemmal dystrophin rescue with dose-dependent restoration of circulating microRNA biomarkers and muscle biophysical properties. **2022**,	0
78	Dominant-negative p53-overexpression in skeletal muscle induces cell death and fiber atrophy in rats. **2022**, 13,	1
77	The potential for Treg-enhancing therapies in tissue, in particular skeletal muscle, regeneration.	
76	A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing. **2022**, 29, 525-537	2
75	Defining the structure-activity relationship for a novel class of allosteric MKP5 inhibitors. **2022**, 243, 114712	0

74	Newborn screening for Duchenne muscular dystrophy-early detection and diagnostic algorithm for female carriers of Duchenne muscular dystrophy.	0
73	Next-Generation SINE Compound KPT-8602 Ameliorates Dystrophic Pathology in Zebrafish and Mouse Models of DMD. **2022**, 10, 2400	0
72	The role of the dystrophin glycoprotein complex in muscle cell mechanotransduction. **2022**, 5,	1
71	Potential limitations of micro-dystrophin gene therapy for Duchenne muscular dystrophy.	0
70	Non-uniform dystrophin re-expression after CRISPR-mediated exon excision in the dystrophin/utrophin double-knockout mouse model of DMD. **2022**,	0
69	Cognitive and behavioral functioning in two neurogenetic disorders; how different are these aspects in Duchenne muscular dystrophy and Neurofibromatosis type 1?. **2022**, 17, e0275803	0
68	NOX4 inhibition promotes the remodeling of dystrophic muscle. **2022**, 7,	1
67	Metabolic, fibrotic, and splicing pathways are all altered in Emery-Dreifuss muscular dystrophy Spectrum patients to differing degrees.	0
66	Characterizing the Occurrence of Key Clinical Milestones in Duchenne Muscular Dystrophy in the United States Using Real-World Data. **2022**, 1-11	0
65	Exercise-Induced Muscle Damage and Protein Intake: A Bibliometric and Visual Analysis. **2022**, 14, 4288	0
64	The implication of hinge 1 and hinge 4 in micro-dystrophin gene therapy for Duchenne muscular dystrophy.	0
63	Gene editing of Duchenne muscular dystrophy using biomineralization-based spCas9 variant nanoparticles. **2022**,	0
62	Single cell sequencing maps skeletal muscle cellular diversity as disease severity increases in dystrophic mouse models. **2022**, 25, 105415	0
61	Myoblast Therapies Constitute a Safe and Efficacious Platform Technology of Regenerative Medicine for the Human Health Industry. **2022**, 625-690	0
60	Enhancing interaction of actin and actin-binding domain 1 of dystrophin with modulators: toward improved gene therapy for Duchenne muscular dystrophy. **2022**, 102675	0
59	Duchenne muscular dystrophy progression induced by downhill running is accompanied by increased endomysial fibrosis and oxidative damage DNA in muscle of mdx mice.	0
58	CRISPR-Cas9 Correction of Duchenne Muscular Dystrophy in Mice by a Self-Complementary AAV Delivery System. **2023**, 411-425	0
57	Viltolarsen: From Preclinical Studies to FDA Approval. **2023**, 31-41	0

56	Current Strategies of Muscular Dystrophy Therapeutics: An Overview. **2023**, 3-30	0
55	Retinal dystrophins and the retinopathy of Duchenne muscular dystrophy. **2022**, 101137	0
54	Physiological Assessment of Muscle, Heart, and Whole Body Function in the Canine Model of Duchenne Muscular Dystrophy. **2023**, 67-103	0
53	Quantitative Evaluation of Exon Skipping in Urine-Derived Cells for Duchenne Muscular Dystrophy. **2023**, 153-164	0
52	Kinematic changes in gait in boys with Duchenne Muscular Dystrophy: Utility of the Gait Deviation Index, the Gait Profile Score and the Gait Variable Scores. **2023**, 100, 157-164	0
51	Myocardial strain imaging in Duchenne muscular dystrophy. 9,	0
50	Electrical Impedance Myography Correlates with Functional Measures of Disease Progression in D2-mdx Mice and Boys with Duchenne Muscular Dystrophy. **2022**, 1-10	0
49	Arthritis and Duchenne Muscular Dystrophy: the role of chondroitin sulfate and its associated proteoglycans in disease pathology and as a diagnostic marker.	0
48	Hydrogen sulfide as a therapeutic option for the treatment of Duchenne muscular dystrophy and other muscle-related diseases. **2022**, 79,	0
47	The importance of dystrophin and the dystrophin associated proteins in vascular smooth muscle. 13,	0
46	Clinical potential of microdystrophin as a surrogate endpoint. **2022**,	0
45	Modeling neuromuscular diseases in zebrafish. 15,	0
44	The Dystrophinopathies. **2022**, 28, 1678-1697	0
43	Reliability and validity of the Turkish version of the Upper Limb Short Questionnaire in Duchenne muscular dystrophy. 1-6	0
42	Glomerular hyperfiltration: part 2□linical significance in children.	0
41	The discovery of the DNA methylation episignature for Duchenne muscular dystrophy. **2022**,	0
40	Dystrophin Acts as a Transplantation Rejection Antigen in Dystrophin-Deficient Mice: Implication for Gene Therapy. **1998**, 160, 4635-4640	9
39	Is the fundamental pathology in Duchenne's muscular dystrophy caused by a failure of glycogenolysis□lycolysis in costameres?. **2023**, 102,	0

38	Pulmonary function tests for evaluating the severity of Duchenne muscular dystrophy disease.	0
37	Assessing the Role of Aquaporin 4 in Skeletal Muscle Function. **2023**, 24, 1489	0
36	Orai1 as a potential fits-all approach therapeutic target for the treatment of DMD. **2023**, 155,	0
35	Multi-omics analysis of sarcospan overexpression in mdx skeletal muscle reveals compensatory remodeling of cytoskeleton-matrix interactions that promote mechanotransduction pathways. **2023**, 13,	1
34	The X-linked Becker muscular dystrophy (bmx) mouse models Becker muscular dystrophy via deletion of murine dystrophin exons 45–47.	0
33	Spectrum of Genetic Variants in the Dystrophin Gene: A Single Centre Retrospective Analysis of 750 Duchenne and Becker Patients from Southern Italy. **2023**, 14, 214	1
32	Eccentric contraction-induced strength loss in dystrophin-deficient muscle: Preparations, protocols, and mechanisms. **2023**, 155,	0
31	Spontaneous transverse colon volvulus in a patient with Duchenne muscular dystrophy: An unreported complication. **2023**, 18, 1306-1310	0
30	Development of Cell Therapy for Duchenne Muscular Dystrophy by iPS Cell-derived Muscle Stem Cell, and Potential of Regenerative Rehabilitation with Cell Therapy. **2022**, 59, 1020-1025	0
29	Phosphorylation alters the mechanical stiffness of a model fragment of the dystrophin homologue utrophin. **2022**, 102847	0
28	Disease progression modeling of the North Star Ambulatory Assessment (NSAA) for Duchenne Muscular Dystrophy (DMD).	0
27	Exons 45–55 Skipping Using Antisense Oligonucleotides in Immortalized Human DMD Muscle Cells. **2023**, 313-325	0
26	The vitamin B3analogue nicotinamide riboside has only very minor effects on reducing muscle damage inmdxmice.	0
25	Insights into Cell-Specific Functions of Microtubules in Skeletal Muscle Development and Homeostasis. **2023**, 24, 2903	1
24	Evaluation of Muscle Proteins for Estimating the Post-Mortem Interval in Veterinary Forensic Pathology. **2023**, 13, 563	0
23	Extracellular vesicles and Duchenne muscular dystrophy pathology: Modulators of disease progression. 14,	0
22	Localized strain characterization of cardiomyopathy in Duchenne muscular dystrophy using novel 4D kinematic analysis of cine cardiovascular magnetic resonance. **2023**, 25,	0
21	Modeling Early Heterogeneous Rates of Progression in Boys with Duchenne Muscular Dystrophy. **2023**, 1-16	0

20	Smooth Muscle Cells of Dystrophic (mdx) Mice Are More Susceptible to Hypoxia; The Protective Effect of Reducing Ca2+ Influx. **2023**, 11, 623	0
19	Recent advances in CRISPR-based genome editing technology and its applications in cardiovascular research. **2023**, 10,	0
18	Mechanisms of expression, trafficking and biophysical activity regulation of voltage-gated cardiac sodium channels. **2023**, 9, 71-94	0
17	Research Progress of Pathogenic Genes Associated with Dilated Cardiomyopathy. **2023**, 13, 3663-3670	0
16	Safety, tolerability and pharmacokinetics of eteplirsen in young boys aged 6–48 months with Duchenne muscular dystrophy amenable to exon 51 skipping. **2023**,	0
15	Trichinella spiralis (Owen, 1835) Induces Increased Dystrophin Expression in Invaded Cross-striated Muscle.	0
14	Altered muscle niche contributes to myogenic deficit in the D2-mdxmodel of severe DMD.	0
13	In Vivo Evaluation of Exon 51 Skipping in hDMD/Dmd-null Mice. **2023**, 327-336	0
12	Differentiation of Human Fetal Muscle Stem Cells from Induced Pluripotent Stem Cells. **2023**, 143-157	0
11	In Vivo Modeling of Skeletal Muscle Diseases Using the CRISPR/Cas9 System in Rats. **2023**, 277-285	0
10	Efficacy and Safety of Viltolarsen in Boys With Duchenne Muscular Dystrophy: Results From the Phase 2, Open-Label, 4-Year Extension Study. **2023**, 1-9	0
9	Myocardial Remodeling with Ventricular Assist Devices.	0
8	Next Generation Exon 51 Skipping Antisense Oligonucleotides for Duchenne Muscular Dystrophy.	0
7	A new immunodeficient Duchenne muscular dystrophy rat model to evaluate engraftment after human cell transplantation. 14,	0
6	Spontaneous transverse colon volvulus in a patient with Duchenne muscular dystrophy: An unreported complication. **2023**,	0
5	Interspecies generation of functional muscle stem cells.	0
4	CRISPR-EDITING THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY.	0
3	Single-Swap Editing for the Correction of Common Duchenne Muscular Dystrophy Mutations. **2023**,	0

2	Toward patient-centered treatment goals for duchenne muscular dystrophy: insights from the Your Voice Study. **2023**, 18,	0
1	Social cognition in DMD and BMD dystrophinopathies: a cross-sectional preliminary study. 1-16	0